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A B S T R A C T
Background
Down’s syndrome occurs when a person has three copies of chromosome 21, or the specific area of chromosome 21 implicated in causing
Down’s syndrome, rather than two. It is the commonest congenital cause of mental disability and also leads to numerous metabolic and
structural problems. It can be life-threatening, or lead to considerable ill health, although some individuals have only mild problems
and can lead relatively normal lives. Having a baby with Down’s syndrome is likely to have a significant impact on family life. The risk
of a Down’s syndrome affected pregnancy increases with advancing maternal age.
Noninvasive screening based on biochemical analysis of maternal serum or urine, or fetal ultrasound measurements, allows estimates
of the risk of a pregnancy being affected and provides information to guide decisions about definitive testing. Before agreeing to
screening tests, parents need to be fully informed about the risks, benefits and possible consequences of such a test. This includes
subsequent choices for further tests they may face, and the implications of both false positive and false negative screening tests (i.e.
invasive diagnostic testing, and the possibility that a miscarried fetus may be chromosomally normal). The decisions that may be faced
by expectant parents inevitably engender a high level of anxiety at all stages of the screening process, and the outcomes of screening can
be associated with considerable physical and psychological morbidity. No screening test can predict the severity of problems a person
with Down’s syndrome will have.
Objectives
To estimate and compare the accuracy of first and second trimester urine markers for the detection of Down’s syndrome.
Search methods
We carried out a sensitive and comprehensive literature search of MEDLINE (1980 to 25 August 2011), EMBASE (1980 to 25 August
2011), BIOSIS via EDINA (1985 to 25 August 2011), CINAHL via OVID (1982 to 25 August 2011), The Database of Abstracts of
Reviews of Effectiveness (The Cochrane Library 2011, Issue 7), MEDION (25 August 2011), The Database of Systematic Reviews and
Meta-Analyses in Laboratory Medicine (25 August 2011), The National Research Register (archived 2007), Health Services Research
Projects in Progress database (25 August 2011). We studied reference lists and published review articles.
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Selection criteria
Studies evaluating tests of maternal urine in women up to 24 weeks of gestation for Down’s syndrome, compared with a reference
standard, either chromosomal verification or macroscopic postnatal inspection.
Data collection and analysis
We extracted data as test positive or test negative results for Down’s and non-Down’s pregnancies allowing estimation of detection rates
(sensitivity) and false positive rates (1-specificity). We performed quality assessment according to QUADAS (Quality Assessment of
Diagnostic Accuracy Studies) criteria. We used hierarchical summary ROC (receiver operating characteristic) meta-analytical methods
to analyse test performance and compare test accuracy. We performed analysis of studies allowing direct comparison between tests. We
investigated the impact of maternal age on test performance in subgroup analyses.
Main results
We included 19 studies involving 18,013 pregnancies (including 527 with Down’s syndrome). Studies were generally of high quality,
although differential verification was common with invasive testing of only high-risk pregnancies. Twenty-four test combinations
were evaluated formed from combinations of the following seven different markers with and without maternal age: AFP (alpha-
fetoprotein), ITA (invasive trophoblast antigen), ß-core fragment, free ßhCG (beta human chorionic gonadotrophin), total hCG,
oestriol, gonadotropin peptide and various marker ratios. The strategies evaluated included three double tests and seven single tests in
combination with maternal age, and one triple test, two double tests and 11 single tests without maternal age. Twelve of the 19 studies
only evaluated the performance of a single test strategy while the remaining seven evaluated at least two test strategies. Two marker
combinations were evaluated in more than four studies; second trimester ß-core fragment (six studies), and second trimester ß-core
fragment with maternal age (five studies).
In direct test comparisons, for a 5% false positive rate (FPR), the diagnostic accuracy of the double marker second trimester ß-core
fragment and oestriol with maternal age test combination was significantly better (ratio of diagnostic odds ratio (RDOR): 2.2 (95%
confidence interval (CI) 1.1 to 4.5), P = 0.02) (summary sensitivity of 73% (CI 57 to 85) at a cut-point of 5% FPR) than that of
the single marker test strategy of second trimester ß-core fragment and maternal age (summary sensitivity of 56% (CI 45 to 66) at a
cut-point of 5% FPR), but was not significantly better (RDOR: 1.5 (0.8 to 2.8), P = 0.21) than that of the second trimester ß-core
fragment to oestriol ratio and maternal age test strategy (summary sensitivity of 71% (CI 51 to 86) at a cut-point of 5% FPR).
Authors’ conclusions
Tests involving second trimester ß-core fragment and oestriol with maternal age are significantly more sensitive than the single marker
second trimester ß-core fragment and maternal age, however, there were few studies. There is a paucity of evidence available to support
the use of urine testing for Down’s syndrome screening in clinical practice where alternatives are available.
P L A I N L A N G U A G E S U M M A R Y
Screening tests for Down’s syndrome in first 24 weeks of pregnancy
Background
Down’s syndrome (also known as Down’s or Trisomy 21) is an incurable genetic disorder that causes significant physical and mental
health problems, and disabilities. However, there is wide variation in how Down’s affects people. Some individuals are severely affected
whilst others have mild problems and are able to lead relatively normal lives. There is no way of predicting how badly a baby might be
affected.
Expectant parents are given the choice to be tested for Down’s during pregnancy to assist them in making decisions. If a mother is
carrying a baby with Down’s, then there is the decision about whether to terminate or continue with the pregnancy. The information
offers parents the opportunity to plan for life with a Down’s child.
The most accurate tests for Down’s involve testing fluid from around the baby (amniocentesis) or tissue from the placenta (chorionic
villus sampling (CVS)) for the abnormal chromosomes associated with Down’s. Both these tests involve inserting needles through
the mother’s abdomen and are known to increase the risk of miscarriage. Thus, the tests are not suitable for offering to all pregnant
women. Rather, tests that measure markers in the mother’s blood, urine or on ultrasound scans of the baby are used for screening.
These screening tests are not perfect, they can miss cases of Down’s and also give a ‘high risk’ test results to a number of women whose
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babies are not affected by Down’s. Thus, pregnancies identified as ‘high risk’ using these screening tests require further testing using
amniocentesis or CVS to confirm a diagnosis of Down’s.
What we did
The aim of this review was to find out which of the urine screening tests done during the first 24 weeks of pregnancy are the most
accurate at predicting the risk of a pregnancy being affected by Down’s. We looked at seven different urine markers that can be used
alone, in ratios or in combination, taken before 24 weeks’ gestation, thus creating 24 screening tests for Down’s. We found 19 studies,
involving 18,013 pregnancies of which 527 had pregnancies affected by Down’s.
What we found
For the first 24 weeks of pregnancy, the evidence does not support the use of urine tests for Down’s syndrome screening. The amount
of evidence is limited. These tests are not offered in routine clinical practice.
Other important information to consider
The urine tests themselves have no adverse effects for the woman. However, some women who have a ‘high risk’ screening test result,
and are given amniocentesis or CVS have a risk of miscarrying a baby unaffected by Down’s. Parents will need to weigh up this risk
when deciding whether or not to have an amniocentesis or CVS following a ‘high risk’ screening test result.
B A C K G R O U N D
This is one of a series of reviews on antenatal screening for
Down’s syndrome following a generic protocol (Alldred 2010) -
see Published notes for more details.
Target condition being diagnosed
Down’s syndrome
Down’s syndrome affects approximately one in 800 live-born ba-
bies (Cuckle 1987a). It results from a person having three, rather
than two, copies of chromosome 21-or the specific area of chro-
mosome 21 implicated in causing Down’s syndrome, as a result of
trisomy or translocation. If not all cells are affected, the pattern is
described as ’mosaic’. Down’s syndrome can cause a wide range of
physical and mental problems. It is the commonest cause of men-
tal disability, and is also associated with a number of congenital
malformations, notably affecting the heart. There is also an in-
creased risk of cancers such as leukaemia, and numerous metabolic
problems including diabetes and thyroid disease. Some of these
problemsmay be life-threatening, or lead to considerable ill health,
while some individuals with Down’s syndrome have only mild
problems and can lead a relatively normal life.
There is no cure for Down’s syndrome, and antenatal diagnosis
allows for preparation for the birth and subsequent care of a baby
with Down’s syndrome, or for the offer of a termination of preg-
nancy. Having a baby with Down’s syndrome is likely to have a
significant impact on family and social life, relationships and par-
ents’ work. Special provisions may need to be made for education
and care of the child, as well as accommodating the possibility of
periods of hospitalisation.
Definitive invasive tests (amniocentesis and chorionic villus sam-
pling (CVS)) exist that allow the diagnosis of Down’s syndrome
before birth, but carry a risk of miscarriage. No test can predict
the severity of problems a person with Down’s syndrome will have.
Noninvasive screening tests based on biochemical analysis of ma-
ternal serum or urine, or fetal ultrasound measurements, allow
an estimate of the risk of a pregnancy being affected and provide
parents with information to enable them to make choices about
definitive testing. Such screening tests are used during the first and
second trimester of pregnancy.
Screening tests for Down’s syndrome
Initially, screening was determined solely by using maternal age to
classify a pregnancy as high or low risk for trisomy 21, as it was
known that older women had a higher chance of carrying a baby
with Down’s syndrome (Penrose 1933).
Further advances in screening were made in the early 1980s, when
Merkatz et al investigated the possibility that low maternal serum
alpha-fetoprotein (AFP), obtained frommaternal blood in the sec-
ond trimester of pregnancy could be associated with chromoso-
mal abnormalities in the fetus. Their retrospective case-control
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study showed a statistically significant relationship between fetal
trisomy, such as Down’s syndrome, and lowered maternal serum
AFP (Merkatz 1984). This was further explored by Cuckle et al in
a larger retrospective trial using data collected as part of a neural
tube defect (NTD) screening project (Cuckle 1984). This work
was followed by calculation of risk estimates using maternal serum
AFP values and maternal age, which ultimately led to the intro-
duction of the two screening parameters in combination (Alfirevic
2004).
In 1987, in a small case-control study of women carrying fe-
tuses with known chromosomal abnormalities, Bogart and col-
leagues investigated maternal serum levels of human chorionic go-
nadotrophin (hCG) as a possible screening tool for chromosomal
abnormalities in the second trimester (Bogart 1987). This fol-
lowed the observations that low hCG levels were associated with
miscarriages, which are commonly associated with fetal chromo-
somal abnormalities. They concluded that high hCG levels were
associated with Down’s syndrome and because hCG levels plateau
at 18 to 24 weeks, that this would be the most appropriate time
for screening. Later work suggested that the ß sub-unit of hCG
was a more effective marker than total hCG (Macri 1990; Macri
1993).
Second trimester unconjugated oestriol (uE3), produced by the
fetal adrenals and the placenta, was also evaluated as a potential
screening marker. In another retrospective case-control study, uE3
was shown to be lower in Down’s syndrome pregnancies compared
with unaffected pregnancies.Whenused in combinationwithAFP
andmaternal age, it appeared to identifymore pregnancies affected
by Down’s syndrome than AFP and age alone (Canick 1988).
Further work suggested that all three serum markers (AFP, hCG
and uE3) showed even higher detection rates when combined with
maternal age (Wald 1988a; Wald 1988b) and appeared to be a
cost-effective screening strategy (Wald 1992a).
Two other serum markers, produced by the placenta, have
been linked with Down’s syndrome, namely pregnancy-associ-
ated plasma protein A or PAPP-A, and Inhibin A. PAPP-A has
been shown to be reduced in the first trimester of Down’s syn-
drome pregnancies, with its most marked reduction in the early
first trimester (Bersinger 1995). Inhibin A is high in the second
trimester in pregnancies affected by Down’s syndrome (Cuckle
1995a; Wallace 1995). There are some issues concerning the bio-
logical stability and hence reliability of this marker, and the effect
this will have on individual risk.
In addition to serum and ultrasound markers for Down’s syn-
drome, work has been carried out looking at urinary markers.
These markers include invasive trophoblast antigen, ß-core frag-
ment, free ßhCG and total hCG (Cole 1999a). There is contro-
versy about their value (Wald 2003a).
Screening and parental choice
Antenatal screening is used for several reasons (Alfirevic 2004), but
the most important is to enable parental choice regarding preg-
nancymanagement and outcome. Before awoman and her partner
opt to have a screening test, they need to be fully informed about
the risks, benefits and possible consequences of such a test. This
includes the choices they may have to face should the result show
that the woman has a high risk of carrying a baby with Down’s
syndrome and the implications of both false positive and false neg-
ative screening tests. They need to be informed of the risk of a
miscarriage due to invasive diagnostic testing, and the possibility
that a miscarried fetus may be chromosomally normal. If, follow-
ing invasive diagnostic testing, the fetus is shown to have Down’s
syndrome, further decisions need to be made about continuation
or termination of the pregnancy, the possibility of adoption and
finally, preparation for parenthood. Equally, if a woman has a test
that shows she is at a low risk of carrying a fetus with Down’s
syndrome, it does not necessarily mean that the baby will be born
with a normal chromosomal make up. This possibility can only be
excluded by an invasive diagnostic test (Alfirevic 2003).The deci-
sions that may be faced by expectant parents inevitably engender
a high level of anxiety at all stages of the screening process, and the
outcomes of screening can be associated with considerable physi-
cal and psychological morbidity. No screening test can predict the
severity of problems a person with Down’s syndrome will have.
Index test(s)
This review examined urine screening tests used in the first and sec-
ond trimester of pregnancy (up to 24 weeks’ gestation) comprised
of the following individual markers; AFP; invasive trophoblast
antigen (ITA) (also knownas hyperglycosylated hCG); ß-core frag-
ment; free ßhCG; total hCG; uE3 (oestriol); gonadotropin pep-
tide; and various marker ratios. These markers can be used indi-
vidually, in combination with age, and can also be used in com-
bination with each other. The risks are calculated by comparing
a woman’s test result for each marker with values for an unaf-
fected population, and multiplying this with her age-related risk.
Where several markers are combined, risks are computed using
risk equations (often implemented in commercial software) that
take into account the correlational relationships between the dif-
ferentmarkers andmarker distributions in affected and unaffected
populations.
Alternative test(s)
Down’s syndrome can be detected during pregnancy with invasive
diagnostic tests such as amniocentesis or CVS, with or without
prior screening. These tests are considered to be reference tests
rather than index or screening tests. The ability to determine fetal
chromosomal make up (also known as a karyotype) from amniotic
fluid samples was demonstrated in 1966 by Steele and Breg (Steele
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1966), and the first antenatal diagnosis of Down’s syndrome was
made in 1968 (Vaklenti 1968). Amniocentesis is an invasive pro-
cedure that involves taking a small sample of the amniotic fluid
(liquor) surrounding the baby, using a needle which goes through
the abdominal wall into the uterus, and is usually performed after
15 weeks’ gestation. Chorionic villus sampling involves taking a
sample of the placental tissue using a needle which goes through
the abdominal wall and uterus or a cannula through the cervix.
It is usually performed between 10 and 13 weeks’ gestation. Am-
niocentesis and CVS are both methods of obtaining fetal chromo-
somematerial, which are then used to diagnose Down’s syndrome.
Both tests use ultrasound scans to guide placement of the needle.
Amniocentesis carries a risk of miscarriage in the order of 1%;
transabdominal CVSmay carry a similar risk (Alfirevic 2003). Re-
cent developments in the use of cell-free fetal DNA detection in
maternal serum are paving the way for noninvasive diagnosis of
Down’s syndrome and other trisomies, however these tests were
not used as reference standards in any of the studies examined.
Many different screening tests are available and offered to preg-
nant women, and these tests are the subject of additional Cochrane
reviews published (Alldred 2012) or currently in preparation, and
other published reviews. Tests being assessed in other Cochrane
reviews include first trimester serum tests; second trimester serum
tests; first trimester ultrasound markers; tests that combine serum
and ultrasound markers; and tests that combine markers from the
first trimester with markers from the second trimester. Second
trimester ultrasound markers have been assessed in a previous sys-
tematic review (Smith-Bindman 2001).
Rationale
This is one of a suite of Cochrane reviews, the aim of which is to
identify all screening tests for Down’s syndrome used in clinical
practice, or evaluated in the research setting, in order to try to iden-
tify the most accurate test(s) available, and to provide clinicians,
policy-makers and women with robust and balanced evidence on
which to base decisions about interpreting test results and imple-
menting screening policies to triage the use of invasive diagnostic
testing. The full set of reviews is described in the generic protocol
(Alldred 2010).
The topic has been split into several different reviews to allow for
greater ease of reading and greater accessibility of data, and also to
allow the reader to focus on separate groups of tests, for example,
first trimester serum tests alone, first trimester ultrasound alone,
first trimester serumandultrasound, second trimester serumalone,
first and second trimester serum, combinations of serum and ul-
trasound markers and urine markers alone. An overview review
will compare the best tests, focusing on commonly used strategies
from each of these groups to give comparative results between the
best tests in the different categories. This review is written with
a global perspective in mind, rather than to conform with any
specific local or national policy, as not all tests will be available in
all areas where screening for Down’s syndrome is carried out.
A systematic review of second trimester ultrasound markers in
the detection of Down’s syndrome fetuses was published in 2001
that concluded that nuchal fold thickening may be useful in de-
tecting Down’s syndrome, but that it was not sensitive enough
to use as a screening test. The review concluded that the other
second trimester ultrasound markers did not usefully distinguish
between Down’s syndrome and pregnancies without Down’s syn-
drome (Smith-Bindman 2001). There has yet to be a systematic
review and meta-analysis of the observed data on serum, urine
and first trimester ultrasound markers, in order to draw rigorous
and robust conclusions about the diagnostic accuracy of available
Down’s syndrome screening tests.
O B J E C T I V E S
The aim of this review was to estimate and compare the accu-
racy of first and second trimester urine markers for the detection
of Down’s syndrome in the antenatal period, both as individual
markers and as combinations of markers. Accuracy is described
by the proportion of fetuses with Down’s syndrome detected by
screening before birth (sensitivity or detection rate), and the pro-
portion of women with a low risk (normal) screening test result
who subsequently had a baby unaffected by Down’s syndrome
(specificity). We grouped our analyses to focus on investigating
the value of adding increasing numbers of markers (comparing
single, dual, triple and quadruple tests).
Investigation of sources of heterogeneity
We planned to investigate whether a uniform screening test is suit-
able for all women, or whether different screening methods are
more applicable to different groups, defined by advanced mater-
nal age, ethnic groups and aspects of the pregnancy and medical
history such as multiple pregnancy, diabetes and family history
of Down’s syndrome. We also considered whether there existed
evidence of overestimation of test accuracy in studies evaluating
risk equations in the derivation sample rather than in a separate
validation sample.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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We included studies in which all women from a given popula-
tion had one or more index test(s) compared to a reference stan-
dard. Both consecutive series and diagnostic case-control study
designs were included. Randomised trials where individuals were
randomised to different screening strategies and all verified using
a reference standard were also eligible for inclusion. Studies in
which test strategies were compared head-to-head, either in the
same women, or between randomised groups were identified for
inclusion in separate comparisons of test strategies. Studies were
excluded if they included less than five Down’s syndrome cases, or
more than 20% of participants were not followed up.
Participants
Pregnant women at less than 24 weeks’ gestation confirmed by
ultrasound, who had not undergone previous testing for Down’s
syndrome in their pregnancy were eligible. Studies were included
if the pregnant women were unselected, or if they represented
groups with increased risk of Down’s syndrome, or difficulty with
conventional screening tests including maternal age greater than
35 years old, multiple pregnancy, diabetes mellitus and family
history of Down’s syndrome.
Index tests
The following index tests were examined; AFP; ITA; ß-core frag-
ment; free ßhCG; total hCG; oestriol (also termed as uE3); go-
nadotropin peptide and variousmarker ratios and combinations of
these markers combined with maternal age. Combinations with-
out maternal age were not included in the test comparisons (Table
1; Table 2), however, information on such test combinations is
provided.
We looked at comparisons of tests in isolation and in various
combinations. These included single (one marker), double (two
markers), triple (three markers), test strategies, all maternal age-
adjusted.
Where tests were used in comparison, we looked at the perfor-
mance of test comparisons according to predicted probabilities
computed using risk equations and dichotomised into high risk
and low risk.
Target conditions
Down’s syndrome in the fetus due to trisomy, translocation or
mosaicism.
Reference standards
Weconsidered several reference standards, involving chromosomal
verification and postnatal macroscopic inspection.
Amniocentesis and CVS are invasive chromosomal verification
tests undertaken during pregnancy. They are highly accurate, but
the process carries a 1% miscarriage rate, and therefore they are
only used in pregnancies considered to be at high risk of Down’s
syndrome, or on the mother’s request. All other types of testing
(postnatal examination, postnatal karyotyping, birth registers and
Down’s syndrome registers) are based on information available at
the end of pregnancy. The greatest concern is not their accuracy,
but the loss of the pregnancy to miscarriage between the urine test
and the reference standard. Miscarriage with cytogenetic testing
of the fetus is included in the reference standard where available.
We anticipated that older studies, and studies undertaken in older
women were more likely to have used invasive chromosomal ver-
ification tests in all women.
Studies undertaken in younger women and more recent studies
were likely to use differential verification as they often only used
prenatal karyotypic testing on fetuses considered screen positive/
high risk according to the screening test; the reference standard for
most unaffected infants being observing a phenotypically normal
baby. Although the accuracy of this combined reference standard
is considered high, it is methodologically a weaker approach as
pregnancies that miscarry between the index test and birth are
likely to be lost from the analysis, and miscarriage is more likely
to occur in Down’s than normal pregnancies. We investigated the
impact of the likely missing false negative results in sensitivity
analyses.
Search methods for identification of studies
Electronic searches
We applied a sensitive search strategy to search the following
databases. We used one broad generic search strategy to identify
studies for all reviews in this series.
Databases searched included;
• MEDLINE via OVID (1980 to 25 August 2011)
• EMBASE via Dialog Datastar (1980 to 25 August 2011)
• BIOSIS via EDINA (1985 to 25 August 2011)
• CINAHL via OVID (1982 to 25 August 2011)
• The Database of Abstracts of Reviews of Effectiveness (The
Cochrane Library 2011, Issue 7)
• MEDION (25 August 2011)
• The Database of Systematic Reviews and Meta-Analyses in
Laboratory Medicine (www.ifcc.org/) (25 August 2011)
• The National Research Register (archived 2007)
• Health Services Research Projects in Progress database (
HSRPROJ) (25 August 2011)
The search strategy combined three sets of search terms (see
Appendix 1). The first set was made up of named tests, general
terms used for screening/diagnostic tests and statistical terms.Note
that the statistical terms were used to increase sensitivity and were
not used as a methodological filter to increase specificity. The sec-
ond set was made up of terms that encompass Down syndrome
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and the third set made up of terms to limit the testing to pregnant
women. All termswithin each set were combinedwith the Boolean
operator OR and then the three sets were combined using AND.
The terms used were a combination of subject headings and free
text terms. The search strategy was adapted to suit each database
searched.
We attempted to identify cumulative papers that reported data
from the same data set, and we contacted authors to obtain clari-
fication of the overlap between data presented in these papers, in
order to prevent data from the same women being analysed more
than once.
Searching other resources
In addition, we examined references cited in studies identified as
being potentially relevant, and those cited by previous reviews.
We contacted authors of studies where further information was
required. We did not apply a diagnostic test filter, and we did not
apply language restrictions to the search.
We carried out forward citation searching of relevant items, us-
ing the search strategy in ISI citation indices, Google scholar and
Pubmed ‘related articles’.
Data collection and analysis
Selection of studies
Two review authors screened the titles and abstracts (where avail-
able) of all studies identified by the search strategy. We obtained
full-text versions of studies identified as being potentially relevant
and two review authors independently assessed these for inclusion,
using a study eligibility screening pro forma according to the pre-
specified inclusion criteria. Any disagreement between the two re-
view authors was settled by consensus, or where necessary, by a
third party.
Data extraction and management
We developed a data extraction form and piloted the form using
a subset of 20 identified studies (from all identified studies in
this suite of reviews). Two review authors independently extracted
data, andwhere disagreement or uncertainty existed, a third review
author validated the information extracted.
Data on each marker were extracted as binary test positive/test
negative results for Down’s and non-Down’s pregnancies, with a
high risk-result, as definedby each individual study, being regarded
as test positive (suggestive or diagnostic of Down’s syndrome),
and a low-risk result being regarded as test negative (suggestive
of absence of Down’s syndrome). Where results were reported at
several thresholds, we extracted data at each threshold.
We noted those in special groups that posed either increased risk of
Down’s syndrome or difficulty with conventional screening tests,
including maternal age greater than 35 years old, multiple preg-
nancy, diabetes mellitus and family history of Down’s syndrome.
Assessment of methodological quality
Weused amodified version of theQUADAS tool (Whiting 2003),
a quality assessment tool for use in systematic reviews of diagnostic
accuracy studies, to assess the methodological quality of included
studies. We anticipated that a key methodological issue would be
the potential for bias arising from the differential use of invasive
testing and follow-up for the reference standard according to in-
dex test results, bias arising due to higher loss to miscarriage in
false negatives than true negatives. We chose to code this issue
as originating from differential verification in the QUADAS tool:
we are aware that it could also be coded under delay in obtaining
the reference standard, and reporting of withdrawals. We omit-
ted the QUADAS item assessing quality according to length of
time between index and reference tests, as Down’s syndrome is
either present or absent rather than a condition that evolves and
resolves, and disregarding the differential reference standard issue
thus any length of delay is acceptable. Two review authors assessed
each included study separately. Any disagreement between the two
authors was settled by consensus, or where necessary, by a third
party. Each item in the QUADAS tool was marked as ‘yes’, ‘no’ or
‘unclear’, and scores were summarised graphically. We did not use
a summary quality score.
QUADAS criteria included the following 10 questions.
1. Was the spectrum of women representative of the women
who will receive the test in practice? (Criteria met if the sample
was selected from a wide range of childbearing ages, or selected
from a specified ‘high-risk’ group such as over 35s, family history
of Down’s syndrome, multiple pregnancy or diabetes mellitus,
provided all affected and unaffected fetuses included that could
be tested at the time point when the screening test would be
applied; criteria not met if the sample taken from a select or
unrepresentative group of women (i.e. private practice), was an
atypical screening population or recruited at a later time point
when selection could be affected by selective fetal loss).
2. Is the reference standard likely to correctly classify the target
condition? (Amniocentesis, CVS, postnatal karyotyping,
miscarriage with cytogenetic testing of the fetus, a phenotypically
normal baby or birth registers are all regarded as meeting this
criteria).
3. Did the whole sample or a random selection of the sample
receive verification using a reference standard of diagnosis?
4. Did women receive the same reference standard regardless
of the index test result?
5. Was the reference standard independent of the index test
result (i.e. the index test did not form part of the reference
standard)?
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6. Were the index test results interpreted without knowledge
of the results of the reference standard?
7. Were the reference standard results interpreted without
knowledge of the results of the index test?
8. Were the same clinical data (i.e. maternal age and weight,
ethnic origin, gestational age) available when test results were
interpreted as would be available when the test is used in practice?
9. Were uninterpretable/intermediate test results reported?
10. Were withdrawals from the study explained?
Statistical analysis and data synthesis
We initially examined each test or test strategy at each of the com-
mon risk thresholds used to define test positivity by plotting esti-
mates of sensitivity and specificity from each study on forest plots
and in receiver operating characteristic (ROC) space. Test strate-
gies were selected for further investigation if they were evaluated
in four or more studies or, if there were three or fewer studies,
but the individual study results indicated performance likely to be
superior to a sensitivity of 70% and specificity of 90%.
Estimation of average sensitivity and specificity
The analysis for each test strategy was undertaken first restricting
to studies that reported a common threshold to estimate average
sensitivity and specificity for each test at each threshold. Although
data on all thresholds were extracted, we present only key common
thresholds close to risks of 1:384, 1:250 and the 5% false positive
rate (FPR), unless other thresholdsweremore commonly reported.
Where combinations of tests were used in a risk score, we extracted
the result for the test combination using the risk score and not the
individual components that made up the test.
We undertook meta-analyses using hierarchical summary ROC
(HSROC)models, which included estimationof random effects in
accuracy and threshold parameters when there were four or more
studies. Otherwise, average sensitivity and specificity values were
computed by using univariate random-effects logistic regression
models to average logit sensitivity and logit specificity separately
because of insufficient number of studies to reliably estimate all
the parameters in the HSROC model. It is common in this field
for studies to report sensitivity for a fixed specificity (usually a
5% FPR). This removes the requirement to account for the cor-
relation between sensitivity and specificity across studies by using
a bivariate meta-analytical method since all specificities are the
same value. Thus, at a fixed specificity value, logit sensitivities were
pooled using a univariate random-effects model. This model was
further simplified to a fixed-effect model when there were only
two or three studies and heterogeneity was not observed on the
SROC plot. All analyses were undertaken using the NLMIXED
procedure in SAS (version 9.2; SAS Institute, Cary, NC) and the
xtmelogit command in Stata version 11.2 (Stata-Corp, College
Station, TX, USA).
Comparisons between tests
We made comparisons between tests, first by utilising all avail-
able studies, selecting one threshold from each study to estimate
a SROC curve without restricting to a common threshold. The
threshold was chosen for each study according to the following
order of preference: a) the risk threshold closest to one in 250; b)
a multiples of the median (MoM) or presence/absence threshold;
c) the performance closest to a 5% FPR or 95th percentile. The
5% FPR was chosen as a cut-off point as this is the cut-off most
commonly reported in the literature. The analysis that used all
available studies was performed by including the most evaluated
or best performing test strategies in a single HSROC model. The
model included two indicator terms for each test to allow for dif-
ferences in accuracy and threshold. As there were very few studies
for each test, a symmetric summary ROC curve was assumed. In
addition, because the model failed to converge, we assumed fixed-
effect for the threshold and accuracy parameters. An estimate of
the sensitivity of each test for a 5% FPR was derived from the
SROC curve, and we obtained associated confidence intervals us-
ing the delta method.
Direct comparisons between tests were based on results of very few
studies, and were analysed using a simplified HSROCmodel with
fixed-effect and symmetrical underlying SROC curves because the
number of studies was insufficient to estimate between study het-
erogeneity in accuracy and threshold or asymmetry in the shape
of the SROC curves. We used a separate model to make each pair-
wise comparison. We assessed comparisons between tests by using
likelihood ratio tests to test if the differences in accuracy were sta-
tistically significant or not. We expressed the differences as ratios
of diagnostic odds ratios and reported with 95% confidence inter-
vals. As studies rarely report data cross-classified by both tests for
Down’s and normal pregnancies, the analytical method did not
take full account of the pairing of test results, but the restriction
to direct head-to-head comparisons should have removed the po-
tential confounding of test comparisons with other features of the
studies. The strength of evidence for differences in performance of
test strategies relied on evidence from both the direct and indirect
comparisons.
Investigations of heterogeneity
Had there been 10 or more studies available for a test, we planned
to investigate heterogeneity by adding covariate terms to the
HSROC model to assess the effect of a covariate on accuracy and
threshold.
Sensitivity analyses
In many of the included studies, mothers with pregnancies iden-
tified as high risk for Down’s syndrome by the urine testing were
offered immediate definitive testing by amniocentesis, whereas the
remainder were assessed for Down’s syndrome by inspection at
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birth. Such delayed and differential verification will introduce bias
most likely through there being greater loss to miscarriage in the
Down’s syndrome pregnancies that were not detected by the urine
testing (the false negative diagnoses). Testing and detection of mis-
carriages is impractical in many situations, and no clear data are
available on the magnitude of these miscarriage rates.
To account for the possible bias introduced by such a mechanism,
we planned to perform sensitivity analyses by increasing the per-
centage of false negatives in studies where delayed verification in
test negatives occurred (Mol 1999). We planned to incrementally
increase the percentage from 10% to 50%, the final value repre-
senting a scenario where a third of more Down’s pregnancies than
normal pregnancies were likely to miscarry, thought to be higher
than the likely value. We intended to conduct the sensitivity anal-
yses on the analysis investigating the effect of maternal age on test
sensitivity.
R E S U L T S
Results of the search
The search for the whole suite of reviews identified a total of
15,394 papers, once the results from each bibliographic database
were combined and duplicates were removed. After screening out
obviously inappropriate papers based on their title and abstract,
1145 papers remained and we obtained full-text copies for formal
assessment of eligibility. From these, a total of 269 papers were
deemed eligible and were included in the suite of reviews. We
included a total of 19 studies (reported in 29 publications) in this
review of urine tests, involving 18,013 pregnancies, of which 527
were Down’s syndrome pregnancies.
A total of 24 different test strategies or combinations, at one or
more thresholds, were evaluated in the 19 studies. These tests were
produced from combinations of seven different urine tests (and
their ratios) with andwithoutmaternal age: AFP; ITA; ß-core frag-
ment; free ßhCG; total hCG; oestriol; gonadotropin peptide and
various marker ratios. Strategies evaluated included three double
tests and seven single tests in combination with maternal age, and
one triple test, two double tests and 11 single tests without mater-
nal age. Twelve of the 19 studies only evaluated the performance
of a single test strategy while the remaining seven evaluated at least
two test strategies.
The following combinations evaluated included four ormore stud-
ies.
1. Second trimester ß-core fragment (six studies; 9615 women
with 193 affected Down’s pregnancies)
2. Second trimester ß-core fragment and maternal age (five
studies; 3419 women with 155 Down’s pregnancies)
Methodological quality of included studies
We judged the studies to be of highmethodological quality inmost
categories (Figure 1). Due to the nature of testing for Down’s syn-
drome screening and the potential side effects of invasive testing,
differential verification is almost universal in the general screening
population, as most women whose screening test result is defined
as low risk will have their screening test verified at birth, rather
than by invasive diagnosis in the antenatal period. Additionally,
it was not always possible to ascertain from the included studies
whether or not the results of index tests and reference standards
were blinded. It would be difficult to blind clinicians performing
invasive diagnostic tests (reference standards) to the index test re-
sult, unless all women received the same reference standard, which
would not be appropriate in most scenarios. Any biases secondary
to a lack of clinician blinding are likely to be minimal.
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Most studies seemed to indicate 100% follow-up, however there
will inevitably be losses to follow-up due to women moving out
of area, for example. Studies sometimes accounted for these and
it is unlikely that there were enough losses to follow-up to have
introduced significant bias. There was likely under-ascertainment
of miscarriage, and very few papers accounted for miscarriage, or
performed tissue karyotyping in pregnancies resulting in miscar-
riage. Some studies attempted to adjust for predicted miscarriage
rate and the incidence of Down’s syndrome in this specific pop-
ulation, but most did not. We have not attempted to adjust for
expected miscarriage rate in this review. There is a higher natural
miscarriage rate in the first trimester, however this will be uniform
across studies and therefore unlikely to introduce significant bias.
Some studies that provided estimates of risk using multivariable
equations used the same data set to evaluate performance of the
risk equation as was used to derive the equation. This is often
thought to lead to over-estimation of test performance.
Findings
1) Second trimester ß-core fragment
Results for this single test were derived from six studies (Cole
1999b; Cuckle 1995b; Cuckle 1999a; Isozaki 1997; Spencer 1996;
Wald 2003), and included 9615 women in whom 193 pregnancies
were known to be affected by Down’s syndrome. Two studies (
Cole 1999b; Cuckle 1999a) contributed over 7000 pregnancies to
the data. Six studies (Cole 1999b; Cuckle 1995b; Cuckle 1999a;
Isozaki 1997; Spencer 1996; Wald 2003) presented data for a cut-
point of 5% FPR and the estimated sensitivity was 41% (95%
confidence interval (CI) 20 to 66).
2) Second trimester ß-core fragment and maternal
age
Results for this single test were derived from five studies (
Bahado-Singh 1999; Bahado-Singh 1999a; Cole 1999b; Hsu
1999; Spencer 1996), and included 3419 women in whom 155
pregnancies were known to be affected by Down’s syndrome. Cole
1999b contributed over 1000 pregnancies to the data. The studies
presented data at a cut-point of 5% FPR and the summary sensi-
tivity was 56% (95% CI 45 to 66).
3) Other test combinations
Of the 22 test combinations evaluated in three or fewer stud-
ies, nine test combinations demonstrated estimated sensitivities of
more than 70% and estimated specificities of more than 90%. Six
of these were evaluated in single studies (see Summary of findings),
and the following three test combinations were evaluated in two
or more studies.
1. Second trimester ß-core fragment to oestriol ratio
evaluated in two studies (Cole 1997b; Cole 1999b), with a
summary sensitivity of 74% (95% CI 58 to 86) at a cut-point of
5% FPR.
2. Second trimester ß-core fragment to oestriol ratio and
maternal age evaluated in three studies (Bahado-Singh 1999;
Cole 1999b; Hsu 1999), with a summary sensitivity of 71%
(95% CI 51 to 86) at a cut-point of 5% FPR.
3. Second trimester ß-core fragment, oestriol and maternal
age evaluated in two studies (Cole 1999b; Hsu 1999), with a
summary sensitivity of 73% (95% CI 57 to 85) at a cut-point of
5% FPR.
Comparative analyses of the five selected test
strategies
For each test we obtained the detection rate (sensitivity) for a fixed
FPR (1-specificity), a metric which is commonly used in Down’s
syndrome screening to describe test performance. We chose to
estimate detection rates at a 5% FPR in common with much of
the literature. Figure 2 shows point estimates of the detection rate
(and their 95% CIs) at a 5% FPR based on all available data for
the five test strategies; the test strategies are ordered according to
decreasingdetection rates. The plot shows that all five test strategies
have detection rates between 56% and 90%. The combination of
second trimester AFP and ß-core fragment to oestriol ratio with
maternal age showed the highest detection rate with an estimated
detection rate of 90% (CI 55 to 100), based on data from one
study with 10 affected cases out of a total of 356 pregnancies. The
worst performing strategywas the combination of ß-core fragment
to oestriol ratio and maternal age, with an estimated detection rate
of 56% (CI 45 to 66), based on data from five studies with 155
affected cases out of a total of 3419 pregnancies.
11Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Detection rates (% sensitivity) at a 5% false positive rate for the five most evaluated or best
performing test strategies. The estimates are shown with 95% confidence intervals. The test strategies are
ordered on the plot according to decreasing detection rate. The number of studies, cases and women included
for each test strategy are shown on the horizontal axis.
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Table 1 shows pair-wise direct comparisons (head-to-head) where
studies were available. Such comparisons are regarded as providing
the strongest evidence as they are unconfounded. The table shows
the ratio of diagnostic odds ratio (RDOR) with 95% CI and P
values for each test combination, the number of studies (K) for
which data were available. The table shows that the diagnostic
accuracy of the double marker combination of second trimester
ß-core fragment and oestriol with maternal age was significantly
better (RDOR 2.2 (95% CI 1.1 to 4.5); P = 0.02) than the single
marker second trimester ß-core fragment and maternal age test
strategy but was not significantly better (RDOR 1.5 (95% CI
0.8 to 2.8); P = 0.21) than that of the second trimester ß-core
fragment to oestriol ratio and maternal age test strategy. However,
the comparisons in this table were based on two or three studies
and are unlikely to be powered to detect differences in detection
rates.
Table 2 shows the same comparisons made using all available data
(as used to create Figure 2). Results are in agreementwith the direct
comparisons, and in addition, showed no significant differences
between any of the other pair of tests for which direct comparisons
were not available. However, these comparisons are potentially
confounded by differences between the studies, and the evidence
is limited.
Investigation of heterogeneity and sensitivity analyses
None of the tests was evaluated by 10 or more studies and so we
were unable to investigate the effect of maternal age or any other
potential source of heterogeneity. The planned sensitivity analyses,
looking at differential verification and any resultant bias, were also
not possible.
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Summary of findings
Review Question What is the accuracy of urine based markers for screening for Down’s syndrome?
Population Pregnant women at less than 24 weeks’ gestation confirmed by ultrasound, who had not undergone previous testing for Down’s syndrome. Most studies were
undertaken in women identified to be high risk based on maternal age
Settings All settings
Numbers of studies, preg-
nancies and Down’s syn-
drome cases
19 studies (reported in 29 publications) involving 18,013 pregnancies of which 527 were Down’s syndrome pregnancies
Index tests Risk scores computed using maternal age and first and second trimester urine markers for AFP; ITA; ß -core fragment; free ßhCG; total hCG; oestriol (also
termed as uE3); gonadotropin peptide
Reference standards Chromosomal verification (amniocentesis and CVS undertaken during pregnancy, and postnatal karyotyping) and postnatal macroscopic inspection
Study limitations Seven studies only used selective chromosomal verification during pregnancy, and were at risk of under-ascertainment of Down’s syndrome cases due loss
of the pregnancy to miscarriage between the serum test and the reference standard
Test Studies Women (Cases) Sensitivity* (95% CI) Specificity* (95% CI) Threshold
Test without maternal age
Single tests
First trimester free ßhCG 1 516 (86) 5 (1 to 11) 95 (92 to 97) 5% FPR
First trimester ß -core frag-
ment
1 516 (86) 10 (5 to 19) 95 (92 to 97) 5% FPR
First trimester ITA 2 579 (94) 15 (2 to 62) 95 5% FPR
First trimester total hCG 1 516 (86) 17 (10 to 27) 95 (92 to 97) 5% FPR1
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Second trimester oestriol 2 1472 (47) 23 (8 to 49) 95 5% FPR
Second trimester total hCG 1 390 (65) 31 (20 to 43) 95 (92 to 97) 5% FPR
Second trimester free ßhCG 3 1517 (107) 32 (12 to 63) 95 5% FPR
Second trimester ß -core frag-
ment
6 9613 (193) 41 (20 to 66) 95 5% FPR
Second trimester ITA 3 2748 (131) 43 (35 to 51) 95 5% FPR
Second trimester ß -core frag-
ment to oestriol ratio
2 1649 (35) 74 (58 to 86) 95 5% FPR
Second trimester
gonadotropin test
1 105 (14) 93 (66 to 100) 95 (88 to 98) 1:384 risk
Double tests
Second trimester AFP and ITA 1 524 (24) 79 (58 to 93) 95 (93 to 97) 5% FPR
Second trimester ß -core frag-
ment and oestriol
1 315 (24) 83 (63 to 95) 95 (92 to 97) 5% FPR
Triple tests
Second trimester AFP, uE3
and ITA
1 524 (24) 79 (58 to 93) 95 (93 to 97) 5% FPR
Test with maternal age
Single tests
Second trimester oestriol 1 474 (69) 49 (37 to 62) 95 (92 to 97) 5% FPR
Second trimester ß -core frag-
ment
5 3419 (155) 56 (45 to 66) 95 5% FPR
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Second trimester free ßhCG 2 879 (98) 57 (47 to 67) 95 5% FPR
Second trimester free ßhCG to
oestriol ratio
1 474 (69) 64 (51 to 75) 95 (92 to 97) 5% FPR
Second trimester ß -core frag-
ment to free ßhCG
1 474 (69) 67 (54 to 78) 95 (92 to 97) 5% FPR
Second trimester ITA 1 1016 (23) 70 (47 to 87) 95 (93 to 96) 5% FPR
Second trimester ß -core frag-
ment to oestriol ratio
3 2088 (105) 71 (51 to 86) 95 5% FPR
Double tests
Second trimester oestriol and
free ßhCG
1 474 (69) 68 (56 to 79) 95 (92 to 97) 5% FPR
Second trimester ß -core frag-
ment and oestriol
2 1631 (92) 73 (57 to 85) 95 5% FPR
Second trimester AFP and ß-
core fragment to oestriol ratio
1 356 (10) 90 (55 to 100) 95 (93 to 97) 1:58 risk
*Tests evaluated by at least one study are presented in the table. Where two studies reported the same threshold, estimates of summary
sensitivity and summary specificity were obtained by using univariate fixed effects logistic regression models to pool sensitivities and
specificities separately. if the threshold used was a 5% FPR, then only the sensitivities were pooled.
AFP: alpha-fetoprotein; ßhCG: beta human chorionic gonadotrophin;CI: confidence interval; CVS: chorionic villus sampling; FPR: false
positive rate; hCG: beta human chorionic gonadotrophin;ITA: invasive trophoblast antigen; uE3: unconjugated oestriol
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D I S C U S S I O N
Summary of main results
The systematic review found 19 studies evaluating urinary mark-
ers for Down’s syndrome screening. Very few studies provided un-
confounded comparisons of test strategies by applying and com-
paring several strategies using the same urine sample; the majority
of studies only evaluating a single test combination. A summary
of results for the 24 strategies is given in Summary of findings.
The following key findings were noted.
1. There is evidence from direct comparison to support the
use of multiple marker urine tests in combination with age for
screening - the double marker combination of second trimester
ß-core fragment and oestriol with maternal age test strategy was
significantly better (ratio of diagnostic odds ratio (RDOR) 2.2
(95% CI 1.1 to 4.5); P = 0.02) than the single marker second
trimester ß-core fragment and maternal age. This is reflected in
the indirect comparison of the two tests.
2. There was little evidence that urine markers are of value in
screening for Down’s syndrome. Marker combinations evaluated
by more than three studies showed low detection rates for a 5%
false positive rate (FPR). More promising markers were
investigated in fewer than three studies.
3. In indirect comparisons, with the exception of the
difference in accuracy between the single marker second
trimester ß-core fragment and maternal age test and the double
marker combination of second trimester ß-core fragment and
oestriol with maternal age, there was no significant difference in
the detection rates between tests, however, the number of
included studies was small.
Strengths and weaknesses of the review
This is the first comprehensive systematic review of urine tests for
Down’s syndrome screening. We examined papers from around
the world, covering a wide cross-section of women in varying
populations. We contacted authors to verify data where necessary
to give as complete a picture as possible while trying to avoid
replication of data.
There were a number of factors that have made meta-analysis of
the data difficult, which we have tried to adapt for in order to
allow for comparability of data presented in different studies.
1. There were many different cut-points used to define
pregnancies as high or low risk for Down’s syndrome. This
means that direct comparison is more difficult than if all studies
used the same cut-point to dichotomise their populations.
2. There were many different risk equations and software
applications in use for combination of multiple markers, which
were often not described in the papers. This means that risks
may be calculated by different formulae, and they may not be
directly comparable for this reason.
3. Different laboratories and clinics run different assays and
use different machines and methods. This may influence raw
results and subsequent risk calculations. Many laboratories have
a quality assessment/audit trail, however, this may not necessarily
be standard across the board, for example, how many assays are
run, how often medians are calculated and adjusted for a given
population and how quickly samples are tested from initially
being taken.
4. Very few studies make direct comparisons between tests,
making it difficult to detect if there is a real difference between
tests (i.e. how different tests perform in the same population).
There are differences in populations, with assay medians being
affected, for example, by race. It is not certain whether it is
appropriate to make comparisons between populations which are
inherently different.
5. We were unable to perform any of the subgroup analyses
that we had originally intended to, as the data simply were not
available. The vast majority of papers looking at pregnancies
conceived by in vitro fertilisation (IVF), affected by diabetes,
multiple gestation or a family history of Down’s syndrome
involved unaffected pregnancies only.
Applicability of findings to the review question
When planning a screening policy or a clinical screening pro-
gramme, clinicians and policy makers need to make decisions
about a finite number of tests or type of tests that can be offered.
These policies are often driven by both the needs of a specific pop-
ulation and by financial resources. Economic analysis was con-
sidered to be outside the scope of this review. Many of the tests
examined as part of this review are already commercially available
and in use in the clinical setting. The studies were carried out on
populations of typical pregnant women and therefore, the results
should be considered comparable with most pregnant populations
encountered in every day clinical practice.
We were unable to extract information about the harms of testing,
information about miscarriage rates and uptake of definitive test-
ing as the data were not often available. While it is unlikely that
major differences between the tests evaluated here exist in terms
of direct harms of testing, as they are all based on a single urine
sample, differences in accuracy may lead to differences in the use
of definitive testing and its consequent adverse outcomes.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Urine testing for Down’s syndrome is not commonly used, with
serum and ultrasound testing being widely clinically available.
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We would not recommend the introduction of urine testing for
Down’s syndrome screening on the basis of the review findings,
or that urine testing should replace serum or ultrasound testing
where it is available. There is a paucity of evidence available to
support the use of urine testing in clinical practice where alterna-
tives are available.
Implications for research
Further evaluation of urine tests is required before definitive rec-
ommendations canbemade about their use in clinical practice. Fu-
ture studies should ensure that adequate sample sizes are recruited,
and make comparisons of several alternative test combinations on
the same urine samples. Such direct comparisons minimise con-
founding and allow a clear focus on testing the incremental ben-
efit of increasingly complex and expensive testing strategies. The
reporting of test accuracy studies can be improved by adhering to
the STARD reporting guideline Bossuyt 2003. Three key aspects
are: 1) formally testing the statistical significance of differences in
test performance in direct comparisons and estimating incremen-
tal changes in detection rates (together with confidence intervals),
2) clearly reporting the number of mothers studied and their re-
sults, and 3) reporting the numbers of women who are lost to
follow-up.
For the purposes of meta-analysis and to allow for comparisons
to be made between different tests and combinations, we recom-
mend the publication of consensus standard algorithms for esti-
mating risk, and reporting of test performance at a standard set of
thresholds. This would be difficult to achieve and implement, but
an attempt at consensus should be made.
A C K N OW L E D G E M E N T S
We acknowledge the assistance of the Pregnancy and Childirth
Cochrane Review Group Editorial base with writing the searches
and other aspects of this review.
As part of the pre-publication editorial process, this review has
been commented on by three peers (an editor and two referees who
are external to the editorial team) and a member of the Pregnancy
and Childbirth Group’s international panel of consumers.
This project was supported by the National Institute for Health
Research, via Cochrane Infrastructure funding to Cochrane Preg-
nancy and Childbirth. The views and opinions expressed therein
are those of the authors and do not necessarily reflect those of the
Systematic Reviews Programme, NIHR, NHS or the Department
of Health.
R E F E R E N C E S
References to studies included in this review
Bahado-Singh 1998 {published data only}
Bahado-Singh RO, Oz UA, Deren O, Acuna E, Cermik D,
Mahoney MJ, et al. A new screening protocol combining
urine beta-core fragment and ultrasonography for Down
syndrome detection. American Journal of Obstetrics and
Gynecology 1998;178(4):779–82.
Bahado-Singh 1998b {published data only}
Bahado-Singh RO, Oz U, Kovanci E, Cermik D, Flores D,
Copel J, et al. New triple screen test for Down syndrome:
combined urine analytes and serum AFP. Journal of
Maternal-Fetal Medicine 1998;7(3):111–4.
Bahado-Singh 1999 {published data only}
Bahado-Singh R, Oz U, Kovanci E, Cermik D, Copel
J, Mahoney MJ, et al. A high-sensitivity alternative to
“routine” genetic amniocentesis: multiple urinary analytes,
nuchal thickness, and age. American Journal of Obstetrics
and Gynecology 1999;180(1 pt 1):169–73.
Bahado-Singh 1999a {published data only}
Bahado Singh, Oz U, Rinne K, Hunter D, Cole L,
Mahoney MJ, et al. Elevated maternal urine level of beta-
core fragment of human chorionic gonadotropin versus
serum triple test in the second-trimester detection of Down
syndrome. American Journal of Obstetrics and Gynecology
1999;181(4):929–33.
Bahado-Singh 2000 {published data only}
∗ Bahado-Singh R, Oz U, Shahabi S, Omrani A, Mahoney
M, Cole L. Urine hyperglycosylated hCG plus ultrasound
biometry for detection of down syndrome in the second
trimester in a high-risk population. Obstetrics & Gynecology
2000;95(6 pt 1):889–94.
Cole LA, Omrani A, Cermik D, Singh RO, Mahoney MJ.
Hyperglycosylated hCG, a potential alternative to hCG in
Down syndrome screening. Prenatal Diagnosis 1998;18(9):
926–33.
Cole LA, Shahabi S, Oz UA, Bahado-Singh RO, Mahoney
MJ. Hyperglycosylated human chorionic gonadotropin
(invasive trophoblast antigen) immunoassay: a new basis for
gestational Down syndrome screening. Clinical Chemistry
1999;45(12):2109–19.
Cole LA, Shahabi S, Oz UA, Rinne KM, Omrani A,
Bahado-Singh RO, et al. Urinary screening tests for fetal
Down syndrome: II. Hyperglycosylated hCG. Prenatal
Diagnosis 1999;19(4):351–9.
Bahado-Singh 2000a {published data only}
Bahado-Singh, Oz U, Shahabi S, Mahoney MJ, Baumgarten
A, Cole L. Comparison of urinary hyperglycosylated human
chorionic gonadotropin concentration with the serum
18Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
triple screen for Down syndrome detection in high-risk
pregnancies. American Journal of Obstetrics and Gynecology
2000;183(5):1114–8.
Canick 1995 {published data only}
Canick JA, Kellner LH, Saller DN Jr, Palomaki GE, Walker
RP, Osathanondh R. Second-trimester levels of maternal
urinary gonadotropin peptide in down syndrome pregnancy.
Prenatal Diagnosis 1995;15(8):739–44.
Cole 1997a {published data only}
Cole LA, Jacobs M, Isozaki T, Palomaki GE, Bahado-Singh
RO, Mahoney MJ. Screening for Down syndrome using
urine hCG free beta-subunit in the second trimester of
pregnancy. Prenatal Diagnosis 1997;17(12):1107–11.
Cole 1997b {published data only}
Cole LA, Acuna E, Isozaki T, Palomaki GE, Bahado-Singh
RO, Mahoney MO. Combining beta-core fragment and
total oestriol measurements to test for Down syndrome
pregnancies. Prenatal Diagnosis 1997;17(12):1125–33.
Cole 1999b {published data only}
Cole LA, Rinne KM, Mahajan SM, Oz UA, Shahabi S,
Mahoney MJ, et al. Urinary screening tests for fetal Down
syndrome: I. Fresh beta-core fragment.[see comment].
Prenatal Diagnosis 1999;19(4):340–50.
Cuckle 1995b {published data only}
Cuckle HS, Iles RK, Chard T. Urinary beta-core human
chorionic gonadotrophin: a new approach to Down’s
syndrome screening. Prenatal Diagnosis 1994;14(10):
953–8.
∗ Cuckle HS, Iles RK, Sehmi IK, Chard T, Oakey RE,
Davies S, et al. Urinary multiple marker screening for
Down’s syndrome.[see comment]. Prenatal Diagnosis 1995;
15(8):745–51.
Cuckle 1999 {published data only}
Cuckle HS, Shahabi S, Sehmi IK, Jones R, Cole LA.
Maternal urine hyperglycosylated hCG in pregnancies with
Down syndrome. Prenatal Diagnosis. 1999;19(10):918–20.
Cuckle 1999a {published data only}
Cuckle HS, Canick JA, Kellner LH. Collaborative study of
maternal urine beta -core human chorionic gonadotrophin
screening for Down syndrome. Prenatal Diagnosis 1999;19
(10):911–7.
Hsu 1999 {published data only}
Hsu JJ, Hsu TY, Hsieh TT, Soong YK, Hsieh FJ, Spencer
K. Urine free beta-hCG and total estriol for Down
syndrome screening during the second trimester in an Asian
population. Obstetrics & Gynecology 1999;94(1):107–11.
Hsu JJ, Hung TH, Liou JD, Hsieh TT, Soong YK. Elevated
second-trimester maternal urine free beta-human chorionic
gonadotropin levels in Asian pregnancies with fetal
chromosomal abnormalities. Fetal Diagnosis and Therapy
1998;13(6):352–6.
∗ Hsu JJ, Spencer K, Aitken DA, Crossley J, Choi T, Ozaki
M, et al. Urinary free beta hCG, beta core fragment and
total oestriol as markers of Down syndrome in the second
trimester of pregnancy. Prenatal Diagnosis 1999;19:146–58.
Hsu JJ, Spencer K, Hung TH, Hsieh TT, Soong YK.
Second-trimester maternal urine human chorionic
gonadotrophin beta-core fragment concentrations in Asian
pregnancies with fetal chromosomal abnormalities. Human
Reproduction 1999;14(9):2381–5.
Isozaki 1997 {published data only}
Isozaki T, Palomaki GE, Bahado-Singh RO, Cole LA.
Screening for Down syndrome pregnancy using beta-core
fragment: prospective study. Prenatal Diagnosis 1997;17(5):
407–13.
Palomaki 2004a {published data only}
Palomaki GE, Knight GJ, Roberson MM, Cunningham
GC, Lee JE, Strom CM, et al. Invasive trophoblast antigen
(hyperglycosylated human chorionic gonadotropin) in
second-trimester maternal urine as a marker for down
syndrome: preliminary results of an observational study on
fresh samples. Clinical Chemistry 2004;50(1):182–9.
Spencer 1996 {published data only}
Spencer K, Aitken DA, Macri JN, Buchanan PD. Urine free
beta hCG and beta core in pregnancies affected by Down’s
syndrome. Prenatal Diagnosis 1996;16(7):605–13.
Wald 2003 {published data only}
Wald NJ, Rodeck C, Hackshaw AK, Rudnicka A. SURUSS
in perspective. Seminars in Perinatology 2005;29(4):225–35.
Wald NJ, Rodeck C, Hackshaw AK, Rudnicka A. SURUSS
in perspective.[see comment]. BJOG: an international
journal of obstetrics and gynaecology 2004;111(6):521–31.
Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty
L, Mackinson AM. First and second trimester antenatal
screening for Down’s syndrome: the results of the Serum,
Urine and Ultrasound Screening Study (SURUSS). Journal
of Medical Screening 2003;10(2):56–104.
∗ Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty
L, Mackinson AM, SURUSS Research Group. First and
second trimester antenatal screening for Down’s syndrome:
the results of the Serum, Urine and Ultrasound Screening
Study (SURUSS). Health Technology Assessment (Winchester,
England) 2003;7(11):1–77.
Weinans 2000 {published data only}
Weinans MJ, Butler SA, Mantingh A, Cole LA. Urinary
hyperglycosylated hCG in first trimester screening for
chromosomal abnormalities. Prenatal Diagnosis 2000;20
(12):976–8.
References to studies excluded from this review
Abbas 1995 {published data only}
Abbas A, Chard T, Nicolaides K. Fetal and maternal hCG
concentration in aneuploid pregnancies. British Journal of
Obstetrics and Gynaecology 1995;102(7):561–3.
Abdul-Hamid 2004 {published data only}
Abdul-Hamid S, Fox R, Martin I. Maternal serum screening
for trisomy 21 in women with a false positive result in last
pregnancy. Journal of Obstetrics & Gynaecology 2004;24(4):
374–6.
19Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Abraha 1999 {published data only}
Abraha HD, Noble PL, Nicolaides KH, Sherwood RA.
Maternal serum S100 protein in normal and Down
syndrome pregnancies. Prenatal Diagnosis 1999;19(4):
334–6.
Adekunle 1999 {published data only}
Adekunle O, Gopee A, el-Sayed M, Thilaganathan B.
Increased first trimester nuchal translucency: pregnancy
and infant outcomes after routine screening for Down’s
syndrome in an unselected antenatal population. British
Journal of Radiology 1999;72(857):457–60.
Aitken 1993 {published data only}
Aitken DA, McCaw G, Crossley JA, Berry E, Connor JM,
Spencer K, et al. First-trimester biochemical screening for
fetal chromosome abnormalities and neural tube defects.
Prenatal Diagnosis 1993;13(8):681–9.
Aitken 1996a {published data only}
Aitken DA, Syvertsen BS, Crossley JA, Berry E, Connor
JM. Heat-stable and immunoreactive placental alkaline
phosphatase in maternal serum from Down’s syndrome and
trisomy 18 pregnancies.[see comment]. Prenatal Diagnosis
1996;16(11):1051–4.
Aitken 1996b {published data only}
Aitken DA, Wallace EM, Crossley JA, Swanston IA, Van
Pareren Y, Van Maarle M, et al. Dimeric Inhibin A as a
marker for Down’s syndrome in early pregnancy. New
England Journal of Medicine 1996;334(19):1231–6.
Akbas 2001 {published data only}
Akbas SH, Ozben T, Alper O, Ugur A, Yucel G, Luleci
G. Maternal serum screening for Down’s syndrome, open
neural tube defects and trisomy 18. Clinical Chemistry &
Laboratory Medicine 2001;39(6):487–90.
Antona 1998 {published data only}
Antona D, Wallace EM, Shearing C, Ashby JP, Groome NP.
Inhibin A and pro-alphaC Inhibin A in Down syndrome
and normal pregnancies. Prenatal Diagnosis 1998;18(11):
1122–6.
Antsaklis 1999 {published data only}
Antsaklis A, Papantoniou N, Mesogitis S, Michalas S,
Aravantinos D. Pregnant women of 35 years of age or
more: maternal serum markers or amniocentesis?. Journal
of Obstetrics and Gynaecology 1999;19(3):253–6.
Ashwood 1987 {published data only}
Ashwood ER, Cheng E, Luthy DA. Maternal serum
alpha-fetoprotein and fetal trisomy-21 in women 35 years
and older: implications for alpha-fetoprotein screening
programs. American Journal of Medical Genetics 1987;26(3):
531–9.
Asrani 2005 {published data only}
Asrani CH. Triple marker. National Journal of Homoeopathy
2005;7(3):174.
Audibert 2001b {published data only}
Audibert F, Dommergues M, Benattar C, Taieb J, Thalabard
JC, Frydman R. Screening for Down syndrome using first-
trimester ultrasound and second-trimester maternal serum
markers in a low-risk population: a prospective longitudinal
study. Ultrasound in Obstetrics & Gynecology 2001;18(1):
26–31.
Axt-Fleidner 2006 {published data only}
Axt-Fliedner R, Schwarze A, Kreiselmaier P, Krapp M,
Smrcek J, Diedrich K. Umbilical cord diameter at 11-14
weeks of gestation: relationship to nuchal translucency,
ductus venous blood flow and chromosomal defects. Fetal
Diagnosis and Therapy 2006;21(4):390–5.
Azuma 2002 {published data only}
Azuma M, Yamamoto R, Wakui Y, Minobe S, Satomura S,
Fujimoto S. A novel method for the detection of Down
syndrome with the use of four serum markers. American
Journal of Obstetrics and Gynecology 2002;187(1):197–201.
Baghagho 2004 {published data only}
Baghagho EE, Kharboush IF, El-Kaffash DM, KarKour TA,
Ismail SR, Mortada MM. Maternal serum alpha fetoprotein
among pregnant females in Alexandria. Journal of the
Egyptian Public Health Association 2004;79(1-2):59–81.
Bahado-Singh 1995 {published data only}
Bahado Singh, Goldstein I, Uerpairojkit B, Copel JA,
Mahoney MJ, Baumgarten A. Normal nuchal thickness in
the midtrimester indicates reduced risk of Down syndrome
in pregnancies with abnormal triple-screen results. American
Journal of Obstetrics and Gynecology 1995;173(4):1106–0.
Bahado-Singh 1996 {published data only}
Bahado-Singh RO, Tan A, Deren O, Hunter D, Copel J,
Mahoney MJ. Risk of Down syndrome and any clinically
significant chromosome defect in pregnancies with
abnormal triple-screen and normal targeted ultrasonography
results. American Journal of Obstetrics and Gynecology 1996;
175(4 Pt 1):824–9.
Bahado-Singh 1999b {published data only}
Bahado-Singh RO, Oz AU, Flores D, Cermik D, Acuna
E, Mahoney MJ, et al. Nuchal thickness, urine ß-core
fragment level, and maternal age for down syndrome
screening. American Journal of Obstetrics and Gynecology
1999;180(2 Pt 1):491–5.
Bahado-Singh 2002 {published data only}
Bahado-Singh RO, Shahabi S, Karaca M, Mahoney MJ,
Cole L, Oz UA. The comprehensive midtrimester test:
high-sensitivity Down syndrome test. American Journal of
Obstetrics and Gynecology 2002;186(4):803–8.
Bahado-Singh 2003 {published data only}
Bahado-Singh RO, Cheng CC, Matta P, Small M, Mahoney
MJ. Combined serum and ultrasound screening for
detection of fetal aneuploidy. Seminars in Perinatology 2003;
27(2):145–51.
Bar-Hava 2001 {published data only}
Bar-Hava I, Yitzhak M, Krissi H, Shohat M, Shalev J,
Czitron B, et al. Triple-test screening in in vitro fertilization
pregnancies. Journal of Assisted Reproduction and Genetics
2001;18(4):226–9.
20Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Barkai 1996 {published data only}
Barkai G, Goldman B, Ries L, Chaki R, Dor J, Cuckle H.
Down’s syndrome screening marker levels following assisted
reproduction. Prenatal Diagnosis 1996;16(12):1111–4.
Barnabei 1995 {published data only}
Barnabei VM, Krantz DA, Macri JN, Larsen JW Jr.
Enhanced twin pregnancy detection within an open neural
tube defect and Down syndrome screening protocol using
free-ß hCG and AFP. Prenatal Diagnosis 1995;15(12):
1131–4.
Bartels 1988 {published data only}
Bartels I, Lindemann A. Maternal levels of pregnancy-
specific ß 1-glycoprotein (SP-1) are elevated in pregnancies
affected by Down’s syndrome. Human Genetics 1988;80(1):
46–8.
Bartels 1993 {published data only}
Bartels I, Hoppe-Sievert B, Bockel B, Herold S, Caesar J.
Adjustment formulae for maternal serum alpha-fetoprotein,
human chorionic gonadotropin, and unconjugated oestriol
to maternal weight and smoking. Prenatal Diagnosis 1993;
13(2):123–30.
Barth 1991 {published data only}
Barth WH Jr, Frigoletto FD Jr, Krauss CM, MacMillin
MD, Stryker JM, Benacerraf BR. Ultrasound detection of
fetal aneuploidy in women with elevated maternal serum
alpha-fetoprotein. Obstetrics & Gynecology 1991;77(6):
897–900.
Baviera 2004 {published data only}
Baviera G, Carbone C, Corrado F, Mastrantonio P. Placental
growth hormone in Down’s syndrome screening. Journal of
Maternal-Fetal & Neonatal Medicine 2004;16(4):241–3.
Bazzett 1998 {published data only}
Bazzett LB, Yaron Y, O’Brien JE, Critchfield G, Kramer RL,
Ayoub M, et al. Fetal gender impact on multiple-marker
screening results. American Journal of Medical Genetics
1998;76(5):369–71.
Bellver 2005 {published data only}
Bellver J, Lara C, Soares SR, Ramirez A, Pellicer A, Remohi
J, et al. First trimester biochemical screening for Down’s
syndrome in singleton pregnancies conceived by assisted
reproduction. Human Reproduction 2005;20(9):2623–7.
Benn 1995 {published data only}
Benn PA, Horne D, Briganti S, Greenstein RM. Prenatal
diagnosis of diverse chromosome abnormalities in a
population of women identified by triple-marker testing as
screen positive for Down syndrome. American Journal of
Obstetrics and Gynecology 1995;173(2):496–501.
Benn 1996 {published data only}
Benn PA, Horne D, Craffey A, Collins R, Ramsdell L,
Greenstein R. Maternal serum screening for birth defects:
results of a Connecticut regional program. Connecticut
Medicine 1996;60(6):323–7.
Benn 1997 {published data only}
Benn PA, Clive JM, Collins R. Medians for second-trimester
maternal serum alpha-fetoprotein, human chorionic
gonadotropin, and unconjugated estriol; differences
between races or ethnic groups. Clinical Chemistry 1997;43
(2):333–7.
Benn 1998 {published data only}
Benn PA. Preliminary evidence for associations between
second-trimester human chorionic gonadotropin and
unconjugated oestriol levels with pregnancy outcome in
Down syndrome pregnancies. Prenatal Diagnosis 1998;18
(4):319–24.
Benn 2001 {published data only}
Benn PA, Ying J, Beazoglou T, Egan JF. Estimates for the
sensitivity and false-positive rates for second trimester
serum screening for Down syndrome and trisomy 18 with
adjustment for cross-identification and double-positive
results. Prenatal Diagnosis 2001;21(1):46–51.
Benn 2002 {published data only}
Benn PA, Kaminsky LM, Ying J, Borgida AF, Egan JF.
Combined second-trimester biochemical and ultrasound
screening for Down syndrome. Obstetrics & Gynecology
2002;100(6):1168–76.
Benn 2003a {published data only}
Benn PA, Fang M, Egan JFX, Horne D, Collins R.
Incorporation of inhibin-A in second-trimester screening
for Down syndrome. Obstetrics and Gynecology 2003;101
(3):451–4.
Benn 2003b {published data only}
Benn P. Improved antenatal screening for Down’s syndrome.
Lancet 2003;361(9360):794–5.
Benn 2005a {published data only}
Benn P, Wright D, Cuckle H. Practical strategies in
contingent sequential screening for Down syndrome.
Prenatal Diagnosis 2005;25(8):645–52.
Benn 2005b {published data only}
Benn P, Donnenfeld AE. Sequential Down syndrome
screening: the importance of first and second trimester
test correlations when calculating risk. Journal of Genetic
Counseling 2005;14(6):409–13.
Berry 1995 {published data only}
Berry E, Aitken DA, Crossley JA, Macri JN, Connor JM.
Analysis of maternal serum alpha-fetoprotein and free ß
human chorionic gonadotrophin in the first trimester:
implications for Down’s syndrome screening. Prenatal
Diagnosis 1995;15(6):555–65.
Berry 1997 {published data only}
Berry E, Aitken DA, Crossley JA, Macri JN, Connor JM.
Screening for Down’s syndrome: changes in marker levels
and detection rates between first and second trimesters.
British Journal of Obstetrics and Gynaecology 1997;104(7):
811–7.
Bersinger 1994 {published data only}
Bersinger NA, Brizot ML, Johnson A, Snijders RJ, Abbott
J, Schneider H, et al. First trimester maternal serum
pregnancy-associated plasma protein A and pregnancy-
specific ß 1-glycoprotein in fetal trisomies. British Journal of
Obstetrics and Gynaecology 1994;101(11):970–4.
21Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bersinger 2000 {published data only}
Bersinger NA, Xin WZ. Glycosylation of pregnancy-
associated plasma protein a (PAPP-A) and pregnancy-
specific (ß)(1)-glycoprotein (SP1): relevance for fetal down
syndrome screening and for placental function studies.
Immuno-Analyse et Biologie Specialisee 2000;15(6):402–8.
Bersinger 2001 {published data only}
Bersinger NA, Chanson A, Crazzolara S, Hänggi W, Pescia
G, Scheier M, et al. Serum levels of placenta protein
markers: the relevance of differences between spontaneous
and after in vitro fertilization pregnancies for fetal trisomy
screening. Journal fur Fertilitat und Reproduktion 2001;11
(3):7–13.
Bersinger 2003 {published data only}
Bersinger NA, Noble P, Nicolaides KH. First-trimester
maternal serum PAPP-A, SP1 and M-CSF levels in normal
and trisomic twin pregnancies. Prenatal Diagnosis 2003;23
(2):157–62.
Bersinger 2004 {published data only}
Bersinger NA, Wunder D, Vanderlick F, Chanson A, Pescia
G, Janecek P, et al. Maternal serum levels of placental
proteins after in vitro fertilisation and their implications for
prenatal screening. Prenatal Diagnosis 2004;24(6):471–7.
Bersinger 2005 {published data only}
Bersinger NA, Vanderlick F, Birkhäuser MH, Janecek P,
Wunder D. First trimester serum concentrations of placental
proteins in singleton and multiple IVF pregnancies:
implications for Down syndrome screening. Immuno-
Analyse et Biologie Specialisee 2005;20(1):21–7.
Biggio 2004 {published data only}
Biggio JR Jr, Morris TC, Owen J, Stringer JSA. An
outcomes analysis of five prenatal screening strategies for
trisomy 21 in women younger than 35 years. American
Journal of Obstetrics and Gynecology 2004;190(3):721–9.
Bindra 2002 {published data only}
Bindra R, Heath V, Nicolaides KH. Screening for
chromosomal defects by fetal nuchal translucency at 11 to
14 weeks. Clinical Obstetrics and Gynecology 2002;45(3):
661–70.
Blundell 1999 {published data only}
Blundell G, Ashby JP, Martin C, Shearing CH, Langdale-
Brown B, Keeling J, et al. Clinical follow-up of high
mid-trimester maternal serum intact human chorionic
gonadotrophin concentrations in singleton pregnancies.
Prenatal Diagnosis 1999;19(3):219–23.
Boots 1989 {published data only}
Boots LR, Davis RO, Foster JM, Goldenberg RL. Maternal
serum alpha-fetoprotein prenatal screening for Down
syndrome. Alabama Medicine 1989;59(1):25–7.
Borruto 2002 {published data only}
Borruto F, Comparetto C, Acanfora L, Bertini G, Rubaltelli
FF. Role of ultrasound evaluation of nuchal translucency in
prenatal diagnosis. Clinical & Experimental Obstetrics &
Gynecology 2002;29(4):235–41.
Boue 1990 {published data only}
Boue A, Muller F. Screening for Down’s syndrome
with maternal serum human chorionic gonadotropin at
midtrimester. Current Opinion in Pediatrics 1990;2(6):
1157–60.
Bradley 1994 {published data only}
Bradley LA, Horwitz JA, Dowman AC, Ponting NR,
Peterson LM. Triple marker screening for fetal Down
syndrome. International Pediatrics 1994;9(3):168–74.
Braithwaite 1996 {published data only}
Braithwaite JM, Economides DL. Nuchal translucency and
screening for Down’s syndrome. Contemporary Reviews in
Obstetrics and Gynaecology 1996;8(2):75–81.
Brambati 1995 {published data only}
Brambati B, Cislaghi C, Tului L, Alberti E, Amidani
M, Colombo U, et al. First-trimester Down’s syndrome
screening using nuchal translucency: a prospective study in
women undergoing chorionic villus sampling. Ultrasound
in Obstetrics & Gynecology 1995;5(1):9–14.
Brambati 1996 {published data only}
Brambati B, Tului L, Alberti E. Sonography in the
first trimester screening of trisomy 21 and other fetal
aneuploidies. Early Pregnancy 1996;2(3):155–67.
Brizot 1995a {published data only}
Brizot ML, Bersinger NA, Xydias G, Snijders RJ, Nicolaides
KH. Maternal serum Schwangerschafts protein-1 (SP1) and
fetal chromosomal abnormalities at 10-13 weeks’ gestation.
Early Human Development. 1995;43(1):31–6.
Brizot 1995b {published data only}
Brizot ML, Kuhn P, Bersinger NA, Snijders RJ, Nicolaides
KH. First trimester maternal serum alpha-fetoprotein in
fetal trisomies. British Journal of Obstetrics and Gynaecology
1995;102(1):31–4.
Brizzi 1989b {published data only}
Brizzi L, Cariati E, Periti E, Nannini R, Torricelli F, Cappelli
G, et al. Evaluation of maternal serum alpha-fetoprotein
and ultrasound examination to screen fetal chromosomal
abnormalities. Journal of Nuclear Medicine & Allied Sciences
1989;33(3 Suppl):85–8.
Brock 1990 {published data only}
Brock DJ, Barron L, Holloway S, Liston WA, Hillier SG,
Seppala M. First-trimester maternal serum biochemical
indicators in Down syndrome. Prenatal Diagnosis 1990;10
(4):245–51.
Campogrande 2001 {published data only}
Campogrande M, Viora E, Errante G, Bastonero S,
Sciarrone A, Grassi Pirrone P, et al. Correlations between
first and second trimester markers for Down’s syndrome
screening. Journal of Medical Screening 2001;8(3):163–4.
Canick 1988 {published data only}
Canick JA, Knight GJ, Palomaki GE, Haddow JE,
Cuckle HS, Wald NJ. Low second trimester maternal
serum unconjugated oestriol in pregnancies with Down’s
syndrome. British Journal of Obstetrics and Gynaecology
1988;95(4):330–3.
22Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Canick 1995b {published data only}
Canick JA, Kellner LH, Saller DN Jr, Palomaki GE, Walker
RP, Osathanondh R. Second-trimester levels of maternal
urinary gonadotropin peptide in down syndrome pregnancy.
Prenatal Diagnosis 1995;15(8):739–44.
Canini 2002 {published data only}
Canini S, Prefumo F, Famularo L, Venturini PL, Palazzese
V, De Biasio P. Comparison of first trimester, second
trimester and integrated Down’s syndrome screening results
in unaffected pregnancies. Clinical Chemistry & Laboratory
Medicine 2002;40(6):600–3.
Cans 1998 {published data only}
Cans C, Amblard F, Devillard F, Pison H, Jalbert P, Jouk
PS. Population screening for aneuploidy using maternal age
and ultrasound. Prenatal Diagnosis 1998;18(7):683–92.
Carreras 1991 {published data only}
Carreras de Paz JJ, Silva Mendoza JM, Violante Diaz
M, Cerrillo Hinojosa M, Ahued Ahued JR. [Proposed
normal values for alpha fetoprotein in maternal serum for
the detection of neural tube closure defects and Down
syndrome. Preliminary study]. [Spanish]. Ginecologia y
Obstetricia de Mexico 1991;59:261–4.
Chen 1999 {published data only}
Chen FM. Integrated screening for Down’s syndrome.
Journal of Family Practice 1999;48(11):846–7.
Chen 2002 {published data only}
Chen M, Lam YH, Tang MH, Lee CP, Sin SY, Tang R, et al.
The effect of ethnic origin on nuchal translucency at 10-14
weeks of gestation. Prenatal Diagnosis 2002;22(7):576–8.
Chen 2004 {published data only}
Chen M, Lam YH, Lee CP, Tang MHY. Ultrasound
screening of fetal structural abnormalities at 12 to 14 weeks
in Hong Kong. Prenatal Diagnosis 2004;24(2):92–7.
Chen 2005 {published data only}
Chen CP, Lin CJ, Wang W. Impact of second-trimester
maternal serum screening on prenatal diagnosis of Down
syndrome and the use of amniocentesis in the Taiwanese
population. Taiwanese Journal of Obstetrics and Gynecology
2005;44(1):31–5.
Cheng 1993 {published data only}
Cheng EY, Luthy DA, Zebelman AM, Williams MA,
Lieppman RE, Hickok DE. A prospective evaluation of a
second-trimester screening test for fetal Down syndrome
using maternal serum alpha-fetoprotein, hCG, and
unconjugated estriol. Obstetrics & Gynecology 1993;81(1):
72–7.
Cheng 1999 {published data only}
Cheng PJ, Liu CM, Chang SD, Lin YT, Soong YK.
Elevated second-trimester maternal serum hCG in women
undergoing haemodialysis. Prenatal Diagnosis 1999;19(10):
955–8.
Cheng 2004a {published data only}
Cheng CC, Bahado-Singh RO, Chen SC, Tsai MS.
Pregnancy outcomes with increased nuchal translucency
after routine Down syndrome screening. International
Journal of Gynaecology & Obstetrics 2004;84(1):5–9.
Cheng 2004b {published data only}
Cheng PJ, Chu DC, Chueh HY, See LC, Chang HC, Weng
DR. Elevated maternal midtrimester serum free ß-human
chorionic gonadotropin levels in vegetarian pregnancies that
cause increased false-positive Down syndrome screening
results. American Journal of Obstetrics and Gynecology 2004;
190(2):442–7.
Chitayat 2002 {published data only}
Chitayat D, Farrell SA, Huang T, Meier C, Wyatt PR,
Summers AM. Double-positive maternal serum screening
results for down syndrome and open neural tube defects: an
indicator for fetal structural or chromosomal abnormalities
and adverse obstetric outcomes. American Journal of
Obstetrics and Gynecology 2002;187(3):758–63.
Christiansen 2002 {published data only}
Christiansen M, Hogdall EV, Larsen SO, Hogdall C. The
variation of risk estimates through pregnancy in second
trimester maternal serum screening for Down syndrome.
Prenatal Diagnosis 2002;22(5):385–7.
Christiansen 2007 {published data only}
Christiansen M, Sorensen TL, Norgaard-Pedersen B.
Human placental lactogen is a first-trimester maternal
serum marker of Down syndrome. Prenatal Diagnosis 2007;
27(1):1–5.
Chung 2000 {published data only}
Chung BL, Kim YP, Nam MH. The application of three-
dimensional ultrasound to nuchal translucency thickness
measurement at 10-14 weeks of gestation. Prenatal and
Neonatal Medicine 2000;5(1):17–21.
CNGOF 1996 {published data only}
Anon. Blood screening of Down’s syndrome (Trisomy 21)
and reimbursement of karyotype for women under 38.
Revue Francaise de Gynecologie et d’Obstetrique 1996;91(11):
575–7.
Cole 1996 {published data only}
Cole L, Isozaki T, Palomaki G, Canick J, Iles R, Kellner
L, et al. Detection of ß-core fragment in second trimester
Down’s syndrome pregnancies. [Review]. Early Human
Development 1996;47 Suppl:S47–S8.
Comas 2001 {published data only}
Comas C, Antolín E, Torrents M, Muñoz A, Figueras F,
Echevarría M, et al. Early screening for chromosomal
abnormalities: new strategies combining biochemical,
sonographic and doppler parameters. Prenatal and Neonatal
Medicine 2001;6(2):95–102.
Comas 2002a {published data only}
Comas C, Torrents M, Munoz A, Antolin E, Figueras F,
Echevarria M. Measurement of nuchal translucency as a
single strategy in trisomy 21 screening: should we use
any other marker?. Obstetrics & Gynecology 2002;100(4):
648–54.
23Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comas 2002b {published data only}
Comas C, Carrera JM. Early sonographic screening for
chromosomal abnormalities. Ultrasound Review of Obstetrics
and Gynecology 2002;2(2):88–91.
Comstock 2006 {published data only}
Comstock CH, Malone FD, Ball RH, Nyberg DA, Saade
GR, Berkowitz RL, et al. FASTER Research Consortium. Is
there a nuchal translucency millimeter measurement above
which there is no added benefit from first trimester serum
screening?. American Journal of Obstetrics and Gynecology.
2006;195(3):843–7.
Conde-Agudelo 1998 {published data only}
Conde-Agudelo A, Kafury-Goeta AC. Triple-marker test as
screening for down syndrome: a meta-analysis. Obstetrical
and Gynecological Survey 1998;53(6):369–76.
Crossley 1991 {published data only}
Crossley JA, Aitken DA, Connor JM. Prenatal screening for
chromosome abnormalities using maternal serum chorionic
gonadotrophin, alpha-fetoprotein, and age. Prenatal
Diagnosis 1991;11(2):83–101.
Crossley 1993 {published data only}
Crossley JA, Aitken DA, Connor JM. Second-trimester
unconjugated oestriol levels in maternal serum from
chromosomally abnormal pregnancies using an optimized
assay.[see comment]. Prenatal Diagnosis 1993;13(4):
271–80.
Crossley 1996 {published data only}
Crossley JA, Berry E, Aitken DA, Connor JM. Insulin-
dependent diabetes mellitus and prenatal screening results:
current experience from a regional screening programme.
Prenatal Diagnosis 1996;16(11):1039–42.
Crossley 2002a {published data only}
Crossley JA, Aitken DA, Waugh SM, Kelly T, Connor
JM. Maternal smoking: age distribution, levels of alpha-
fetoprotein and human chorionic gonadotrophin, and effect
on detection of Down syndrome pregnancies in second-
trimester screening. Prenatal Diagnosis 2002;22(3):247–55.
Cuckle 1984 {published data only}
Cuckle HS, Wald NJ, Lindenbaum RH. Maternal serum
alpha-fetoprotein measurement: a screening test for Down
syndrome. Lancet 1984;i(8383):926–9.
Cuckle 1987a {published data only}
Cuckle HS, Wald NJ, Thompson SG. Estimating a woman’s
risk of having a pregnancy associated with Down’s syndrome
using her age and serum alpha-fetoprotein level. British
Journal of Obstetrics and Gynaecology 1987;94(5):387–402.
Cuckle 1987b {published data only}
Cuckle HS, Nanchahal K, Wald NJ. Maternal serum alpha-
fetoprotein and ethnic origin. British Journal of Obstetrics
and Gynaecology 1987;94(11):1111–2.
Cuckle 1990 {published data only}
Cuckle HS, Wald NJ, Densem JW, Royston P, Knight GJ,
Haddow JE, et al. The effect of smoking in pregnancy
on maternal serum alpha-fetoprotein, unconjugated
oestriol, human chorionic gonadotrophin, progesterone and
dehydroepiandrosterone sulphate levels. British Journal of
Obstetrics and Gynaecology 1990;97(3):272–4.
Cuckle 1996 {published data only}
Cuckle HS, Holding S, Jones R, Groome NP, Wallace
EM. Combining Inhibin A with existing second-trimester
markers in maternal serum screening for Down’s syndrome.
Prenatal Diagnosis 1996;16(12):1095–100.
Cuckle 1999b {published data only}
Cuckle HS, Sehmi I, Jones R, Evans LW. Maternal serum
activin A and follistatin levels in pregnancies with Down
syndrome. Prenatal Diagnosis. 1999;19(6):513–6.
Cuckle 1999c {published data only}
Cuckle HS, Van Lith JM. Appropriate biochemical
parameters in first-trimester screening for Down
syndrome.[see comment]. Prenatal Diagnosis 1999;19(6):
505–12.
Cullen 1990 {published data only}
Cullen MT, Gabrielli S, Green JJ, Rizzo N, Mahoney
MJ, Salafia C, et al. Diagnosis and significance of cystic
hygroma in the first trimester. Prenatal Diagnosis 1990;10
(10):643–51.
Cusick 2004 {published data only}
Cusick W, Provenzano J, Sullivan CA, Gallousis FM, Rodis
JF. Fetal nasal bone length in euploid and aneuploid fetuses
between 11 and 20 weeks’ gestation: a prospective study.
Journal of Ultrasound in Medicine 2004;23(10):1327–33.
D’Ottavio 1997 {published data only}
D’Ottavio G, Meir YJ, Rustico MA, Pecile V, Fischer-
Tamaro L, Conoscenti G, et al. Screening for fetal anomalies
by ultrasound at 14 and 21 weeks. Ultrasound in Obstetrics
& Gynecology 1997;10(6):375–80.
Dancoine 2001 {published data only}
Dancoine F, Couplet G, Mainardi A, Sukno F, Jaumain P,
Nowak E, et al. Antenatal screening for Dawn’s syndrome
with serum markers: influence of maternal weight, smoking
habits and diabetes. Immuno-Analyse et Biologie Specialisee
2001;16(6):381–9.
De Biasio, 1999 {published data only}
De Biasio, Siccardi M, Volpe G, Famularo L, Santi F, Canini
S. First-trimester screening for down syndrome using nuchal
translucency measurement with free ß-hCG and PAPP-A
between 10 and 13 weeks of pregnancy - the combined test.
Prenatal Diagnosis 1999;19(4):360–3.
De Biasio, 2001 {published data only}
De Biasio, Ferrero S, Prefumo F, Canini S, Marchini
P, Bruzzone I, et al. Down’s syndrome: first trimester
approach. Italian Journal of Gynaecology and Obstetrics
2001;13(1):22–6.
De Biasio 2000 {published data only}
De Biasio P, Canini S, Prefumo F, Famularo L, Venturini
PL. Extent of correlation between first and second trimester
markers for Down’s syndrome screening. Journal of Medical
Screening 2000;7(3):163.
24Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
De Graaf 1991 {published data only}
De Graaf I, Cuckle HS, Pajkrt E, Leschot NJ, Bleker OP,
Van Lith JM. Co-variables in first trimester maternal serum
screening. Prenatal Diagnosis 1991;20(3):186–9.
De Graaf 1999 {published data only}
De Graaf I, Pajkrt E, Bilardo CM, Leschot NJ, Cuckle HS,
Van Lith JM. Early pregnancy screening for fetal aneuploidy
with serum markers and nuchal translucency. Prenatal
Diagnosis 1999;19(5):458–62.
DeVore 2001 {published data only}
DeVore GR, Romero R. Combined use of genetic
sonography and maternal serum triple-marker screening: an
effective method for increasing the detection of trisomy 21
in women younger than 35 years.[see comment]. Journal of
Ultrasound in Medicine. 2001;20(6):645–54.
Dickerson 1994 {published data only}
Dickerson VM. Multiple marker screening. Western Journal
of Medicine 1994;161(2):161.
Dimaio 1987 {published data only}
Dimaio MS, Baumgarten A, Greenstein RM, Saal HM,
Mahoney MJ. Screening for fetal Down’s syndrome in
pregnancy by measuring maternal serum alpha-fetoprotein
levels. New England Journal of Medicine 1987;317(6):
342–6.
Doran 1986 {published data only}
Doran TA, Cadesky K, Wong PY, Mastrogiacomo C,
Capello T. Maternal serum alpha-fetoprotein and fetal
autosomal trisomies. American Journal of Obstetrics and
Gynecology 1986;154(2):277–81.
Drugan 1996a {published data only}
Drugan A, Reichler A, Bronstein M, Johnson MP, Sokol RJ,
Evans MI. Abnormal biochemical serum screening versus
2nd-trimester ultrasound-detected minor anomalies as
predictors of aneuploidy in low-risk women. Fetal Diagnosis
and Therapy 1996;11(5):301–5.
Drugan 1996b {published data only}
Drugan A, O’Brien JE, Dvorin E, Krivchenia EL, Johnson
MP, Sokol RJ, et al. Multiple marker screening in multifetal
gestations: failure to predict adverse pregnancy outcomes.
Fetal Diagnosis and Therapy 1996;11(1):16–9.
Drysdale 2002 {published data only}
Drysdale K, Ridley D, Walker K, Higgins B, Dean T. First-
trimester pregnancy scanning as a screening tool for high-
risk and abnormal pregnancies in a district general hospital
setting. Journal of Obstetrics & Gynaecology 2002;22(2):
159–65.
Ebell 1999 {published data only}
Ebell M. Is the integrated test better for screening for
Down’s syndrome than the traditional triple test?. Evidence-
Based Practice 1999;2(11):4–5.
Economides 1998 {published data only}
Economides DL,Whitlow BJ, Kadir R, LazanakisM, Verdin
SM. First trimester sonographic detection of chromosomal
abnormalities in an unselected population. British Journal
of Obstetrics and Gynaecology 1998;105(1):58–62.
Erickson 2004 {published data only}
Erickson JA, Ashwood ER, Gin CA. Evaluation of a
dimeric inhibin-A assay for assessing fetal Down syndrome:
establishment, comparison, and monitoring of median
concentrations for normal pregnancies. Archives of Pathology
& Laboratory Medicine 2004;128(4):415–20.
Evans 1996 {published data only}
Evans MI, O’Brien JE, Dvorin E, Krivchenia EL, Drugan
A, Hume RF Jr, et al. Similarity of insulin-dependent
diabetics’ and non-insulin-dependent diabetics’ levels of ß-
hCG and unconjugated estriol with controls: no need to
adjust as with alpha-fetoprotein. Journal of the Society for
Gynecologic Investigation 1996;3(1):20–2.
Falcon 2005 {published data only}
Falcon O, Cavoretto P, Peralta CF, Csapo B, Nicolaides
KH. Fetal head-to-trunk volume ratio in chromosomally
abnormal fetuses at 11 + 0 to 13 + 6 weeks of gestation.
Ultrasound in Obstetrics & Gynecology 2005;26(7):755–60.
Falcon 2006 {published data only}
Falcon O, Faiola S, Huggon I, Allan L, Nicolaides KH. Fetal
tricuspid regurgitation at the 11 + 0 to 13 + 6-week scan:
association with chromosomal defects and reproducibility
of the method. Ultrasound in Obstetrics & Gynecology 2006;
27(6):609–12.
Ford 1998 {published data only}
Ford C, Moore AJ, Jordan PA, Bartlett WA, Wyldes MP,
Jones AF, et al. The value of screening for Down’s syndrome
in a socioeconomically deprived area with a high ethnic
population.[see comment]. British Journal of Obstetrics and
Gynaecology 1998;105(8):855–9.
Frishman 1997 {published data only}
Frishman GN, Canick JA, Hogan JW, Hackett RJ, Kellner
LH, Saller DN Jr. Serum triple-marker screening in in vitro
fertilization and naturally conceived pregnancies. Obstetrics
& Gynecology 1997;90(1):98–101.
Fukada 2000 {published data only}
Fukada Y, Takizawa M, Amemiya A, Yoda H, Kohno
K, Hoshi K. Detection of aneuploidy with fetal nuchal
translucency and maternal serum markers in Japanese
women. Acta Obstetricia et Gynecologica Scandinavica 2000;
79(12):1124–5.
Ghidini 1998 {published data only}
Ghidini A, Spong CY, Grier RE, Walker CN, Pezzullo JC.
Is maternal serum triple screening a better predictor of
Down syndrome in female than in male fetuses?. Prenatal
Diagnosis 1998;18(2):123–6.
Goldie 1995 {published data only}
Goldie DJ, Astley JP, Beaman JM, Bickley DA, Gunneberg
A, Jones SR. Screening for Down’s syndrome: the first two
years experience in Bristol. Journal of Medical Screening
1995;2(4):207–10.
Gonçalves 2004 {published data only}
Gonçalves LF, Espinoza J, Lee W, Schoen ML, Devers P,
Mazor M, et al. Phenotypic characteristics of absent and
hypoplastic nasal bones in fetuses with down syndrome:
25Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
description by 3-dimensional ultrasonography and clinical
significance. Journal of Ultrasound in Medicine 2004;23
(12):1619–27.
Goodburn 1994 {published data only}
Goodburn SF, Yates JR, Raggatt PR, Carr C, Ferguson-
Smith ME, Kershaw AJ, et al. Second-trimester maternal
serum screening using alpha-fetoprotein, human chorionic
gonadotrophin, and unconjugated oestriol: experience of
a regional programme. Prenatal Diagnosis 1994;14(5):
391–402.
Grozdea 2002 {published data only}
Grozdea J, De La Farge F, Bourrouillou G, Calot M,
Cambus JP, Valdiguie P. Maternal serum urea resistant
alkaline phosphatase in Down syndrome pregnancy. Early
Human Development 2002;67(1-2):55–9.
Gyselaers 2004a {published data only}
Gyselaers WJ, Vereecken AJ, Van Herck EJ, Straetmans DP,
Martens GE, De Jonge ET, et al. Screening for trisomy
21 in Flanders: a 10 years review of 40.490 pregnancies
screened by maternal serum. European Journal of Obstetrics,
Gynecology, & Reproductive Biology 2004;115(2):185–9.
Gyselaers 2004b {published data only}
Gyselaers WJA, Vereecken AJ, Van Herck, Straetmans DPL,
De Jonge, Ombelet WUA, et al. Single-step maternal
serum screening for trisomy 21 in the era of combined or
integrated screening. Gynecologic and Obstetric Investigation
2004;58(4):221–4.
Gyselaers 2006a {published data only}
Gyselaers WJ, Vereecken AJ, Van Herck EJ, Straetmans
DP, Ombelet WU, Nijhuis JG. Nuchal translucency
thickness measurements for fetal aneuploidy screening: Log
NT-MoM or Delta-NT, performer-specific medians and
ultrasound training. Journal of Medical Screening 2006;13
(1):4–7.
Gyselaers 2006b {published data only}
Gyselaers WJ, Roets ER, Van Holsbeke CD, Vereecken AJ,
Van Herck EJ, Straetmans DP, et al. Sequential triage in the
first trimester may enhance advanced ultrasound scanning
in population screening for trisomy 21. Ultrasound in
Obstetrics & Gynecology 2006;27(6):622–7.
Hackshaw 1995 {published data only}
Hackshaw AK, Densem J, Wald NJ. Repeat maternal serum
testing for Down’s syndrome screening using multiple
markers with special reference to free alpha and free ß-hCG.
Prenatal Diagnosis 1995;15(12):1125–30.
Hackshaw 2001 {published data only}
Hackshaw AK, Wald NJ. Repeat testing in antenatal
screening for Down syndrome using dimeric inhibin-A in
combination with other maternal serum markers. Prenatal
Diagnosis 2001;21(1):58–61.
Haddow 1992 {published data only}
Haddow JE, Palomaki GE, Knight GJ, Williams J,
Pulkkinen A, Canick J, et al. Prenatal screening for Down’s
syndrome with use of maternal serum markers. New
England Journal of Medicine 1992;327(9):588–93.
Hafner 1995 {published data only}
Hafner E, Schuchter K, Philipp K. Screening for
chromosomal abnormalities in an unselected population
by fetal nuchal translucency. Ultrasound in Obstetrics &
Gynecology 1995;6(5):330–3.
Hallahan 1998 {published data only}
Hallahan TW, Krantz DA, Tului L, Alberti E, Buchanan
PD, Orlandi F, et al. Comparison of urinary free ß (hCG)
and ß-core (hCG) in prenatal screening for chromosomal
abnormalities. Prenatal Diagnosis 1998;18(9):893–900.
Harrison 2006 {published data only}
Harrison G, Goldie D. Second-trimester Down’s syndrome
serum screening: double, triple or quadruple marker
testing?. Annals of Clinical Biochemistry 2006;43(1):67–72.
Harry 2006 {published data only}
Harry WG, Reed KL. Nuchal translucency and first-
trimester screening. Journal of the Society for Gynecologic
Investigation 2006;13(3):153–4.
Hayashi 1995 {published data only}
Hayashi M, Kozu H. Maternal urinary ß-core fragment of
hCG/creatinine ratios and fetal chromosomal abnormalities
in the second trimester of pregnancy. Prenatal Diagnosis
1995;15(1):11–6.
Hayashi 1996 {published data only}
Hayashi M, Kozu H, Takei H. Maternal urinary free ß-
subunit of human chorionic gonadotrophin: creatinine
ratios and fetal chromosomal abnormalities in the second
trimester of pregnancy. British Journal of Obstetrics and
Gynaecology 1996;103(6):577–80.
Heikkila 1997 {published data only}
Heikkila A, Ryynanen M, Kirkinen P, Saarikoski S. Results
and views of women in population-wide pregnancy
screening for trisomy 21 in east Finland. Fetal Diagnosis and
Therapy 1997;12(2):93–6.
Heinonen 1996 {published data only}
Heinonen S, Ryynanen M, Kirkinen P, Hippelainen M,
Saarikoski S. Effect of in vitro fertilization on human
chorionic gonadotropin serum concentrations and Down’s
syndrome screening. Fertility and Sterility 1996;66(3):
398–403.
Herman 2000 {published data only}
Herman A, Weinraub Z, Dreazen E, Arieli S, Rozansky
S, Bukovsky I, et al. Combined first trimester nuchal
translucency and second trimester biochemical screening
tests among normal pregnancies. Prenatal Diagnosis 2000;
20(10):781–4.
Herman 2003 {published data only}
Herman A, Dreazen E, Tovbin Y, Reish O, Bukovsky I,
Maymon R. Correlation and overlapping between nuchal
translucency and triple test among Down syndrome-
affected pregnancies. Fetal Diagnosis and Therapy 2003;18
(3):196–200.
26Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Herrou 1992 {published data only}
Herrou M, Leporrier N, Leymarie P. Screening for fetal
Down syndrome with maternal serum hCG and oestriol: a
prospective study. Prenatal Diagnosis 1992;12(11):887–92.
Hershey 1985 {published data only}
Hershey DW, Crandall BF, Schroth PS. Maternal serum
alpha-fetoprotein screening of fetal trisomies. American
Journal of Obstetrics and Gynecology 1985;153(2):224–5.
Hershey 1986 {published data only}
Hershey DW, Crandall BF, Perdue S. Combining maternal
age and serum alpha-fetoprotein to predict the risk of Down
syndrome. Obstetrics & Gynecology 1986;68(2):177–80.
Hewitt 1993 {published data only}
Hewitt B. Nuchal translucency in the first trimester.
Australian & New Zealand Journal of Obstetrics &
Gynaecology 1993;33(4):389–91.
Hogdall 1992 {published data only}
Hogdall CK, Hogdall EV, Arends J, Norgaard-Pedersen
B, Smidt-Jensen S, Larsen SO. CA-125 as a maternal
serum marker for Down’s syndrome in the first and second
trimesters. Prenatal Diagnosis 1992;12(3):223–7.
Hong Kong Practitioner 2001 {published data only}
Anon. Screening tests in pregnancy. Hong Kong Practitioner
2001;23(10):461–5.
Howe 2000 {published data only}
Howe DT, Gornall R, Wellesley D, Boyle T, Barber J. Six
year survey of screening for Down’s syndrome by maternal
age and mid-trimester ultrasound scans. BMJ 2000;320
(7235):606–10.
Hsiao 1991 {published data only}
Hsiao KJ, Lee SY, Chuang HC. [Antenatal screening of
maternal alpha-fetoprotein with dried-blood spot samples
on filter paper]. [Chinese]. Journal of the Formosan Medical
Association 1991;90(6):598–604.
Hsieh 1999 {published data only}
Hsieh TT, Hsu JJ, Lo LM, Liou JD, Soong YK. Maternal
urine alpha-fetoprotein concentrations between 14 and 21
weeks of gestation. Changgeng Yi Xue Za Zhi 1999;22(2):
234–9.
Hsu 1997b {published data only}
Hsu JJ, Hsieh TT, Soong YK. Influence of maternal age and
weight on second-trimester serum alpha-fetoprotein, total
and free ß human chorionic gonadotropin levels. Changgeng
Yi Xue Za Zhi. 1997;20(3):181–6.
Hsu 1998a {published data only}
Hsu JJ, Hsieh TT, Hung TH, Chiang CH. Midtrimester
maternal serum free ß-human chorionic gonadotropin
levels: normal reference values for Taiwanese women.
Changgeng Yi Xue Za Zhi 1998;21(3):277–82.
Hsu 1999b {published data only}
Hsu JJ, Hsieh TT, Hung TH, Chen KC, Soong YK. Urine
free ß-human chorionic gonadotropin levels between 14 and
21 weeks of gestation in Taiwanese pregnancies. Changgeng
Yi Xue Za Zhi 1999;22(1):11–6.
Huang 2003 {published data only}
Huang T, Summers AM, Wyatt PR, Meier C, Cote GB.
Maternal serum marker medians in Aboriginal Canadian
women. Prenatal Diagnosis 2003;23(2):98–100.
Huggon 2004 {published data only}
Huggon IC, Turan O, Allan LD. Doppler assessment of
cardiac function at 11-14 weeks’ gestation in fetuses with
normal and increased nuchal translucency. Ultrasound in
Obstetrics & Gynecology 2004;24(4):390–8.
Hui 2003 {published data only}
Hui PW, Tang MH, Lam YH, Ng EH, Yeung WS, Ho
PC. Maternal serum hCG and alpha-fetoprotein levels in
pregnancies conceived after IVF or ICSI with fresh and
frozen-thawed embryos. Human Reproduction 2003;18(3):
572–5.
Hui 2005 {published data only}
Hui PW, Tang MH, Lam YH, Yeung WS, Ng EH, Ho
PC. Nuchal translucency in pregnancies conceived after
assisted reproduction technology. Ultrasound in Obstetrics
& Gynecology 2005;25(3):234–8.
Hultén 2004 {published data only}
Hultén M. Combined serum and nuchal translucency
screening in the first trimester achieves 85% to 90%
detection rate for Down and Edward syndromes. Evidence-
Based Healthcare 2004;8(2):82–4.
Hung 2003 {published data only}
Hung JH, Fu CY, Yuan CC, Chen CL, Yang ML, Shu
LP, et al. Nuchal translucence incorporated into a one-
stage multifactorial screening model for Down syndrome
prediction at second-trimester pregnancy. Ultrasound in
Medicine & Biology 2003;29(12):1667–74.
Hurley 1993 {published data only}
Hurley PA, Ward RH, Teisner B, Iles RK, Lucas M,
Grudzinskas JG. Serum PAPP-A measurements in first-
trimester screening for Down syndrome. Prenatal Diagnosis
1993;13(10):903–8.
Huttly 2004 {published data only}
Huttly W, Rudnicka A, Wald NJ. Second-trimester prenatal
screening markers for Down syndrome in women with
insulin-dependent diabetes mellitus. Prenatal Diagnosis
2004;24(10):804–7.
Hwa 2004 {published data only}
Hwa HL, Yen MF, Hsieh FJ, Ko TM, Chen TH. Evaluation
of second trimester maternal serum screening for Down’s
Syndrome using the Spiegelhalter-Knill-Jones (S-KJ)
approach. Journal of Perinatal Medicine 2004;32(5):
407–12.
Iles 1996 {published data only}
Iles RK. Urinary analysis for Down’s syndrome: Is the
measurement of urinary ß-core the future of biochemical
screening for Down’s syndrome. Early Human Development
1996;47(Suppl.):S41–S45.
Ind 1994 {published data only}
Ind TEJ, Iles RK, Cuckle HS, Chard T. Second
trimester maternal serum placental alkaline phosphatase
27Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
concentrations in Down’s syndrome. Journal of Obstetrics
and Gynaecology 1994;14(5):305–8.
Jean-Pierre 2005 {published data only}
Jean-Pierre C. Fetal nasal bone: review of first trimester
findings. Ultrasound Review of Obstetrics and Gynecology
2005;5(2):102–4.
Johnson 1991 {published data only}
Johnson A, Cowchock FS, Darby M, Wapner R, Jackson
LG. First-trimester maternal serum alpha-fetoprotein and
chorionic gonadotropin in aneuploid pregnancies. Prenatal
Diagnosis 1991;11(7):443–50.
Johnson 1993 {published data only}
Johnson MP, Johnson A, Holzgreve W, Isada NB, Wapner
RJ, Treadwell MC, et al. First-trimester simple hygroma:
cause and outcome. American Journal of Obstetrics and
Gynecology 1993;168(1):156–61.
Jorgensen 1999 {published data only}
Jorgensen FS, Valentin L, Salvesen KA, Jorgensen C,
Jensen FR, Bang J, et al. MULTISCAN--a Scandinavian
multicenter second trimester obstetric ultrasound and
serum screening study. Acta Obstetricia et Gynecologica
Scandinavica 1999;78(6):501–10.
Josefsson 1998 {published data only}
Josefsson A, Molander E, Selbing A. Nuchal translucency as
a screening test for chromosomal abnormalities in a routine
first trimester ultrasound examination. Acta Obstetricia et
Gynecologica Scandinavica 1998;77(5):497–9.
Jou 2001 {published data only}
Jou HJ, Shih JC, Wu SC, Li TC, Tzeng CY, Hsieh FJ.
First-trimester Down’s syndrome screening by fetal nuchal
translucency measurement in Taiwan. Journal of the
Formosan Medical Association 2001;100(4):257–61.
Kagan 2006 {published data only}
Kagan KO, Avgidou K, Molina FS, Gajewska K, Nicolaides
KH. Relation between increased fetal nuchal translucency
thickness and chromosomal defects.[see comment].
Obstetrics & Gynecology 2006;107(1):6–10.
Kautzmann 1995 {published data only}
Kautzmann M, Solis RL, Luberta A, Fernandez JL, Navarro
J, Rodriguez L, et al. Study of the efficiency of screening for
trisomy 21 based on maternal serum levels of AFP and hCG
combined with maternal age. Journal of Clinical Ligand
Assay 1995;18(3):181–5.
Keith 1992 {published data only}
Keith D. Maternal serum screening for neural tube defects
and Down syndrome. Clinical Laboratory Science 1992;5
(5):274–6.
Kelekci 2004 {published data only}
Kelekci S, Yazicioglu HF, Oguz S, Inan I, Yilmaz B, Sonmez
S. Nasal bone measurement during the 1st trimester: is it
useful?. Gynecologic & Obstetric Investigation 2004;58(2):
91–5.
Kellner 1995a {published data only}
Kellner LH, Weiner Z, Weiss RR, Neuer M, Martin GM,
Mueenuddin M, et al. Triple marker (alpha-fetoprotein,
unconjugated estriol, human chorionic gonadotropin)
versus alpha-fetoprotein plus free-ß subunit in second-
trimester maternal serum screening for fetal Down
syndrome: a prospective comparison study.[see comment].
American Journal of Obstetrics and Gynecology 1995;173(4):
1306–9.
Kellner 1995b {published data only}
Kellner LH, Weiss RR, Weiner Z, Neuer M, Martin GM,
Schulman H, et al. The advantages of using triple-marker
screening for chromosomal abnormalities. American Journal
of Obstetrics and Gynecology 1995;172(3):831–6.
Kellner 1997 {published data only}
Kellner LH, Canick JA, Palomaki GE, Neveux LM, Saller
DN Jr, Walker RP, et al. Levels of urinary ß-core fragment,
total oestriol, and the ratio of the two in second-trimester
screening for Down syndrome. Prenatal Diagnosis 1997;17
(12):1135–41.
Knight 1990 {published data only}
Knight GJ, Palomaki GE. Maternal serum alpha fetoprotein
screening for fetal down syndrome. Journal of Clinical
Immunoassay 1990;13(1):23–9.
Knight 2001 {published data only}
Knight GJ, Palomaki GE, Neveux LM, Haddow JE,
Lambert-Messerlian GM. Clinical validation of a new
dimeric inhibin-A assay suitable for second trimester Down’s
syndrome screening. Journal of Medical Screening 2001;8
(1):2–7.
Knight 2005 {published data only}
Knight GJ, Palomaki GE, Neveux LM, Smith DE, Kloza
EM, Pulkkinen A, et al. Integrated serum screening for
Down syndrome in primary obstetric practice. Prenatal
Diagnosis 2005;25(12):1162–7.
Koos 2006 {published data only}
Koos BJ. First-trimester screening: lessons from clinical
trials and implementation. Current Opinion in Obstetrics
and Gynecology 2006;18(2):152–5.
Kornman 1996 {published data only}
Kornman LH, Morssink LP, Beekhuis JR, de Wolf BT,
Heringa MP, Mantingh A. Nuchal translucency cannot be
used as a screening test for chromosomal abnormalities in
the first trimester of pregnancy in a routine ultrasound
practice.[see comment]. Prenatal Diagnosis 1996;16(9):
797–805.
Kornman 1997 {published data only}
Kornman LH, Morssink LP, Wortelboer MJ, Beekhuis JR,
de Wolf BT, Pratt JJ, et al. Maternal urinary ß-core hCG in
chromosomally abnormal pregnancies in the first trimester.
Prenatal Diagnosis 1997;17(2):135–9.
Kramer 1998 {published data only}
Kramer RL, Yaron Y, O’Brien JE, Critchfield G, Ayoub
M, Johnson MP, et al. Effect of adjustment of maternal
serum alpha-fetoprotein levels in insulin-dependent diabetes
mellitus. American Journal of Medical Genetics 1998;75(2):
176–8.
28Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Krantz 1996 {published data only}
Krantz DA, Larsen JW, Buchanan PD, Macri JN. First-
trimester Down syndrome screening: free ß-human
chorionic gonadotropin and pregnancy-associated plasma
protein A. American Journal of Obstetrics and Gynecology
1996;174(2):612–6.
Krantz 2005 {published data only}
Krantz DA, Hallahan TW, Macri VJ, Macri JN. Maternal
weight and ethnic adjustment within a first-trimester Down
syndrome and trisomy 18 screening program. Prenatal
Diagnosis 2005;25(8):635–40.
Kulch 1993 {published data only}
Kulch P, Keener S, Matsumoto M, Crandall BF.
Racial differences in maternal serum human chorionic
gonadotropin and unconjugated oestriol levels. Prenatal
Diagnosis 1993;13(3):191–5.
Lai 1998 {published data only}
Lai FM, Yeo GS. Down syndrome screening in Singapore-
-the effectiveness of a second trimester serum screening
policy modelled on 29,360 pregnancies in KK Women’s and
Children’s Hospital. Singapore Medical Journal 1998;39(2):
69–75.
Lai 2003 {published data only}
Lai TH, Chen SC, Tsai MS, Lee FK, Wei CF. First-trimester
screening for Down syndrome in singleton pregnancies
achieved by intrauterine insemination. Journal of Assisted
Reproduction and Genetics 2003;20(8):327–31.
Laigaard 2006a {published data only}
Laigaard J, Cuckle H, Wewer UM, Christiansen M.
Maternal serum ADAM12 levels in Down and Edwards’
syndrome pregnancies at 9-12 weeks’ gestation. Prenatal
Diagnosis 2006;26(8):689–91.
Laigaard 2006b {published data only}
Laigaard J, Spencer K, Christiansen M, Cowans NJ, Larsen
SO, Pedersen BN, et al. ADAM 12 as a first-trimester
maternal serum marker in screening for Down syndrome.
Prenatal Diagnosis 2006;26(10):973–9.
Lam 1997 {published data only}
Lam YH, Tang MH, Tang LC, Lee CP, Ho PK. Second-
trimester maternal urinary gonadotrophin peptide screening
for fetal Down syndrome in Asian women. Prenatal
Diagnosis 1997;17(12):1101–6.
Lam 1998 {published data only}
Lam YH, Ghosh A, Tang MH, Tang LC, Lee CP, Sin SY,
et al. Second-trimester maternal serum alpha-fetoprotein
and human chorionic gonadotrophin screening for Down’s
syndrome in Hong Kong. Prenatal Diagnosis 1998;18(6):
585–9.
Lam 1999a {published data only}
Lam YH, Yeung WS, Tang MH, Ng EH, So WW,
Ho PC. Maternal serum alpha-fetoprotein and human
chorionic gonadotrophin in pregnancies conceived after
intracytoplasmic sperm injection and conventional in-vitro
fertilization. Human Reproduction 1999;14(8):2120–3.
Lam 1999b {published data only}
Lam YH, Tang MH. Second-trimester maternal serum
inhibin-A screening for fetal Down syndrome in Asian
women. Prenatal Diagnosis 1999;19(5):463–7.
Lam 2000 {published data only}
Lam YH, Tang MH, Lee CP, Sin SY, Tang R, Wong HS,
et al. Acceptability of serum screening as an alternative to
cytogenetic diagnosis of down syndrome among women 35
years or older in Hong Kong. Prenatal Diagnosis 2000;20
(6):487–90.
Lam 2001 {published data only}
Lam YH, Tang MH. The effect of fetal gender on second-
trimester maternal serum inhibin-A concentration. Prenatal
Diagnosis 2001;21(8):662–4.
Lambert-Messerlian 1996 {published data only}
Lambert-Messerlian GM, Canick JA, Palomaki GE,
Schneyer AL. Second trimester levels of maternal serum
inhibin A, total inhibin, alpha inhibin precursor, and activin
in Down’s syndrome pregnancy. Journal of Medical Screening
1996;3(2):58–62.
Lambert-Messerlian 1998 {published data only}
Lambert-Messerlian, Luisi S, Florio P, Mazza V, Canick
JA, Petraglia F. Second trimester levels of maternal serum
total activin A and placental inhibin/activin alpha and ßA
subunit messenger ribonucleic acids in Down syndrome
pregnancy. European Journal of Endocrinology 1998;138(4):
425–9.
Lehavi 2005 {published data only}
Lehavi O, Aizenstein O, Evans MI, Yaron Y. 2nd-trimester
maternal serum human chorionic gonadotropin and alpha-
fetoprotein levels in male and female fetuses with Down
syndrome. Fetal Diagnosis and Therapy 2005;20(3):235–8.
Leung 2006 {published data only}
Leung TY, Spencer K, Leung TN, Fung TY, Lau TK.
Higher median levels of free ß-hCG and PAPP-A in the
first trimester of pregnancy in a Chinese ethnic group.
Implication for first trimester combined screening for
Down’s syndrome in the Chinese population. Fetal
Diagnosis and Therapy 2006;21(1):140–3.
Leymarie 1993 {published data only}
Leymarie P, Leporrier N. Maternal serum markers and
prenatal screening for Down syndrome. Archives Francaises
de Pediatrie 1993;50(5):455–7.
Li 1998 {published data only}
Li G, Huang X. [Clinical uses of maternal serum markers in
the prenatal diagnosis] [Chinese]. Chung-Hua Fu Chan Ko
Tsa Chih 1998;33(4):252–4.
Li 1999 {published data only}
Li W, Zhou Y. [Measurement of pregnancy-associated
plasma protein A in maternal peripheral blood and Down
syndrome] [Chinese]. Chung-Hua Fu Chan Ko Tsa Chih
1999;34(10):631–3.
Liao 1997 {published data only}
Liao S, Wang Y, Ye G. [AFP, uE3, ß-hCG levels applied for
prenatal diagnosis of Down’s syndrome]. [Chinese]. Chung-
Hua Fu Chan Ko Tsa Chih 1997;32(11):655–8.
29Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Liao 2001 {published data only}
Liao AW, Heath V, Kametas N, Spencer K, Nicolaides
KH. First-trimester screening for trisomy 21 in singleton
pregnancies achieved by assisted reproduction. Human
Reproduction 2001;16(7):1501–4.
Lim 2002 {published data only}
Lim KI, Pugash D, Dansereau J, Wilson RD. Nuchal index:
a gestational age independent ultrasound marker for the
detection of Down syndrome. Prenatal Diagnosis 2002;22
(13):1233–7.
Lippman 1987 {published data only}
Lippman A, Evans JA. Screening for maternal serum alpha-
fetoprotein: what about the low side?. Canadian Medical
Association Journal 1987;136(8):801–4.
Liu 2003 {published data only}
Liu JT, Hao N, Sun NH, Wang FY, Xu YH, Gai MY,
et al. [Screening by maternal serum markers for Down’s
syndrome]. [Chinese]. Chung-Kuo i Hsueh Ko Hsueh Yuan
Hsueh Pao Acta Academiae Medicinae Sinicae 2003;25(2):
156–9.
Lustig 1988 {published data only}
Lustig L, Clarke S, Cunningham G, Schonberg R,
Tompkinson G. California’s experience with low MS-AFP
results. American Journal of Medical Genetics 1988;31(1):
211–22.
MacDonald 1991 {published data only}
MacDonald ML, Wagner RM, Slotnick RN. Sensitivity and
specificity of screening for Down syndrome with alpha-
fetoprotein, hCG, unconjugated estriol, and maternal
age.[see comment]. Obstetrics & Gynecology 1991;77(1):
63–8.
Macintosh 1994 {published data only}
Macintosh MCM, Iles R, Teisner B, Sharma K, Chard T,
Grudzinskas J, et al. Maternal serum human chorionic
gonadotrophin and pregnancy-associated plasma protein A,
markers for fetal Down syndrome at 8-14 weeks. Prenatal
Diagnosis 1994;14(3):203–8.
Macintosh 1997 {published data only}
Macintosh MCM, Nicolaides KH, Noble P, Chard T, Gunn
L, Iles R. Urinary ß-core hCG: screening for aneuploidies in
early pregnancy (11-14 weeks’ gestation). Prenatal Diagnosis
1997;17(5):401–5.
Macri 1994 {published data only}
Macri JN, Kasturi RV, Krantz DA, Cook EJ, Moore ND,
Young JA, et al. Maternal serum Down syndrome screening:
free ß-protein is a more effective marker than human
chorionic gonadotropin.[see comment]. American Journal
of Obstetrics and Gynecology 1990;163(4):1248–53.
∗ Macri JN, Spencer K, Garver K, Buchanan PD, Say
B, Carpenter NJ, et al. Maternal serum free ß hCG
screening: results of studies including 480 cases of Down
syndrome.[see comment]. Prenatal Diagnosis 1994;14(2):
97–103.
Spencer K, Macri JN. Early detection of Down’s syndrome
using free ß human choriogonadotropin. Annals of Clinical
Biochemistry 1992;19(3):349–50.
Macri 1996 {published data only}
Macri JN, Anderson RW, Krantz DA, Larsen JW, Buchanan
PD. Prenatal maternal dried blood screening with alpha-
fetoprotein and free ß-human chorionic gonadotropin for
open neural tube defect and Down syndrome. American
Journal of Obstetrics and Gynecology 1996;174(2):566–72.
Malone 1998 {published data only}
Malone FD, D’Alton ME. Ultrasound clinics. Fetal nuchal
fold translucency screening. Contemporary OB/GYN 1998;
43(3):117–8.
Malone 2003 {published data only}
Malone FD, D’Alton ME. First-trimester sonographic
screening for Down syndrome. Obstetrics and Gynecology
2003;102(5):1066–79.
Mangione 2001 {published data only}
Mangione R, Guyon F, Taine L, Wen ZQ, Roux D,
Vergnaud A, et al. Pregnancy outcome and prognosis in
fetuses with increased first-trimester nuchal translucency.
Fetal Diagnosis and Therapy 2001;16(6):360–3.
Maymon 2001a {published data only}
Maymon R, Shulman A. Comparison of triple serum
screening and pregnancy outcome in oocyte donation versus
IVF pregnancies. Human Reproduction 2001;16(4):691–5.
Maymon 2001b {published data only}
Maymon R, Dreazen E, Buckovsky I, Weinraub Z, Herman
A. Does a ’notched’ nuchal translucency indicate Down
syndrome fetuses or other adverse pregnancy outcome?.
Prenatal Diagnosis 2001;21(5):403–8.
Maymon 2002 {published data only}
Maymon R, Shulman A. Serial first- and second-trimester
Down’s syndrome screening tests among IVF-versus
naturally-conceived singletons. Human Reproduction 2002;
17(4):1081–5.
Maymon 2004 {published data only}
Maymon R, Shulman A. Integrated first- and second-
trimester Down syndrome screening test among unaffected
IVF pregnancies. Prenatal Diagnosis 2004;24(2):125–9.
Maymon 2005 {published data only}
Maymon R, Cuckle H, Jones R, Reish O, Sharony R,
Herman A. Predicting the result of additional second-
trimester markers from a woman’s first-trimester marker
profile: a new concept in Down syndrome screening.
Prenatal Diagnosis 2005;25(12):1102–6.
McDuffie 1996 {published data only}
McDuffie RS Jr, Haverkamp AD, Stark CF, Haverkamp
C, Barth CK. Prenatal screening using maternal serum
alpha-fetoprotein, human chorionic gonadotropin, and
unconjugated estriol: two-year experience in a health
maintenance organization. Journal of Maternal-Fetal
Medicine 1996;5(2):70–3.
Meier 2002 {published data only}
Meier C, Huang T, Wyatt PR, Summers AM. Accuracy of
expected risk of Down syndrome using the second-trimester
triple test. Clinical Chemistry 2002;48(4):653–5.
30Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Merkatz 1984 {published data only}
Merkatz IR, Nitowsky HM, Macri JN, Johnson WE. An
association between low maternal serum alpha-fetoprotein
and fetal chromosomal abnormalities. American Journal of
Obstetrics and Gynecology 1984;148(7):886–94.
Merz 2005 {published data only}
Merz E. The fetal nasal bone in the first trimester - precise
assessment using 3D sonography. Ultraschall in der Medizin
2005;26(5):365–6.
Metzenbauer 2001 {published data only}
Metzenbauer M, Hafner E, Hoefinger D, Schuchter K,
Stangl G, Ogris E, et al. Three-dimensional ultrasound
measurement of the placental volume in early pregnancy:
method and correlation with biochemical placenta
parameters. Placenta 2001;22(6):602–5.
Metzenbauer 2002 {published data only}
Metzenbauer M, Hafner E, Schuchter K, Philipp K. First-
trimester placental volume as a marker for chromosomal
anomalies: preliminary results from an unselected
population. Ultrasound in Obstetrics & Gynecology 2002;19
(3):240–2.
Mikic 1999 {published data only}
Mikic TS, Johnson P. Second trimester maternal serum ß
human chorionic gonadotrophin and pregnancy outcome.
British Journal of Obstetrics and Gynaecology 1999;106(6):
598–600.
Miller 1991 {published data only}
Miller CH, O’Brien TJ, Chatelain S, Butler BB, Quirk JG.
Alteration in age-specific risks for chromosomal trisomy by
maternal serum alpha-fetoprotein and human chorionic
gonadotropin screening. Prenatal Diagnosis 1991;11(3):
153–8.
Milunsky 1989 {published data only}
Milunsky A, Jick SS, Bruell CL, Maclaughlin DS, Tsung Y-
K, Jick H, et al. Predictive values relative risks and overall
benefits of high and low maternal serum alpha fetoprotein
screening in singleton pregnancies - new epidemiological
data. American Journal of Obstetrics and Gynecology 1989;
161(2):291–7.
Milunsky 1996 {published data only}
Milunsky A, Nebiolo L. Maternal serum triple analyte
screening and adverse pregnancy outcome. Fetal Diagnosis
and Therapy 1996;11(4):249–53.
Minobe 2002 {published data only}
Minobe S. [A study on the screening of prenatal trisomy 21
using the fucosylated alpha-fetoprotein ratio measured by
a liquid-phase binding assay]. [Japanese]. Hokkaido Igaku
Zasshi - Hokkaido Journal of Medical Science 2002;77(6):
527–32.
Miyamura 1999 {published data only}
Miyamura T, Saito N, Touno A, Nagata S, Hidaki T,
Ishimaru T, et al. Multicenter study for maternal serum
triple markers to establish Japanese standards: maternal
serum marker study group, Japan Association of Prenatal
Diagnostics. Acta Obstetrica et Gynaecologica Japonica 1999;
51(11):1042–8.
Moghadam 1998 {published data only}
Moghadam S, Engel W, Bougoussa M, Hennen G, Igout
A, Sancken U. Maternal serum placental growth hormone
and insulinlike growth factor binding proteins 1 and 3
in pregnancies affected by fetal aneuploidy and other
abnormalities: implications for prenatal diagnosis of trisomy
21. Fetal Diagnosis and Therapy 1998;13(5):291–7.
Monni 2000 {published data only}
Monni G, Zoppi MA, Ibba RM, Putzolu M, Floris M.
Nuchal translucency in multiple pregnancies. Croatian
Medical Journal 2000;41(3):266–9.
Monni 2002 {published data only}
Monni G, Zoppi MA. New ultrasonographic markers of
aneuploidies: nasal bones. Ultrasound Review of Obstetrics
and Gynecology 2002;2(4):229–34.
Mooney 1994 {published data only}
Mooney RA, Peterson J, French CA, Saller DN Jr, Arvan
DA. Effectiveness of combining maternal serum alpha-
fetoprotein and hCG in a second-trimester screening
program for Down syndrome. Obstetrics and Gynecology
1994;84(2):298–303.
Muller 1994 {published data only}
Muller F, Bussieres L, Pelissier MC, Oury JF, Boue C, Uzan
S, et al. Do racial differences exist in second-trimester
maternal hCG levels? A study of 23,369 women. Prenatal
Diagnosis 1994;14(7):633–6.
Muller 1996b {published data only}
Muller F, Dommergues M, Bussieres L, Aegerter P, Le Fiblec
B, Uzan S, et al. Prenatal screening for Down syndrome:
should first trimester ultrasound replace maternal serum
screening?. Early Human Development 1996;47 Suppl:
S37–S39.
Muller 1999 {published data only}
Muller F, Ngo S, Rebiffe M, Oury JF, Uzan S, Satge D.
Maternal serum s100b protein is ineffective for Down
syndrome screening. Prenatal Diagnosis 1999;19(11):1086.
Muller 2002a {published data only}
Muller F, Dreux S, Oury JF, Luton D, Uzan S, Uzan M,
et al. Down syndrome maternal serum marker screening
after 18 weeks’ gestation. Prenatal Diagnosis 2002;22(11):
1001–4.
Muller 2002b {published data only}
Muller F, Forestier F, Dingeon B, for the ABA Study
Group. Second trimester trisomy 21 maternal serum
marker screening. Results of a countrywide study of 854,
902 women. Prenatal Diagnosis 2002;22(10):925–9.
Muller 2003 {published data only}
Muller F, Dreux S, Lemeur A, Sault C, Desgres J, Bernard
MA, et al. Medically assisted reproduction and second-
trimester maternal serum marker screening for Down
syndrome. Prenatal Diagnosis 2003;23(13):1073–6.
Murta 2002 {published data only}
Murta CG, Moron AF, Avila MA, Weiner CP. Application
of ductus venosus Doppler velocimetry for the detection of
31Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
fetal aneuploidy in the first trimester of pregnancy. Fetal
Diagnosis and Therapy 2002;17(5):308–14.
Musone 2000 {published data only}
Musone R, Bonafiglia R, Menditto A, Paccone M, Cassese
E, Russo G, et al. Fetuses with cystic hygroma. A
retrospective study. Panminerva Medica 2000;42(1):39–43.
Musto 1986 {published data only}
Musto JD, Pizzolante JM, Chesarone VP, Sassi AM, Sane
R. Alpha-fetoprotein: an enhanced-sensitivity assay for
neural tube defect and Down syndrome evaluation. Clinical
Chemistry 1986;32(7):1412.
Myrick 1990 {published data only}
Myrick JE, Caudill SP, Hubert IL, Robinson MK, Adams
MJ Jr, Pueschel SM. Identification of haptoglobin alpha-
2FF variants in mid-trimester maternal serum as potential
markers for Down syndrome. Applied & Theoretical
Electrophoresis 1990;1(5):233–41.
Neveux 1996a {published data only}
Neveux LM, Palomaki GE, Larrivee DA, Knight GJ,
Haddow JE. Refinements in managing maternal weight
adjustment for interpreting prenatal screening results.
Prenatal Diagnosis 1996;16(12):1115–9.
Neveux 1996b {published data only}
Neveux LM, Palomaki GE, Knight GJ, Haddow JE.
Multiple marker screening for Down syndrome in twin
pregnancies. Prenatal Diagnosis 1996;16(1):29–34.
Ng 2004 {published data only}
Ng EK, El-Sheikhah A, Chiu RW, Chan KC, Hogg
M, Bindra R, et al. Evaluation of human chorionic
gonadotropin ß-subunit mRNA concentrations in maternal
serum in aneuploid pregnancies: a feasibility study. Clinical
Chemistry 2004;50(6):1055–7.
Nicolaides 1992 {published data only}
Nicolaides KH, ZAR G, Snijders RJM, Gosden CM. Fetal
nuchal oedema associated malformations and chromosomal
defects. Fetal Diagnosis and Therapy 1992;7(2):123–31.
Nicolaides 2000 {published data only}
Nicolaides KH, Cicero S, Liao AW. One-stop clinic for
assessment of risk of chromosomal defects at 12 weeks
of gestation. Prenatal and Neonatal Medicine 2000;5(3):
145–54.
Nicolaides 2004 {published data only}
Nicolaides KH. Nuchal translucency and other first-
trimester sonographic markers of chromosomal
abnormalities. American Journal of Obstetrics and Gynecology
2004;191(1):45–67.
Nicolaides 2005a {published data only}
Nicolaides KH, Wegrzyn P. [First trimester diagnosis of
chromosomal defects][Polish]. Ginekologia Polska 2005;76
(1):1–8.
Nicolaides 2005b {published data only}
Nicolaides KH, Wegrzyn P. [Sonographic features of
chromosomal defects at 11(+0) to 13(+6) weeks of gestation]
[Polish]. Ginekologia Polska 2005;76(6):423–30.
Nicolaides 2005c {published data only}
Nicolaides KH, Wegrzyn P. [Increased nuchal translucency
with normal karyotype]. [Polish]. Ginekologia Polska 2005;
76(8):593–601.
Nicolaides 2005d {published data only}
Nicolaides KH, Wegrzyn P. [Fetal nuchal translucency].
[Polish]. Ginekologia Polska 2005;76(3):179–86.
Nicolaides 2005e {published data only}
Nicolaides KH, Wegrzyn P. [Fetal nuchal translucency
thickness and risk for chromosomal defects]. [Polish].
Ginekologia Polska 2005;76(4):257–63.
Nicolaides 2005f {published data only}
Nicolaides Kypros H. First-trimester screening for
chromosomal abnormalities. Seminars in Perinatology
(Philadelphia) 2005;29(4):190–4.
Niemimaa 2001 {published data only}
Niemimaa M, Heinonen S, Seppala M, Hippelainen M,
Martikainen H, Ryynanen M. First-trimester screening
for Down’s syndrome in in vitro fertilization pregnancies.
Fertility & Sterility 2001;76(6):1282–3.
Niemimaa 2002 {published data only}
Niemimaa M, Suonpaa M, Heinonen S, Seppala M,
Bloigu R, Ryynanen M. Maternal serum human chorionic
gonadotrophin and pregnancy-associated plasma protein A
in twin pregnancies in the first trimester. Prenatal Diagnosis
2002;22(3):183–5.
Niemimaa 2003 {published data only}
Niemimaa M, Heinonen S, Seppala M, Ryynanen M. The
influence of smoking on the pregnancy-associated plasma
protein A, free ß human chorionic gonadotrophin and
nuchal translucency. BJOG: an international journal of
obstetrics and gynaecology 2003;110(7):664–7.
Noble 1997 {published data only}
Noble PL, Snijders RJ, Abraha HD, Sherwood RA,
Nicolaides KH. Maternal serum free ß-hCG at 10 to 14
weeks of gestation in trisomic twin pregnancies. British
Journal of Obstetrics and Gynaecology 1997;104(6):741–3.
Norgaard-Pedersen 1990 {published data only}
Norgaard-Pedersen B, Larsen SO, Arends J, Svenstrup B,
Tabor A. Maternal serum markers in screening for Down
syndrome. Clinical Genetics 1990;37(1):35–43.
Norton 1992 {published data only}
Norton ME, Golbus MS. Maternal serum CA 125 for
aneuploidy detection in early pregnancy. Prenatal Diagnosis
1992;12(9):779–81.
O’Brien 1997a {published data only}
Brien JE, Dvorin E, Yaron Y, Ayoub M, Johnson MP,
Hume RF Jr, et al. Differential increases in AFP, hCG, and
uE3 in twin pregnancies: Impact on attempts to quantify
Down syndrome screening calculations. American Journal of
Medical Genetics 1997;73(2):109–12.
O’Brien 1997b {published data only}
Brien JE, Dvorin E, Drugan A, Johnson MP, Yaron Y,
Evans MI. Race-ethnicity-specific variation in multiple-
32Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
marker biochemical screening: Alpha-fetoprotein, hCG,
and estriol. Obstetrics and Gynecology 1997;89(3):355–8.
Odibo 2004 {published data only}
Odibo AO, Sehdev HM, Dunn L, McDonald R, Macones
GA. The association between fetal nasal bone hypoplasia
and aneuploidy. Obstetrics & Gynecology 2004;104(6):
1229–33.
Ognibene 1999 {published data only}
Ognibene A, Ciuti R, Tozzi P, Messeri G. Maternal
serum superoxide dismutase (SOD): a possible marker
for screening Down syndrome affected pregnancies.[see
comment]. Prenatal Diagnosis 1999;19(11):1058–60.
Olajide 1989 {published data only}
Olajide F, Kitau MJ, Chard T. Maternal serum AFP levels
in the first trimester of pregnancy. European Journal of
Obstetrics, Gynecology, & Reproductive Biology 1989;30(2):
123–8.
Onda 1996 {published data only}
Onda T, Kitagawa M, Takeda O, Sago H, Kubonoya K,
Iinuma K, et al. Triple marker screening in native Japanese
women. Prenatal Diagnosis 1996;16(8):713–7.
Onda 1998 {published data only}
Onda T, Tanaka T, Takeda O, Kitagawa M, Kuwabara Y,
Yamamoto H, et al. Agreement between predicted risk and
prevalence of Down syndrome in second-trimester triple-
marker screening in Japan. Prenatal Diagnosis 1998;18(9):
956–8.
Onda 2000 {published data only}
Onda T, Tanaka T, Yoshida K, Nakamura Y, Kudo R,
Yamamoto H, et al. Triple marker screening for trisomy
21, trisomy 18 and open neural tube defects in singleton
pregnancies of native Japanese pregnant women. Journal of
Obstetrics & Gynaecology Research 2000;26(6):441–7.
Orlandi 2002 {published data only}
Orlandi F, Rossi C, Allegra A, Krantz D, Hallahan T,
Orlandi E, et al. First trimester screening with free ß-hCG,
PAPP-A and nuchal translucency in pregnancies conceived
with assisted reproduction. Prenatal Diagnosis 2002;22(8):
718–21.
Páez 2004 {published data only}
Páez L, Peña E, González F, Bello F, Bellorín J, Espinoza F, et
al. Plasma protein “A” and chorionic gonadotropin at first
trimester pregnancy. Informe Medico 2004;6(2):99–109.
Palka 1998 {published data only}
Palka G, Guanciali Franchi P, Papponetti M, Marcuccitti J,
Morizio E, Calabrese G, et al. Prenatal diagnosis using the
triple test. Minerva Ginecologica 1998;50(10):411–5.
Palomaki 1989 {published data only}
Palomaki GE,Williams J, Haddow JE. Combining maternal
serum alpha-fetoprotein measurements and age to screen
for Down syndrome in pregnant women under age 35.
American Journal of Obstetrics and Gynecology 1989;160(3):
575–81.
Palomaki 1993 {published data only}
Palomaki GE, Knight GJ, Haddow JE, Canick JA,Wald NJ,
Kennard A. Cigarette smoking and levels of maternal serum
alpha-fetoprotein, unconjugated estriol, and hCG: impact
on Down syndrome screening. Obstetrics and Gynecology
1993;81(5):675–8.
Palomaki 1994 {published data only}
Palomaki GE, Knight GJ, Haddow JE. Human chorionic
gonadotropin and unconjugated oestriol measurements in
insulin-dependent diabetic pregnant women being screened
for fetal Down syndrome. Prenatal Diagnosis 1994;14(1):
65–8.
Palomaki 1996 {published data only}
Palomaki GE, Neveux LM, Haddow JE. Can reliable
Down’s syndrome detection rates be determined from
prenatal screening intervention trials?. Journal of Medical
Screening 1996;3(1):12–7.
Palomaki 2005 {published data only}
Palomaki GE, Knight GJ, Neveux LM, Pandian R, Haddow
JE. Maternal serum invasive trophoblast antigen and first-
trimester Down syndrome screening. Clinical Chemistry
2005;51(8):1499–504.
Panburana 2001 {published data only}
Panburana P, Ajjimakorn S, Tungkajiwangoon P. First
trimester Down Syndrome screening by nuchal translucency
in a Thai population. International Journal of Gynaecology
& Obstetrics 2001;75(3):311–2.
Pandya 1994 {published data only}
Pandya PP, Brizot ML, Kuhn P, Snijders RJ, Nicolaides KH.
First-trimester fetal nuchal translucency thickness and risk
for trisomies. Obstetrics & Gynecology 1994;84(3):420–3.
Pandya 1995 {published data only}
Pandya PP, Santiago C, Snijders RJM, Nicolaides KH. First
trimester fetal nuchal translucency. Current Opinion in
Obstetrics and Gynecology 1995;7(2):95–102.
Paul 2001 {published data only}
Paul C, Krampl E, Skentou C, Jurkovic D, Nicolaides KH.
Measurement of fetal nuchal translucency thickness by
three-dimensional ultrasound. Ultrasound in Obstetrics &
Gynecology 2001;18(5):481–4.
Peralta 2005 {published data only}
Peralta CF, Falcon O, Wegrzyn P, Faro C, Nicolaides KH.
Assessment of the gap between the fetal nasal bones at 11 to
13 + 6 weeks of gestation by three-dimensional ultrasound.
Ultrasound in Obstetrics & Gynecology 2005;25(5):464–7.
Perenc 1998 {published data only}
Perenc M, Dudarewicz L, Kaluzewski B. Analysis of triple
test results in 27 cases of twin pregnancies. Acta Geneticae
Medicae et Gemellologiae 1998;47(3-4):249–54.
Perheentupa 2002 {published data only}
Perheentupa A, Ruokonen A, Tuomivaara L, Ryynänen
M, Martikainen H. Maternal serum (ß)-HCG and
(alpha)-fetoprotein concentrations in singleton pregnancies
following assisted reproduction. Human Reproduction 2002;
17(3):794–7.
Perona 1998 {published data only}
Perona M, Mancini G, Dall’Amico D, Guaraldo V,
Carbonara A. Influence of smoking habits on Down’s
33Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
syndrome risk evaluation at mid-trimester through
biochemical screening. International Journal of Clinical &
Laboratory Research 1998;28(3):179–82.
Petervari 2000 {published data only}
Petervari L, Varga A, Tanko A, Szabo L, Godo G.
[Significance of nuchal edema in fetuses of pregnant women
under 35 years of age]. [Hungarian]. Orvosi Hetilap 2000;
141(8):399–402.
Petrocik 1989 {published data only}
Petrocik E, Wassman ER, Kelly JC. Prenatal screening for
Down syndrome with maternal serum human chorionic
gonadotropin levels.[see comment]. American Journal of
Obstetrics and Gynecology 1989;161(5):1168–73.
Phillips 1992 {published data only}
Phillips OP, Elias S, Shulman LP, Andersen RN, Morgan
CD, Simpson JL. Maternal serum screening for fetal Down
syndrome in women less than 35 years of age using alpha-
fetoprotein, hCG, and unconjugated estriol: a prospective
2-year study. Obstetrics & Gynecology 1992;80(3):353–8.
Phillips 1993 {published data only}
Phillips OP, Shulman LP, Elias S, Simpson JL. Maternal
serum screening for fetal Down syndrome using alpha-
fetoprotein, human chorionic gonadotrophin, and
unconjugated estriol in adolescents. Adolescent and Pediatric
Gynecology 1993;6(2):91–4.
Pinette 2003 {published data only}
Pinette MG, Egan JF, Wax JR, Blackstone J, Cartin A,
Benn PA. Combined sonographic and biochemical markers
for Down syndrome screening. Journal of Ultrasound in
Medicine 2003;22(11):1185–90.
Platt 2004 {published data only}
Platt LD, Greene N, Johnson A, Zachary J, Thom E, Krantz
D, et al. Sequential pathways of testing after first-trimester
screening for trisomy 21. Obstetrics and Gynecology 2004;
104(4):661–6.
Podobnik 1995 {published data only}
Podobnik M, Singer Z, Podobnik-Sarkanji S, Bulic M. First
trimester diagnosis of cystic hygromata using transvaginal
ultrasound and cytogenetic evaluation. Journal of Perinatal
Medicine 1995;23(4):283–91.
Prefumo 2002 {published data only}
Prefumo F, Thilaganathan B. Agreement between predicted
risk and prevalence of Down syndrome in first trimester
nuchal translucency screening. Prenatal Diagnosis 2002;22
(10):917–8.
Prefumo 2004 {published data only}
Prefumo F, Sairam S, Bhide A, Penna L, Hollis B,
Thilaganathan B. Maternal ethnic origin and fetal nasal
bones at 11-14 weeks of gestation. BJOG: an international
journal of obstetrics & gynaecology 2004;111(2):109–12.
Price 1998 {published data only}
Price KM,Van Lith JM, Silman R,Mantingh A,Grudzinskas
JG. First trimester maternal serum concentrations of fetal
antigen 2 in normal pregnancies and those affected by
trisomy 21. Human Reproduction 1998;13(6):1706–8.
Raty 2000 {published data only}
Raty R, Virtanen A, Koskinen P, Laitinen P, Forsstrom J,
Salonen R, et al. Maternal midtrimester serum AFP and
free ß-hCG levels in in vitro fertilization twin pregnancies.
Prenatal Diagnosis 2000;20(3):221–3.
Räty 2002 {published data only}
Räty R, Virtanen A, Koskinen P, Anttila L, Forsström J,
Laitinen P, et al. Serum free (ß)-HCG and alpha-fetoprotein
levels in IVF, ICSI and frozen embryo transfer pregnancies
in maternal mid-trimester serum screening for Down’s
syndrome. Human Reproduction 2002;17(2):481–4.
Rembouskos 2004 {published data only}
Rembouskos G, Cicero S, Longo D, Vandecruys H,
Nicolaides KH. Assessment of the fetal nasal bone at 11-
14 weeks of gestation by three-dimensional ultrasound.
Ultrasound in Obstetrics & Gynecology 2004;23(3):232–6.
Ren 1992 {published data only}
Ren S-G, Braunstein GD. Human chorionic gonadotropin.
Seminars in Reproductive Endocrinology 1992;10(2):95–105.
Renier 1998 {published data only}
Renier MA, Vereecken A, Van Herck E, Straetmans D,
Ramaekers P, Buytaert P. Second trimester maternal dimeric
inhibin-A in the multiple-marker screening test for Down’s
syndrome. Human Reproduction 1998;13(3):744–8.
Resta 1990 {published data only}
Resta RG, Nyberg D. The role of ultrasound in screening
for Down syndrome. Birth Defects: Original Article Series
1990;26(3):104.
Reynders 1997 {published data only}
Reynders CS, Pauker SP, Benacerraf BR. First trimester
isolated fetal nuchal lucency: significance and outcome.
Journal of Ultrasound in Medicine 1997;16(2):101–5.
Reynolds 1989 {published data only}
Reynolds TM, Penney MD. The mathematical basis
of multivariate risk screening: with special reference to
screening for Down’s syndrome associated pregnancy.
Annals of Clinical Biochemistry 1989;27(5):452–8.
Reynolds 1999 {published data only}
Reynolds TM, Schaeffer HJ, Schlensker S. Estimation of
Down’s syndrome risks in the first trimester of pregnancy:
experience of testing with PAPP-A, total hCG and free
ß- hCG levels in maternal blood samples in a German
population. Clinical Laboratory 1999;45(1-2):49–53.
Ribbert 1996 {published data only}
Ribbert LS, Kornman LH, de Wolf BT, Simons AH, Jansen
CA, Beekhuis JR, et al. Maternal serum screening for fetal
Down syndrome in IVF pregnancies. Prenatal Diagnosis
1996;16(1):35–8.
Rice 2005 {published data only}
Rice JD, McIntosh SF, Halstead AC. Second-trimester
maternal serum screening for Down syndrome in in vitro
fertilization pregnancies. Prenatal Diagnosis 2005;25(3):
234–8.
34Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rich 1991 {published data only}
Rich N, Boots L, Davis R, Finley S. Efficiency of maternal
serum hCG AFP and free estriol in the identification of
trisomy 21 and other complications of pregnancy. Journal
of the Alabama Academy of Science 1991;62(2-3):135.
Roberts 1995 {published data only}
Roberts LJ, Bewley S, Mackinson AM, Rodeck CH. First
trimester fetal nuchal translucency: problems with screening
the general population. 1. British Journal of Obstetrics and
Gynaecology 1995;102(5):381–5.
Robertson 1991 {published data only}
Robertson EF. Maternal serum screening for neural tube
defects and Down’s syndrome.[see comment]. Medical
Journal of Australia 1991;155(2):67–8.
Rode 2003 {published data only}
Rode L, Wojdemann KR, Shalmi AC, Larsen SO, Sundberg
K, Norgaard-Pedersen B, et al. Combined first- and second-
trimester screening for Down syndrome: an evaluation of
proMBP as a marker. Prenatal Diagnosis 2003;23(7):593–8.
Ronge 2006 {published data only}
Ronge R. Combined first trimester screening for Down’s
syndrome is superior to quadruple test. Geburtshilfe und
Frauenheilkunde 2006;66(4):332.
Rose 1995 {published data only}
Rose NC, Mennuti MT. Multiple marker screening for
women 35 and older. Contemporary OB/GYN 1995;40(9):
55–6.
Ross 1997 {published data only}
Ross HL, Elias S. Maternal serum screening for fetal genetic
disorders. Obstetrics & Gynecology Clinics of North America
1997;24(1):33–47.
Rotmensch 1996 {published data only}
Rotmensch S, Liberati M, Kardana A, Copel JA, Ben-Rafael
Z, Cole LA. Nicked free ß-subunit of human chorionic
gonadotropin: a potential new marker for Down syndrome
screening. American Journal of Obstetrics and Gynecology
1996;174(2):609–11.
Rotmensch 1999 {published data only}
Rotmensch S, Celentano C, Shalev J, Vishne TH, Lipitz S,
Ben-Rafael Z, et al. Midtrimester maternal serum screening
after multifetal pregnancy reduction in pregnancies
conceived by in vitro fertilization. Journal of Assisted
Reproduction and Genetics 1999;16(1):8–12.
Rozenberg 2006 {published data only}
Rozenberg P, Bussieres L, Chevret S, Bernard JP, Malagrida
L, Cuckle H, et al. Screening for Down syndrome
using first-trimester combined screening followed by
second-trimester ultrasound examination in an unselected
population. American Journal of Obstetrics and Gynecology
2006;195(5):1379–87.
Rudnicka 2002 {published data only}
Rudnicka AR,Wald NJ, Huttly W, Hackshaw AK. Influence
of maternal smoking on the birth prevalence of Down
syndrome and on second trimester screening performance.
Prenatal Diagnosis 2002;22(10):893–7.
Ryall 1992 {published data only}
Ryall RG, Staples AJ, Robertson EF, Pollard AC. Improved
performance in a prenatal screening programme for Down’s
syndrome incorporating serum-free hCG subunit analyses.
Prenatal Diagnosis 1992;12(4):251–61.
Ryall 2001 {published data only}
Ryall RG, Callen D, Cocciolone R, Duvnjak A, Esca R,
Frantzis N, et al. Karyotypes found in the population
declared at increased risk of Down syndrome following
maternal serum screening. Prenatal Diagnosis 2001;21(7):
553–7.
Sabriá 2002 {published data only}
Sabriá J, Cabrero D, Bach C. Aneuploidy screening:
ultrasound versus biochemistry. Ultrasound Review of
Obstetrics and Gynecology 2002;2(4):221–8.
Sacchini 2003 {published data only}
Sacchini C, El-Sheikhah A, Cicero S, Rembouskos G,
Nicolaides KH. Ear length in trisomy 21 fetuses at 11-14
weeks of gestation. Ultrasound in Obstetrics & Gynecology
2003;22(5):460–3.
Saller 1997 {published data only}
Saller DN Jr, Canick JA, Kellner LH, Rose NC, Garza
J, French CA, et al. Maternal serum analyte levels in
pregnancies with fetal Down syndrome resulting from
translocations. American Journal of Obstetrics and Gynecology
1997;177(4):879–81.
Salomon 2001 {published data only}
Salomon LJ, Bernard JP, Taupin P, Benard C, Ville Y.
Relationship between nuchal translucency at 11-14 weeks
and nuchal fold at 20-24 weeks of gestation. Ultrasound in
Obstetrics & Gynecology 2001;18(6):636–7.
Salonen 1997 {published data only}
Salonen R, Turpeinen U, Kurki L, Lappalainen M, Ammala
P, Hiilesmaa V, et al. Maternal serum screening for
Down’s syndrome on population basis. Acta Obstetricia et
Gynecologica Scandinavica 1997;76(9):817–21.
Saltvedt 2005 {published data only}
Saltvedt S, Almstrom H, Kublickas M, Valentin L, Bottinga
R, Bui TH, et al. Screening for Down syndrome based on
maternal age or fetal nuchal translucency: a randomized
controlled trial in 39,572 pregnancies. Ultrasound in
Obstetrics & Gynecology 2005;25(6):537–45.
Saridogan 1996 {published data only}
Saridogan E, Djahanbakhch O, Naftalin AA. Screening
for Down’s syndrome: experience in an inner city health
district. British Journal of Obstetrics and Gynaecology 1996;
103(12):1205–11.
Savoldelli 1993 {published data only}
Savoldelli G, Binkert F, Achermann J, Schmid W.
Ultrasound screening for chromosomal anomalies in the
first trimester of pregnancy. Prenatal Diagnosis 1993;13(6):
513–8.
Schiott 2006 {published data only}
Schiott KM, Christiansen M, Petersen OB, Sorensen TL,
Uldbjerg N. The “Consecutive Combined Test”--using
35Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
double test from week 8 + 0 and nuchal translucency scan,
for first trimester screening for Down syndrome. Prenatal
Diagnosis 2006;26(12):1105–9.
Schuchter 1998 {published data only}
Schuchter K, Wald N, Hackshaw AK, Hafner E, Liebhart
E. The distribution of nuchal translucency at 10-13 weeks
of pregnancy. Prenatal Diagnosis 1998;18(3):281–6.
Scott 1995 {published data only}
Scott F, Boogert A, Smart S, Anderson J. Maternal serum
screening and routine 18-week ultrasound in the detection
of all chromosomal abnormalities. Australian & New
Zealand Journal of Obstetrics & Gynaecology 1995;35(2):
165–8.
Seeds 1990 {published data only}
Seeds JW, Watson WJ. Ultrasound and maternal serum
alpha-fetoprotein screening: a complementary relationship.
Ultrasound Quarterly 1990;8(2):145–66.
Seki 1995 {published data only}
Seki K, Mitsui C, Nagata I. Measurement of urinary free
ß-human chorionic gonadotropin by immunoradiometric
assay. Gynecologic and Obstetric Investigation 1995;40(3):
162–7.
Shenhav 2003 {published data only}
Shenhav S, Gemer O, Sherman DJ, Peled R, Segal S.
Midtrimester triple-test levels in women with chronic
hypertension and altered renal function. Prenatal Diagnosis
2003;23(2):166–7.
Shintaku 1989 {published data only}
Shintaku Y, Takabayashi T, Sasaki H, Ozawa N, Shinkawa
O, Hamazaki Y, et al. [Screening for chromosomal
anomalies with maternal serum alpha-fetoprotein].
[Japanese]. Nippon Sanka Fujinka Gakkai Zasshi - Acta
Obstetrica et Gynaecologica Japonica 1989;41(2):185–90.
Shulman 2003 {published data only}
Shulman A, Maymon R. Mid-gestation Down syndrome
screening test and pregnancy outcome among unstimulated
assisted-conception pregnancies. Prenatal Diagnosis 2003;
23(8):625–8.
Simon-Bouy 1999 {published data only}
Simon-Bouy B. [Markers for trisomy 21][French]. Fertilite
Contraception Sexualite 1999;27(9):289–91.
Simpson 1986 {published data only}
Simpson JL, Baum LD, Marder R, Elias S, Ober C, Martin
AO. Maternal serum alpha-fetoprotein screening: low and
high values for detection of genetic abnormalities. American
Journal of Obstetrics and Gynecology 1986;155(3):593–7.
Smith 1990 {published data only}
Smith C, Grube GL, Wilson S. Maternal serum alpha-
fetoprotein screening and the role of ultrasound. Journal of
Diagnostic Medical Sonography 1990;6(6):312–6.
Smith 1996 {published data only}
Smith ER, Petersen J, Okorodudu AO, Bissell MG. Does
the addition of unconjugated estriol in maternal serum
screening improve the detection of trisomy 21? A meta-
analysis. Clinical Laboratory Management Review 1996;10
(2):176–81.
Smith 1999 {published data only}
Smith NC, Hau C. A six year study of the antenatal
detection of fetal abnormality in six Scottish health boards.
British Journal of Obstetrics and Gynaecology 1999;106(3):
206–12.
Smith-Bindman 2001 {published data only}
Smith-Bindman R, Hosmer W, Feldstein VA, Deeks JJ,
Goldberg JD. Second-trimester ultrasound to detect fetuses
with Down syndrome: a meta-analysis.[see comment].
JAMA 2001;285(8):1044–55.
Smith-Bindman 2003 {published data only}
Smith-Bindman R, Chu P, Bacchetti P, Waters JJ, Mutton
D, Alberman E. Prenatal screening for Down syndrome in
England and Wales and population-based birth outcomes.
American Journal of Obstetrics and Gynecology 2003;187(4):
980–5.
Snijders 1995 {published data only}
Snijders RJM, Sebire NJ, Nicolaides KH. Maternal age and
gestational age-specific risk for chromosomal defects. Fetal
Diagnosis and Therapy 1995;10(6):356–67.
Snijders 1999 {published data only}
Snijders RJM, Sundberg K, Holzgreve W, Henry G,
Nicolaides KH. Maternal age- and gestation-specific risk for
trisomy 21. Ultrasound in Obstetrics & Gynecology 1999;13
(3):167–70.
Soergel 2006 {published data only}
Soergel P, Pruggmayer M, Schwerdtfeger R, Muhlhaus K,
Scharf A. Screening for trisomy 21 with maternal age, fetal
nuchal translucency and maternal serum biochemistry at
11-14 weeks: a regional experience from Germany. Fetal
Diagnosis and Therapy 2006;21(3):264–8.
Sokol 1998 {published data only}
Sokol AI, Kramer RL, Yaron Y, O’Brien JE, Muller F,
Johnson MP, et al. Age-specific variation in aneuploidy
incidence among biochemical screening programs. American
Journal of Obstetrics and Gynecology 1998;179(4):971–3.
Sonek 2003 {published data only}
Sonek JD. Nasal bone evaluation with ultrasonography:
a marker for fetal aneuploidy. Ultrasound in Obstetrics &
Gynecology 2003;22(1):11–5.
Spencer 1985 {published data only}
Spencer K, Carpenter P. Screening for Down’s syndrome
using serum alpha fetoprotein: a retrospective study
indicating caution. BMJ (Clinical Research Ed.) 1985;290
(6486):1940–3.
Spencer 1991a {published data only}
Spencer K. Evaluation of an assay of the free ß-subunit of
choriogonadotropin and its potential value in screening for
Down’s syndrome. Clinical Chemistry 1991;37(6):809–14.
Spencer 1991b {published data only}
Spencer K. Maternal serum CA125 is not a second
trimester marker for Down’s syndrome. Annals of Clinical
Biochemistry 1991;28(3):299–300.
36Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Spencer 1992 {published data only}
Spencer K, Coombes EJ, Mallard AS, Ward AM. Free ß
human choriogonadotropin in Down’s syndrome screening:
a multicentre study of its role compared with other
biochemical markers.[see comment]. Annals of Clinical
Biochemistry 1992;29(5):506–18.
Spencer 1993a {published data only}
Spencer K, Carpenter P. Prospective study of prenatal
screening for Down’s syndrome with free ß human chorionic
gonadotrophin.[see comment]. BMJ 1993;307(6907):
764–9.
Spencer 1993b {published data only}
Spencer K, Macri JN, Carpenter P, Anderson R, Krantz
DA. Stability of intact chorionic gonadotropin (hCG) in
serum, liquid whole blood, and dried whole-blood filter-
paper spots: impact on screening for Down syndrome by
measurement of free ß-hCG subunit. Clinical Chemistry
1993;39(6):1064–8.
Spencer 1993c {published data only}
Spencer K, Wood PJ, Anthony FW. Elevated levels of
maternal serum inhibin immunoreactivity in second
trimester pregnancies affected by Down’s syndrome. Annals
of Clinical Biochemistry 1993;30(Pt 2):219–20.
Spencer 1993d {published data only}
Spencer K, Macri JN, Anderson RW, Aitken DA, Berry E,
Crossley JA, et al. Dual analyte immunoassay in neural
tube defect and Down’s syndrome screening: results of a
multicentre clinical trial. Annals of Clinical Biochemistry
1993;30(4):394–401.
Spencer 1993e {published data only}
Spencer K. Free alpha-subunit of human chorionic
gonadotropin in Down syndrome. American Journal of
Obstetrics and Gynecology 1993;168(1):132–5.
Spencer 1995 {published data only}
Spencer K. The influence of gravidity on Down’s syndrome
screening with free ß hCG. Prenatal Diagnosis 1995;15(1):
87–9.
Spencer 1996a {published data only}
Spencer K, Wallace EM, Ritoe S. Second-trimester dimeric
inhibin-A in Down’s syndrome screening. Prenatal Diagnosis
1996;16(12):1101–10.
Spencer 1997 {published data only}
Spencer K, Noble P, Snijders RJ, Nicolaides KH. First-
trimester urine free ß hCG, ß core, and total oestriol in
pregnancies affected by Down’s syndrome: implications
for first-trimester screening with nuchal translucency and
serum free ß hCG. Prenatal Diagnosis 1997;17(6):525–38.
Spencer 1998a {published data only}
Spencer K. The influence of smoking on maternal serum
AFP and free ß hCG levels and the impact on screening for
Down syndrome. Prenatal Diagnosis 1998;18(3):225–34.
Spencer 1998b {published data only}
Spencer K, Carpenter P. Is prostate-specific antigen a marker
for pregnancies affected by Down syndrome?. Clinical
Chemistry 1998;44(11):2362–5.
Spencer 1999a {published data only}
Spencer K. Second trimester prenatal screening for Down’s
syndrome using alpha-fetoprotein and free ß hCG: a seven
year review. British Journal of Obstetrics and Gynaecology
1999;106(12):1287–93.
Spencer 1999b {published data only}
Spencer K. Accuracy of Down’s syndrome risks produced in
a prenatal screening program. Annals of Clinical Biochemistry
1999;36(1):101–3.
Spencer 2000a {published data only}
Spencer K, Berry E, Crossley JA, Aitken DA, Nicolaides
KH. Is maternal serum total hCG a marker of trisomy 21 in
the first trimester of pregnancy?. Prenatal Diagnosis 2000;
20(4):311–7.
Spencer 2000b {published data only}
Spencer K. Screening for trisomy 21 in twin pregnancies in
the first trimester using free ß-hCG and PAPP-A, combined
with fetal nuchal translucency thickness. Prenatal Diagnosis
2000;20(2):91–5.
Spencer 2000c {published data only}
Spencer K. The influence of smoking on maternal serum
PAPP-A and free ß hCG levels in the first trimester of
pregnancy. Prenatal Diagnosis 1999;19(11):1065–6.
Spencer 2000d {published data only}
Spencer K, Ong CY, Liao AW, Nicolaides KH. The
influence of parity and gravidity on first trimester markers
of chromosomal abnormality. Prenatal Diagnosis 2000;20
(10):792–4.
Spencer 2000e {published data only}
Spencer K. The influence of fetal sex in screening for Down
syndrome in the second trimester using AFP and free ß-
hCG. Prenatal Diagnosis 2000;20(8):648–51.
Spencer 2000f {published data only}
Spencer K, Ong CY, Liao AW, Nicolaides KH. The
influence of ethnic origin on first trimester biochemical
markers of chromosomal abnormalities. Prenatal Diagnosis
2000;20(6):491–4.
Spencer 2000g {published data only}
Spencer K, Tul N, Nicolaides KH. Maternal serum free ß-
hCG and PAPP-A in fetal sex chromosome defects in the
first trimester. Prenatal Diagnosis 2000;20(5):390–4.
Spencer 2000h {published data only}
Spencer K. Second-trimester prenatal screening for
Down syndrome and the relationship of maternal serum
biochemical markers to pregnancy complications with
adverse outcome. Prenatal Diagnosis 2000;20(8):652–6.
Spencer 2000i {published data only}
Spencer K, Ong CY, Liao AW, Papademetriou D, Nicolaides
KH. The influence of fetal sex in screening for trisomy 21
by fetal nuchal translucency, maternal serum free ß-hCG
and PAPP-A at 10-14 weeks of gestation. Prenatal Diagnosis
2000;20(8):673–5.
Spencer 2001 {published data only}
Spencer K. Age related detection and false positive rates
when screening for Down’s syndrome in the first trimester
37Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
using fetal nuchal translucency and maternal serum free
ßhCG and PAPP-A. BJOG: an international journal of
obstetrics and gynaecology 2001;108(10):1043–6.
Spencer 2001a {published data only}
Spencer K, Liao AW, Ong CY, Geerts L, Nicolaides KH.
First trimester maternal serum placenta growth factor
(PIGF) concentrations in pregnancies with fetal trisomy 21
or trisomy 18. Prenatal Diagnosis 2001;21(9):718–22.
Spencer 2001b {published data only}
Spencer K, Liao AW, Ong CY, Geerts L, Nicolaides KH.
Maternal serum levels of dimeric Inhibin A in pregnancies
affected by trisomy 21 in the first trimester. Prenatal
Diagnosis 2001;21(6):441–4.
Spencer 2001c {published data only}
Spencer K, Liao AW, Skentou H, Ong CY, Nicolaides KH.
Maternal serum levels of total activin-A in first-trimester
trisomy 21 pregnancies. Prenatal Diagnosis 2001;21(4):
270–3.
Spencer 2001d {published data only}
Spencer K. Screening for trisomy 21 in twin pregnancies in
the first trimester: does chorionicity impact on maternal
serum free ß-hCG or PAPP-A levels?. Prenatal Diagnosis
2001;21(9):715–7.
Spencer 2002a {published data only}
Spencer K, Nicolaides KH. A first trimester trisomy
13/trisomy 18 risk algorithm combining fetal nuchal
translucency thickness, maternal serum free ß-hCG and
PAPP-A. Prenatal Diagnosis 2002;22(10):877–9.
Spencer 2002b {published data only}
Spencer K. Accuracy of Down syndrome risks produced
in a first-trimester screening programme incorporating
fetal nuchal translucency thickness and maternal serum
biochemistry. Prenatal Diagnosis 2002;22(3):244–6.
Spencer 2002c {published data only}
Spencer K, Cuckle HS. Screening for chromosomal
anomalies in the first trimester: does repeat maternal serum
screening improve detection rates?. Prenatal Diagnosis 2002;
22(10):903–6.
Spencer 2002d {published data only}
Spencer K, Crossley JA, Aitken DA, Nix AB, Dunstan
FD, Williams K. Temporal changes in maternal serum
biochemical markers of trisomy 21 across the first
and second trimester of pregnancy. Annals of Clinical
Biochemistry 2002;39(6):567–76.
Spencer 2003a {published data only}
Spencer K, Crossley JA, Aitken DA, Nix AB, Dunstan FD,
Williams K. The effect of temporal variation in biochemical
markers of trisomy 21 across the first and second trimesters
of pregnancy on the estimation of individual patient-specific
risks and detection rates for Down’s syndrome. Annals of
Clinical Biochemistry 2003;40(3):219–31.
Spencer 2003b {published data only}
Spencer K. The influence of different sample collection
types on the levels of markers used for Down’s syndrome
screening as measured by the Kryptor Immunosassay
system. Annals of Clinical Biochemistry 2003;40(2):166–8.
Spencer 2003c {published data only}
Spencer K, Bindra R, Nicolaides KH. Maternal weight
correction of maternal serum PAPP-A and free ß-hCG
MoM when screening for trisomy 21 in the first trimester of
pregnancy. Prenatal Diagnosis 2003;23(10):851–5.
Spencer 2003d {published data only}
Spencer K, Nicolaides KH. Screening for trisomy 21 in
twins using first trimester ultrasound and maternal serum
biochemistry in a one-stop clinic: a review of three years
experience. BJOG: an international journal of obstetrics and
gynaecology 2003;110(3):279–80.
Spencer 2004 {published data only}
Spencer K, Bindra R, Cacho AM, Nicolaides KH. The
impact of correcting for smoking status when screening for
chromosomal anomalies using maternal serum biochemistry
and fetal nuchal translucency thickness in the first trimester
of pregnancy. Prenatal Diagnosis 2004;24(3):169–73.
Spencer 2005a {published data only}
Spencer K, Cicero S, Atzei A, Otigbah C, Nicolaides KH.
The influence of maternal insulin-dependent diabetes
on fetal nuchal translucency thickness and first-trimester
maternal serum biochemical markers of aneuploidy.
Prenatal Diagnosis 2005;25(10):927–9.
Spencer 2005b {published data only}
Spencer K, Heath V, El-Sheikhah A, Ong CY, Nicolaides
KH. Ethnicity and the need for correction of biochemical
and ultrasound markers of chromosomal anomalies in
the first trimester: a study of Oriental, Asian and Afro-
Caribbean populations. Prenatal Diagnosis 2005;25(5):
365–9.
Spencer 2005c {published data only}
Spencer K. First trimester maternal serum screening for
Down’s syndrome: an evaluation of the DPC Immulite
2000 free ß-hCG and pregnancy-associated plasma protein-
A assays.[see comment]. Annals of Clinical Biochemistry
2005;42(1):30–40.
Spong 1999 {published data only}
Spong CY, Ghidini A, Stanley-Christian H, Meck JM,
Seydel FD, Pezzullo JC. Risk of abnormal triple screen for
Down syndrome is significantly higher in women with
female fetuses. Prenatal Diagnosis 1999;19(4):337–9.
Stevens 1998 {published data only}
Stevens SL. The use of nuchal lucency as a screening tool
in first trimester sonography. Journal of Diagnostic Medical
Sonography 1998;14(6):251–4.
Stoll 1992 {published data only}
Stoll C. A new approach of prenatal prevention of
constitutional disabilities - the study of markers of maternal
serum. Journal de Medecine de Strasbourg 1992;23(1):25–7.
Su 2002a {published data only}
Su YN, Hsu JJ, Lee CN, Cheng WF, Kung CC, Hsieh FJ.
Raised maternal serum placenta growth factor concentration
38Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
during the second trimester is associated with Down
syndrome. Prenatal Diagnosis 2002;22(1):8–12.
Suchet 1995 {published data only}
Suchet IB. Ultrasonography of the fetal neck in the first
and second trimesters. Part 2. Anomalies of the posterior
nuchal region. Canadian Association of Radiologists Journal
1995;46(5):344–52.
Suchy 1990 {published data only}
Suchy SF, Yeager MT. Down syndrome screening in women
under 35 with maternal serum hCG.Obstetrics & Gynecology
1990;76(1):20–4.
Summers 2003a {published data only}
Summers AM, Farrell SA, Huang T, Meier C, Wyatt PR.
Maternal serum screening in Ontario using the triple marker
test. Journal of Medical Screening 2003;10(3):107–11.
Summers 2003b {published data only}
Summers AM, Huang T, Meier C, Wyatt PR. The
implications of a false positive second-trimester serum
screen for Down syndrome. Obstetrics & Gynecology 2003;
101(6):1301–6.
Suntharasaj 2005 {published data only}
Suntharasaj T, Ratanasiri T, Chanprapaph P, Kengpol C,
Kor-anantakul O, Leetanaporn R, et al. Variability of
nuchal translucency measurement: a multicenter study in
Thailand. Gynecologic & Obstetric Investigation 2005;60(4):
201–5.
Sutton 2004 {published data only}
Sutton JM, Cole LA. Sialic acid-deficient invasive
trophoblast antigen (sd-ITA): a new urinary variant for
gestational Down syndrome screening. Prenatal Diagnosis
2004;24(3):194–7.
Suzuki 1998 {published data only}
Suzuki Y, Takada J, Iwaki T, Isaka K, Takayama M.
Screening for trisomy 21 in the first trimester by
measurement of serum PAPP-A and free ß-hCG. Acta
Obstetrica et Gynaecologica Japonica 1998;50(1):37–40.
Tabor 1987 {published data only}
Tabor A, Larsen SO, Nielsen J, Nielsen J, Philip J, Pilgaard
B, et al. Screening for Down’s syndrome using an iso-risk
curve based on maternal age and serum alpha-fetoprotein
level. British Journal of Obstetrics and Gynaecology 1987;94
(7):636–42.
Tanski 1999 {published data only}
Tanski S, Rosengren SS, Benn PA. Predictive value of the
triple screening test for the phenotype of Down syndrome.
American Journal of Medical Genetics 1999;85(2):123–6.
Thilaganathan 1998 {published data only}
Thilaganathan B, Khare M, Williams B, Wathen NC.
Influence of ethnic origin on nuchal translucency screening
for Down’s syndrome. Ultrasound in Obstetrics & Gynecology
1998;12(2):112–4.
Thilaganathan 1999 {published data only}
Thilaganathan B. First-trimester nuchal translucency
and maternal serum biochemical screening for Down’s
syndrome: a happy union?. Ultrasound in Obstetrics &
Gynecology 1999;13(4):229–30.
Tislaric 2002 {published data only}
Tislaric D, Brajenovic-Milic B, Ristic S, Latin V, Zuvic-
Butorac M, Bacic J, et al. The influence of smoking and
parity on serum markers for Down’s syndrome screening.
Fetal Diagnosis and Therapy 2002;17(1):17–21.
Torok 1997 {published data only}
Torok O, Veress L, Szabo M, Zsupan I, Buczko Z,
Bolodar A, et al. [Biochemical and ultrasonic screening
of chromosomal aneuploidies in the second trimester of
pregnancy]. [Hungarian]. Orvosi Hetilap 1997;138(3):
123–7.
Tsai 2001 {published data only}
Tsai MS, Huang YY, Hwa KY, Cheng CC, Lee FK.
Combined measurement of fetal nuchal translucency,
maternal serum free ß-hCG, and pregnancy-associated
plasma protein A for first-trimester Down’s syndrome
screening. Journal of the Formosan Medical Association 2001;
100(5):319–25.
Valerio 1996 {published data only}
Valerio D, Aiello R, Altieri V, Fagnoni P. Maternal serum
screening of fetal chromosomal abnormalities by AFP, UE3,
hCG and free-ß hCG. Prospective and retrospective results.
Minerva Ginecologica 1996;48(5):169–73.
Van Blerk 1992 {published data only}
Van Blerk M, Smitz J, De Catte L, Kumps C, Van der Elst J,
Van Steirteghem AC. Second-trimester cancer antigen 125
and Down’s syndrome.[see comment]. Prenatal Diagnosis
1992;12(12):1062–6.
Van Heesch, 2006 {published data only}
Van Heesch PN, Schielen PC, Wildhagen MF, Den
Hollander K, Steegers EA, Wildschut HI. Combined first
trimester screening for trisomy 21: lack of agreement
between risk calculation methods. Journal of Perinatal
Medicine 2006;34(2):162–5.
Van Lith 1991 {published data only}
Van Lith JM, Mantingh A, Beekhuis JR, De Bruijn HW,
Breed AS. First trimester CA 125 and Down’s syndrome.
British Journal of Obstetrics and Gynaecology 1991;98(5):
493–4.
Van Lith 1993 {published data only}
Van Lith JM, Mantingh A, De Bruijn HW. Maternal serum
CA 125 levels in pregnancies with chromosomally-normal
and -abnormal fetuses. Dutch Working Party on Prenatal
Diagnosis. Prenatal Diagnosis 1993;13(12):1123–31.
Van Lith 1994 {published data only}
Van Lith JM, Mantingh A, Pratt JJ. First-trimester maternal
serum immunoreactive inhibin in chromosomally normal
and abnormal pregnancies. Dutch Working Party on
Prenatal Diagnosis. Obstetrics and Gynecology 1994;83(5 Pt
1):661–4.
Veress 1986 {published data only}
Veress L, Szabo M, Horvath K, Polgar K, Papp Z. [Low
maternal serum alpha-fetoprotein concentration and Down
39Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
syndrome]. [Hungarian]. Orvosi Hetilap 1986;127(20):
1232–3.
Veress 1988 {published data only}
Veress L, Szabo M, Polgar K, Takacs L, Papp Z. [Prenatal
screening for Down’s syndrome by measuring the AFP
concentration in the maternal serum]. [Hungarian]. Orvosi
Hetilap 1988;129(31):1677.
Vintzileos 2003 {published data only}
Vintzileos A, Walters C, Yeo L. Absent nasal bone in the
prenatal detection of fetuses with trisomy 21 in a high-risk
population. Obstetrics & Gynecology 2003;101(5):905–8.
Wald 1988a {published data only}
Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston
P, Chard T, et al. Maternal serum screening for Down’s
syndrome in early pregnancy. BMJ 1988;297(6653):883–7.
Wald 1988b {published data only}
Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Canick
JA, Haddow JE, et al. Maternal serum unconjugated
oestriol as an antenatal screening test for Down’s syndrome.
British Journal of Obstetrics and Gynaecology 1988;95(4):
334–41.
Wald 1991 {published data only}
Wald N, Cuckle H, Wu TS, George L. Maternal serum
unconjugated oestriol and human chorionic gonadotrophin
levels in twin pregnancies: implications for screening
for Down’s syndrome. British Journal of Obstetrics and
Gynaecology 1991;98(9):905–8.
Wald 1992a {published data only}
Wald NJ, Kennard A, Densem JW, Cuckle HS, Chard
T, Butler L. Antenatal maternal serum screening for
Down’s syndrome: results of a demonstration project.[see
comment]. BMJ 1992;305(6850):391–4.
Wald 1992b {published data only}
Wald NJ, Cuckle HS, Densem JW, Stone RB. Maternal
serum unconjugated oestriol and human chorionic
gonadotrophin levels in pregnancies with insulin-dependent
diabetes: implications for screening for Down’s syndrome.
British Journal of Obstetrics and Gynaecology 1992;99(1):
51–3.
Wald 1992c {published data only}
Wald NJ, Cuckle HS, Densem JW, Kennard A, Smith D.
Maternal serum screening for Down’s syndrome: the effect
of routine ultrasound scan determination of gestational age
and adjustment for maternal weight.[see comment]. British
Journal of Obstetrics and Gynaecology 1992;99(2):144–9.
Wald 1993 {published data only}
Wald N, Densem J, Stone R, Cheng R. The use of free
ß-hCG in antenatal screening for Down’s syndrome.[see
comment]. British Journal of Obstetrics and Gynaecology
1993;100(6):550–7.
Wald 1994a {published data only}
Wald NJ, Densem JW. Maternal serum free alpha-human
chorionic gonadotrophin levels in twin pregnancies:
implications for screening for Down’s syndrome. Prenatal
Diagnosis 1994;14(8):717–9.
Wald 1994b {published data only}
Wald NJ, Watt HC. Choice of serum markers in antenatal
screening for Down’s syndrome. Journal of Medical Screening
1994;1(2):117–20.
Wald 1996a {published data only}
Wald NJ, Watt HC. Serum markers for Down’s syndrome
in relation to number of previous births and maternal age.
Prenatal Diagnosis 1996;16(8):699–703.
Wald 1996b {published data only}
Wald NJ, George L, Smith D, Densem JW, Petterson
K. Serum screening for Down’s syndrome between 8 and
14 weeks of pregnancy. International Prenatal Screening
Research Group.[see comment]. British Journal of Obstetrics
and Gynaecology. 1996;103(5):407–12.
Wald 1996d {published data only}
Wald NJ, Watt HC, George L. Maternal serum inhibin-A
in pregnancies with insulin-dependent diabetes mellitus:
implications for screening for Down’s syndrome. Prenatal
Diagnosis 1996;16(10):923–6.
Wald 1996e {published data only}
Wald NJ, Densem JW, George L, Muttukrishna S, Knight
PG. Prenatal screening for Down’s syndrome using inhibin-
A as a serum marker. Prenatal Diagnosis 1996;16(2):
143–53.
Wald 1997 {published data only}
Wald NJ, Hackshaw AK. Combining ultrasound and
biochemistry in first-trimester screening for Down’s
syndrome.[see comment]. Prenatal Diagnosis 1997;17(9):
821–9.
Wald 1998 {published data only}
Wald NJ, Watt HC, Haddow JE, Knight GJ. Screening
for Down syndrome at 14 weeks of pregnancy. Prenatal
Diagnosis 1998;18(3):291–3.
Wald 1999a {published data only}
Wald NJ, Hackshaw AK, Diamandis EP, Melegos DN.
Maternal serum prostate-specific antigen and Down
syndrome in the first and second trimesters of pregnancy.
Prenatal Diagnosis 1999;19(7):674–6.
Wald 1999b {published data only}
Wald NJ, Watt HC, Norgaard-Pederson B, Christiansen
M. SP1 in pregnancies with Down syndrome in the first
trimester of pregnancy. Prenatal Diagnosis 1999;19(6):
517–20.
Wald 1999c {published data only}
Wald NJ, White N, Morris JK, Huttly WJ, Canick JA.
Serum markers for Down’s syndrome in women who
have had in vitro fertilisation: implications for antenatal
screening. British Journal of Obstetrics and Gynaecology
1999;106(12):1304–6.
Wald 1999d {published data only}
Wald NJ, Watt HC, Hackshaw AK. Integrated screening
for Down’s syndrome on the basis of tests performed during
the first and second trimesters.[see comment]. New England
Journal of Medicine 1999;341(7):461–7.
40Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wald 2003b {published data only}
Wald NJ, Rish S, Hackshaw AK. Combining nuchal
translucency and serum markers in prenatal screening for
Down syndrome in twin pregnancies. Prenatal Diagnosis
2003;23(7):588–92.
Wald 2003c {published data only}
Wald NJ, Huttly WJ, Hackshaw AK. Antenatal screening for
Down’s syndrome with the quadruple test.[see comment].
Lancet 2003;361(9360):835–6.
Wald 2006 {published data only}
Wald NJ, Rudnicka AR, Bestwick JP. Sequential and
contingent prenatal screening for Down syndrome. Prenatal
Diagnosis 2006;26(9):769–77.
Wallace 1994 {published data only}
Wallace EM, Harkness LM, Burns S, Liston WA.
Evaluation of maternal serum immunoreactive inhibin
as a first trimester marker of Down’s syndrome. Clinical
Endocrinology 1994;41(4):483–6.
Wallace 1997 {published data only}
Wallace EM, Crossley JA, Ritoe SC, Groome NP, Aitken
DA. Maternal serum inhibin-A in pregnancies complicated
by insulin dependent diabetes mellitus. British Journal of
Obstetrics and Gynaecology 1997;104(8):946–8.
Ward 2005 {published data only}
Ward A. Nuchal translucency measurement. Synergy (http:/
/www.highbeam.com/doc/1P3-866108421.html) (accessed
2007) 2005.
Watt 1996a {published data only}
Watt HC, Wald NJ, Smith D, Kennard A, Densem J.
Effect of allowing for ethnic group in prenatal screening for
Down’s syndrome. Prenatal Diagnosis 1996;16(8):691–8.
Watt 1996b {published data only}
Watt HC, Wald NJ, George L. Maternal serum inhibin-A
levels in twin pregnancies: implications for screening for
Down’s syndrome. Prenatal Diagnosis 1996;16(10):927–9.
Weinans 2001 {published data only}
Weinans MJN, Pratt JJ, de Wolf HM, Mantingh A. First-
trimester maternal serum human thyroid-stimulating
hormone in chromosomally normal and Down syndrome
pregnancies. Prenatal Diagnosis 2001;21(9):723–5.
Weinans 2004 {published data only}
Weinans MJN, Kooij L, Müller MA, Bilardo KM, Van Lith
JMM, Tymstra T. A comparison of the impact of screen-
positive results obtained from ultrasound and biochemical
screening for Down syndrome in the first trimester: a pilot
study. Prenatal Diagnosis 2004;24(5):347–51.
Welborn 1994 {published data only}
Welborn JL, Timm NS. Trisomy 21 and cystic hygromas in
early gestational age fetuses. American Journal of Perinatology
1994;11(1):19–20.
Wenstrom 1993 {published data only}
Wenstrom KD, Williamson RA, Grant SS, Hudson JD,
Getchell JP. Evaluation of multiple-marker screening for
Down syndrome in a statewide population. American
Journal of Obstetrics and Gynecology 1993;169(4):793–7.
Wenstrom 1995a {published data only}
Wenstrom KD, Owen J, Boots L, Ethier M. The influence
of maternal weight on human chorionic gonadotropin in the
multiple-marker screening test for fetal Down syndrome.
American Journal of Obstetrics and Gynecology 1995;173(4):
1297–300.
Wenstrom 1995b {published data only}
Wenstrom KD, Desai R, Owen J, Dubard MB, Boots
L. Comparison of multiple-marker screening with
amniocentesis for the detection of fetal aneuploidy in
women greater than or equal 35 years old. American Journal
of Obstetrics and Gynecology 1995;173(4):1287–92.
Whitlow 1998a {published data only}
Whitlow BJ, Lazanakis ML, Kadir RA, Chatzipapas I,
Economides DL. The significance of choroid plexus cysts,
echogenic heart foci and renal pyelectasis in the first
trimester. Ultrasound in Obstetrics & Gynecology 1998;12
(6):385–90.
Whitlow 1998b {published data only}
Whitlow BJ, Economides DL. First trimester detection
of fetal abnormalities in an unselected population.
Contemporary Reviews in Obstetrics and Gynaecology 1998;
10(4):245–53.
Whitlow 1999 {published data only}
Whitlow BJ, Chatzipapas IK, Lazanakis ML, Kadir
RA, Economides DL. The value of sonography in early
pregnancy for the detection of fetal abnormalities in an
unselected population. British Journal of Obstetrics and
Gynaecology 1999;106(9):929–36.
Williamson 1994 {published data only}
Williamson R. Expanded maternal serum alpha fetoprotein
screening. Iowa Medicine 1994;84(9):397–400.
Wilson 2000 {published data only}
Wilson K. New first-trimester prenatal screening for down
syndrome. Laboratory Medicine 2000;31(11):591.
Wojdemann 2001 {published data only}
Wojdemann KR, Larsen SO, Shalmi A, Sundberg K,
Christiansen M, Tabor A. First trimester screening for
Down syndrome and assisted reproduction: no basis for
concern. Prenatal Diagnosis 2001;21(7):563–5.
Wong 2003 {published data only}
Wong SF, Choi H, Ho LC. Nasal bone hypoplasia: is it a
common finding amongst chromosomally normal fetuses
of southern Chinese women?. Gynecologic & Obstetric
Investigation 2003;56(2):99–101.
Wright 2006 {published data only}
Wright D, Bradbury I, Cuckle H, Gardosi J, Tonks A,
Standing S, et al. Three-stage contingent screening for
Down syndrome. Prenatal Diagnosis 2006;26(6):528–34.
Yagel 1998 {published data only}
Yagel S, Anteby EY, Hochner-Celnikier D, Ariel I, Chaap T,
Ben Neriah Z. The role of midtrimester targeted fetal organ
screening combined with the “triple test” and maternal
age in the diagnosis of trisomy 21: a retrospective study.
41Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
American Journal of Obstetrics and Gynecology 1998;178(1):
40–4.
Yamamoto 2001a {published data only}
Yamamoto R, Azuma M, Kishida T, Yamada H, Satomura
S, Fujimoto S. Total alpha-fetoprotein and Lens culinaris
agglutinin-reactive alpha-fetoprotein in fetal chromosomal
abnormalities. BJOG: an international journal of obstetrics
and gynaecology 2001;108(11):1154–8.
Yamamoto 2001b {published data only}
Yamamoto R, Azuma M, Hoshi N, Kishida T, Satomura
S, Fujimoto S. Lens culinaris agglutinin-reactive alpha-
fetoprotein, an alternative variant to alpha-fetoprotein
in prenatal screening for Down’s syndrome. Human
Reproduction 2001;16(11):2438–44.
Yamamoto 2001c {published data only}
Yamamoto R, Azuma M, Wakui Y, Kishida T, Yamada H,
Okuyama K, et al. Alpha-fetoprotein microheterogeneity: a
potential biochemical marker for Down’s syndrome. Clinica
Chimica Acta 2001;304(1-2):137–41.
Yaron 2001 {published data only}
Yaron Y, Wolman I, Kupferminc MJ, Ochshorn Y, Many
A, Orr-Urtreger A. Effect of fetal gender on first trimester
markers and on Down syndrome screening. Prenatal
Diagnosis 2001;21(12):1027–30.
Ye 1995 {published data only}
Ye G, Liao S, Zhao X. The possibility of prenatal screening
for fetal abnormalities in second-trimester pregnancies by
measuring AFP, ß-HCG and uE-3 levels. Xi’an Yike Daxue
Xuebao 1995;16(4):408–11.
Yoshida 2000 {published data only}
Yoshida K, Kuwabara Y, Tanaka T, Onda T, Kudo R,
Yamamoto H, et al. Dimeric Inhibin A as a fourth marker
for Down’s syndrome maternal serum screening in native
Japanese women. Journal of Obstetrics and Gynaecology
Research 2000;26(3):171–4.
Zeitune 1991 {published data only}
Zeitune M, Aitken DA, Crossley JA, Yates JR, Cooke
A, Ferguson-Smith MA. Estimating the risk of a fetal
autosomal trisomy at mid-trimester using maternal serum
alpha-fetoprotein and age: a retrospective study of 142
pregnancies. Prenatal Diagnosis 1991;11(11):847–57.
Zelop 2005 {published data only}
Zelop CM, Milewski E, Brault K, Benn P, Borgida AF, Egan
JFX. Variation of fetal nasal bone length in second-trimester
fetuses according to race and ethnicity. Journal of Ultrasound
in Medicine 2005;24(11):1487–9.
Zhao 1998 {published data only}
Zhao Xiaolan, Ye Guoling, Liu Qi. Using maternal
serum PAPP-A and other pregnancy-associated proteins in
screening for fetal abnormalities. Xi’an Yike Daxue Xuebao
1998;19(1):94-6, 110.
Zoppi 2003 {published data only}
Zoppi MA, Ibba RM, Floris M, Manca F, Axiana C, Monni
G. Changes in nuchal translucency thickness in normal and
abnormal karyotype fetuses. BJOG: an international journal
of obstetrics and gynaecology 2003;110(6):584–8.
Additional references
Alfirevic 2003
Alfirevic Z, Sundberg K, Brigham S. Amniocentesis and
chorionic villus sampling for prenatal diagnosis. Cochrane
Database of Systematic Reviews 2003, Issue 3. [DOI:
10.1002/14651858.CD003252]
Alfirevic 2004
Alfirevic Z, Neilson JP. Antenatal screening for Down’s
syndrome. BMJ 2004;9(329(7470)):811–2.
Alldred 2010
Alldred SK, Deeks JJ, Neilson JP, Alfirevic Z. Antenatal
screening for Down’s syndrome: generic protocol. Cochrane
Database of Systematic Reviews 2010, Issue 4. [DOI:
10.1002/14651858.CD007384.pub2]
Alldred 2012
Alldred SK, Deeks JJ, Guo B, Neilson JP, Alfirevic Z. Second
trimester serum tests for Down’s Syndrome screening.
Cochrane Database of Systematic Reviews 2012, Issue 6.
[DOI: 10.1002/14651858.CD009925]
Bersinger 1995
Bersinger NA, Zakher A, Huber U, Pescia G, Schneider
H. A sensitive enzyme immunoassay for pregnancy-
associated plasma protein A (PAPP-A): a possible first
trimester method of screening for Down syndrome and
other trisomies. Archives of Gynecology and Obstetrics 1995;
256(4):185–92.
Bogart 1987
Bogart MH, Pandian MR, Jones OW. Abnormal maternal
serum chorionic gonadotropin levels in pregnancies with
fetal chromosome abnormalities. Prenatal Diagnosis 1987;7
(9):623–30.
Bossuyt 2003
Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou
PP, Irwig LM, et al. Towards complete and accurate
reporting of studies of diagnostic accuracy: the STARD
initiative. BMJ 2003;326(7379):41–4. [PUBMED:
12511463]
Cole 1999a
Cole LA, Shahabi S, Oz UA, Bahado-Singh RO, Mahoney
MJ. Hyperglycosylated hCG (invasive trophoblast antigen)
immunoassay: a new basis for gestational Down syndrome
screening. Clinical Chemistry 1999;45:2109–19.
Cuckle 1995a
Cuckle HS, Holding S, Jones R, Wallace EM, Groome
NP. Maternal serum dimeric inhibin A in second-trimester
Down’s syndrome pregnancies. Prenatal Diagnosis 1995;
Vol. 15, issue 4:385–6.
Macri 1990
Macri JN, Kasturi RV, Krantz DA, Cook EJ, Moore ND,
Young JA, et al. Maternal serum Down syndrome screening:
free beta-protein is a more effective marker than human
42Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
chorionic gonadotropin. American Journal of Obstetrics and
Gynecology 1990;163(4 Pt 1):1248–53.
Macri 1993
Macri JN, Spencer K, Aitken D, Garver K, Buchanan PD,
Muller F, et al. First-trimester free beta (hCG) screening for
Down syndrome. Prenatal Diagnosis 1993;13(7):557–62.
Mol 1999
Mol BW, Lijmer JG, Van der Meulen J, Pajkrt E, Bilardo
CM, Bossuyt PM. Effect of study design on the association
between nuchal translucency measurement and Down
syndrome. Obstetrics and Gynecology 1999;94(5 Pt 2):
864–9.
Penrose 1933
Penrose LS. The relative effects of parental and maternal age
in mongolism. Journal of Genetics 1933;27:219–24.
Steele 1966
Steele MW, Breg WR. Chromosome analysis of human
amniotic-fluid cells. Lancet 1966;i:383–5.
Vaklenti 1968
Vaklenti C, Schutta E.J, Kehaty T. Prenatal diagnosis of
Down’s syndrome. Lancet 1968;ii:220.
Wald 2003a
Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty
L, Mackinson AM, SURUSS Research Group. First and
second trimester antenatal screening for Down’s syndrome:
the results of the Serum, Urine and Ultrasound Screening
Study (SURUSS). Health Technology Assessment (Winchester,
England) 2003;7(11):1–77.
Wallace 1995
Wallace EM, Grant VE, Swanston IA, Groome NP.
Evaluation of maternal serum dimeric inhibin A as a first-
trimester marker of Down’s syndrome. Prenatal Diagnosis
1995;15(4):359–62.
Whiting 2003
Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen
J. The development of QUADAS: a tool for the quality
assessment of studies of diagnostic accuracy included in
systematic reviews. BMC Medical Research Methodology
2003;3:25.
∗ Indicates the major publication for the study
43Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bahado-Singh 1998
Clinical features and settings High-risk referral for invasive testing.
Participants 511 participants.
USA.
August 1996 to January 1997.
Singleton pregnancies.
Pregnant women.
Mean age 37.1 years (SD 2.8 years).
15-24 weeks’ gestation.
Study design Prospective cohort study.
Target condition and reference standard(s) Down’s syndrome: 18 cases.
Reference standard: amniocentesis.
Index and comparator tests Mid-trimester urine ß-core fragment testing (monoclonal antibody B210 assay, 2-step
sandwich method, standardised for creatinine)
Follow-up 100% karyotyping.
Aim of study To ascertain the screening efficiency of a new mid-trimester Down’s syndrome detection
protocol that combines maternal urine testing and ultrasonographic examination
Notes Amniocentesis was being conducted on the basis of maternal age. Women who have
amniocentesis just due to abnormal screening results were excluded from the study
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes Amniocentesis.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
Yes All women underwent the same reference stan-
dard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
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Bahado-Singh 1998 (Continued)
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge
of index test results.
Index test results blinded?
All tests
Yes Urine testing was conducted blind from the re-
sults of amniocentesis.
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Bahado-Singh 1998b
Clinical features and settings High-risk referral for invasive testing.
Participants 356 participants: 10 cases and 346 controls.
USA.
Dates not reported.
Singleton pregnancies.
Pregnant women.
14-24 weeks’ gestation.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 10 cases.
Reference standard: amniocentesis.
Index and comparator tests Seond trimester urine ß-core fragment testing (monoclonal antibody B210 assay, 2-step
sandwich method, standardised for creatinine)
Second trimester serum AFP.
Risk cut points of 1/10, 1/20, 1/30, 1/58, 1/270, 1/526.
Follow-up 100% karyotyping.
Aim of study To determine Down’s syndrome screening efficiency of a new protocol that combines
maternal serum AFP and beta core fragment/total oestriol ratio
Notes
Table of Methodological Quality
Item Authors’ judgement Description
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Bahado-Singh 1998b (Continued)
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes Amniocentesis.
Partial verification avoided?
All tests
Yes All women underwent a reference standard.
Differential verification avoided?
All tests
Yes All women underwent the same reference stan-
dard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge
of index test results
Index test results blinded?
All tests
Yes Index test interpretedwithout knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Bahado-Singh 1999
Clinical features and settings High-risk referral for invasive testing.
Participants 457 participants.
USA.
August 1996 - June 1997.
Pregnant women.
Mean age 37.1 years.
Singleton pregnancies.
15-24 weeks’ gestation.
Study design Prospective cohort study.
Target condition and reference standard(s) Down’s syndrome: 13 cases.
Reference standard: amniocentesis.
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Bahado-Singh 1999 (Continued)
Index and comparator tests Maternal age.
Urinary ß core fragment (monoclonal antibody B210 assay, 2-step sandwich method,
standardised for creatinine)
Urinary beta core fragment/total urinary oestriol ratio.
Follow-up 100% karyotyping.
Aim of study To evaluate Down’s syndrome screening efficiency of a new algorithm of multiple urinary
biochemical and ultrasound markers
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes Amniocentesis.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
Yes All women received the same reference stan-
dard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge
of index test results.
Index test results blinded?
All tests
Yes Index test interpretedwithout knowledge of ref-
erence standard results.
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
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Bahado-Singh 1999a
Clinical features and settings High-risk referral for invasive testing.
Participants 926 participants.
USA.
November 1995 - March 1999.
Pregnant women.
Singleton pregnancies.
15-24 weeks’ gestation.
Euploid/Down’s karyotype only.
Study design Prospective cohort study.
Target condition and reference standard(s) Down’s syndrome: 21 cases.
Reference standard: amniocentesis.
Index and comparator tests Maternal age.
Second trimester urinary ß core fragment (Spot specimens of urine - 2-step sandwich
assay B120 monoclonal antibody)
Second trimester serum AFP.
Frozen serum samples tested for second trimester uE3 and free ßhCG (details of serum
testing methods not given)
Follow-up 100% karyotyping.
Aim of study To compare Down’s syndrome screening efficiency of elevated maternal urine level of
beta core fragment with that of a traditional serum triple test
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes Amniocentesis.
Partial verification avoided?
All tests
Yes All women received a reference standard.
Differential verification avoided?
All tests
Yes All women had the same reference standard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
48Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bahado-Singh 1999a (Continued)
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge
of index test results.
Index test results blinded?
All tests
Yes Index test interpretedwithout knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Bahado-Singh 2000
Clinical features and settings High-risk referral for invasive testing.
Participants 1016 participants.
USA.
May 1995 - June 1998.
Singleton pregnancies.
Pregnant women.
Mean age 37.1 years (19.3-46 years).
14-24 weeks’ gestation.
Euploid or Down’s pregnancies only.
Study design Prospective cohort study.
Target condition and reference standard(s) Down’s syndrome: 23 cases.
Reference standard: amniocentesis.
Index and comparator tests Second trimester urinary hyperglycosylated hCG (Specific monoclonal antibody devel-
oped. 2-step enzyme immunometric assay standardised for creatinine levels)
Follow-up 100% karyotyping.
Aim of study To evaluate the measurement of levels of urine hyperglycosylated hCG in conjunction
with ultrasound biometry for Down’s syndrome risk prediction in an at risk group
Notes
Table of Methodological Quality
Item Authors’ judgement Description
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Bahado-Singh 2000 (Continued)
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes Amniocentesis.
Partial verification avoided?
All tests
Yes All women had a reference standard.
Differential verification avoided?
All tests
Yes All women had the same reference standard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge
of index test results
Index test results blinded?
All tests
Yes Index test interpretedwithout knowledge of ref-
erence standard results.
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Bahado-Singh 2000a
Clinical features and settings High-risk referral for invasive testing.
Participants 524 participants.
USA - single hospital.
August 1995 - April 1999.
Singleton pregnancies.
Pregnant women.
Mean age 36.6 years (SD 5.3 years) in those with Down’s detected and 37.0 years (SD
3.4 years) in those with euploid pregnancies
14-22 weeks’ gestation.
Study design Prospective cohort study.
Target condition and reference standard(s) Down’s syndrome: 24 cases.
Reference standard: amniocentesis.
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Bahado-Singh 2000a (Continued)
Index and comparator tests Maternal age.
Second trimester serum hCG (IMX total β-hCG kit, Abbott Laboratories), uE3 (DSL-
1400 Ultra-sensitive unconjugated Estriol Radioimmunoassay kit) and AFP (IMX AFP
kit, Abbott Laboratories)
Second trimester urinary beta core fragment (Spot specimens of urine - 2-step sandwich
assay B120 monoclonal antibody)
Frozen samples tested for second trimester urinary hyperglycosylated hCG (Specific
monoclonal antibody developed. 2-step enzyme immunometric assay standardised for
creatinine levels)
Follow-up 100% karyotyping.
Aim of study To compare the concentration of hyperglycosylated human chorionic gonadotropin with
serum triple screen for second trimester Down’s syndrome detection
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes Amniocentesis.
Partial verification avoided?
All tests
Yes All women had a reference standard.
Differential verification avoided?
All tests
Yes All women had the same reference standard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results.
Index test results blinded?
All tests
Unclear Unclear if index test interpreted with knowl-
edge of reference standard results.
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
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Bahado-Singh 2000a (Continued)
Withdrawals explained?
All tests
No No details of withdrawals given.
Canick 1995
Clinical features and settings Referral for termination of pregnancy, amniocentesis or routine examination
Participants 105 participants: 14 cases and 91 controls.
USA.
Dates not reported.
Singleton pregnancies.
Pregnant women.
15-21 weeks’ gestation.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 14 cases.
Reference standard: karyotyping on termination of pregnancy or amniocentesis
Index and comparator tests Maternal age.
Frozen samples tested for:
second trimester urinary gonadotropin peptide (Triton UGP EIA assay, Alameda);
second trimester serum hCG (MAIAclone hCG assay, Serono-Baker Diagnostics, Allen-
town)
Follow-up No details given for any follow-up to birth. Reported that the fetal karyotype of control
samples was not always known but assumed that none were aneuploid pregnancies
Aim of study To assess whether urinary gonadotropin peptide is better than serum hCG as a second
trimester screening marker
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening and selective testing of
high-risk women as done in practice
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
No Not all women received a reference stan-
dard.
Differential verification avoided?
All tests
No Women had different reference standards.
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Canick 1995 (Continued)
Incorporation avoided?
All tests
Yes Reference standard was independent of the
index test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without
knowledge of index test results
Index test results blinded?
All tests
Unclear Unclear if index test interpreted without
knowledge of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in stan-
dard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninter-
pretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Cole 1997a
Clinical features and settings High-risk referral for invasive testing.
Participants 722 participants.
USA - single hospital.
August 1995 - May 1996.
Pregnant women.
Singleton pregnancy.
12-24 weeks’ gestation.
Study design Cohort study.
Target condition and reference standard(s) Down’s syndrome: 13 cases.
Reference standard: amniocentesis.
Index and comparator tests Second trimester urinary hCG free beta subunit (Immunoenzymometric assay with
autoantibody FBT11)
Follow-up 100% karyotyping.
Aim of study To evaluate use of second trimester urinary free beta-subunit for Down’s syndrome
screening
Notes
Table of Methodological Quality
Item Authors’ judgement Description
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Cole 1997a (Continued)
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes Amniocentesis.
Partial verification avoided?
All tests
Yes All women had a reference standard.
Differential verification avoided?
All tests
Yes All women had the same reference standard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Yes Index test interpretedwithout knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Cole 1997b
Clinical features and settings High-risk referral for invasive testing.
Participants 492 participants.
USA - single hospital.
August 1995 - May 1996.
Pregnant women.
Singleton pregnancy.
12-24 weeks’ gestation.
Study design Prospective cohort study.
Target condition and reference standard(s) Down’s syndrome: 12 cases.
Reference standard: amniocentesis.
Index and comparator tests Second trimester urinary hCG free beta subunit (B210 2-step sandwich assay)
Second trimester urinary total oestriol (radioimmunoassay, kit fromDiagnostics Products
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Cole 1997b (Continued)
Corporation, Los Angeles)
Follow-up 100% karyotyping.
Aim of study To evaluate use of urinary free beta core fragment combined with urinary total oestriol
for Down’s syndrome screening
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant popula-
tion.
Acceptable reference standard?
All tests
Yes Amniocentesis.
Partial verification avoided?
All tests
Yes All women had a reference standard.
Differential verification avoided?
All tests
Yes All women had the same reference standard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Unclear Unclear if index test interpretedwithout knowl-
edge of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
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Cole 1999b
Clinical features and settings High-risk referral for invasive testing.
Participants 1157 participants.
USA - 3 hospitals.
May 1995 - March 1998.
Pregnant women.
Singleton pregnancy.
11-22 weeks’ gestation.
Study design Prospective cohort study.
Target condition and reference standard(s) Down’s syndrome: 23 cases.
Reference standards: amniocentesis or CVS.
Index and comparator tests Urinary hCG beta-core subunit (B210 2-step sandwich assay).
Urinary total oestriol (radioimmunoassay, kit by Diagnostic Products Corporation, Los
Angeles)
Follow-up 100% karyotyping.
Aim of study To evaluate use of urinary free beta-subunit for Down’s syndrome screening
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes Amniocentesis or CVS.
Partial verification avoided?
All tests
Yes All women had a reference standard.
Differential verification avoided?
All tests
No Women had CVS or amniocentesis depending
on their stage of pregnancy
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Yes Index test interpretedwithout knowledge of ref-
erence standard results
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Cole 1999b (Continued)
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice.
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Cuckle 1995b
Clinical features and settings High-risk referral for invasive testing and testing for bacterial analysis
Participants 315 participants.
UK.
Dates not specified.
Pregnant women: 24 cases undergoing invasive testing and 294 controls undergoing
testing for bacterial analysis
11-23 weeks’ gestation.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 24 cases.
Reference standards: amniocentesis or CVS for cases and follow-up for controls
Index and comparator tests Urinary beta core fragment (Modified radioimmunoassay method)
Urinary total oestrogen (continuous flow reaction based on the Kuber method)
Follow-up No details given of methods of follow-up.
Aim of study To evaluate the use of multiple urinary markers rather than serum in order to screen for
Down’s syndrome
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as
done in practice.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Yes All women had a reference standard.
57Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cuckle 1995b (Continued)
Differential verification avoided?
All tests
No Women had different reference standards.
Incorporation avoided?
All tests
Yes Reference standard was independent of the
index test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without
knowledge of index test results.
Index test results blinded?
All tests
Yes Index test interpreted without knowledge
of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in stan-
dard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninter-
pretable measurements.
Withdrawals explained?
All tests
No No details of withdrawals given.
Cuckle 1999
Clinical features and settings High-risk referral for invasive testing and routine screening
Participants 349 participants: 45 cases and 304 controls.
UK.
Dates not specified.
Pregnant women.
14-19 weeks’ gestation.
Study design Retrospective case-control study.
Target condition and reference standard(s) Down’s syndrome: 45 cases.
Reference standard: amniocentesis, CVS or follow-up to birth
Index and comparator tests Frozen samples tested for urinary hyperglycosylated hCG (Immunoassays by ’Cole’
method corrected for creatinine levels using Jaffes method)
Follow-up Details of follow-up not reported.
Aim of study To determine the distribution of hyperglycosylated hCG levels in pregnancies with
Down’s syndrome
Notes
Table of Methodological Quality
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Cuckle 1999 (Continued)
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Routine screening of typical pregnant pop-
ulation.
Acceptable reference standard?
All tests
Yes Amniocentesis, CVS or follow-up.
Partial verification avoided?
All tests
Yes All women had a reference standard.
Differential verification avoided?
All tests
No Women had different reference standards.
Incorporation avoided?
All tests
Yes Index tests did not form part of the refer-
ence standard.
Reference standard results blinded?
All tests
Yes Reference standard conducted before the
index test.
Index test results blinded?
All tests
Unclear Index test conducted after the reference
standard and no evidence of blinding
Relevant clinical information?
All tests
Yes Information available as would be in stan-
dard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninter-
pretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Cuckle 1999a
Clinical features and settings High-risk referral for invasive testing and routine screening
Participants 6730 participants.
USA, UK and other European countries -multicentre study.
Dates not reported.
Pregnant women.
14-19 weeks’ gestation.
Study design Prospective cohort study.
Target condition and reference standard(s) Down’s syndrome: 39 cases.
Reference standard: amniocentesis, CVS or postnatal examination
Index and comparator tests Maternal urine beta core hCG (Chiron manual assay).
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Cuckle 1999a (Continued)
Follow-up Methods of follow-up not reported.
Aim of study A prospective evaluation of urine beta core hCG for Down’s syndrome
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as
done in practice.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference
standard.
Differential verification avoided?
All tests
No Women had different reference standards.
Incorporation avoided?
All tests
Yes Index tests did not form part of the refer-
ence standard.
Reference standard results blinded?
All tests
No Reference standard interpreted with
knowledge of index test results
Index test results blinded?
All tests
Yes Index test conductedwithout knowledge of
the reference standard
Relevant clinical information?
All tests
Yes Information available as would be in stan-
dard clinical practice
Uninterpretable results reported?
All tests
No No details given for test failures/uninter-
pretable measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Hsu 1999
Clinical features and settings High-risk referral for invasive testing.
Participants 474 participants: 69 cases and 405 controls.
Taiwan and UK.
Dates not specified.
Pregnant women.
60Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hsu 1999 (Continued)
Median age cases 36.0 years (21-44 years), controls 34.5 years (23-43 years)
14-26 weeks’ gestation.
Study design Retrospective case-control study.
Target condition and reference standard(s) Down’s syndrome: 69 cases.
Reference standard: amniocentesis.
Index and comparator tests Maternal age.
Urinary beta core fragment (UGP) (UGF-EIA Toa kit).
Urinary free beta hCG (CIS immunoradiometric assay).
Urinary total oestriol (Orthoclinical diagnostics oestriol (total) II radioimmunoassay kit)
All adjusted for creatinine concentration.
Modelled to standardised population for England and Wales 1991-1994. Cases from
Taiwan
Follow-up 100% karyotyping.
Aim of study To investigate levels of urinary beta core fragment, free beta hCG and total oestriol in a
new large set of Down’s syndrome pregnancies
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes Amniocentesis.
Partial verification avoided?
All tests
Yes All women had a reference standard.
Differential verification avoided?
All tests
Yes All women had the same reference standard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Unclear Unclear if index test interpretedwithout knowl-
edge of reference standard results
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Hsu 1999 (Continued)
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice.
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements.
Withdrawals explained?
All tests
No No details of withdrawals given.
Isozaki 1997
Clinical features and settings High-risk referral for invasive testing.
Participants 726 participants.
USA - single centre.
August 1995 - May 1996.
Pregnant women.
Mean age 35.4 years (SD 4.0 years) in mothers of Down’s syndrome babies and 37 years
(SD 4.3 years) in mothers of healthy babies
Singleton pregnancies.
12-24 weeks’ gestation.
Study design Prospective cohort study.
Target condition and reference standard(s) Down’s syndrome: 13 cases.
Reference standard: amniocentesis.
Index and comparator tests Urinary beta core fragment (B210 monoclonal antibody, 2-step sandwich assay)
Follow-up 100% karyotyping.
Aim of study To present data for prospectively collected samples of urinary beta core fragment for
Down’s syndrome screening
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes Amniocentesis.
Partial verification avoided?
All tests
Yes All women had a reference standard.
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Isozaki 1997 (Continued)
Differential verification avoided?
All tests
Yes All women had the same reference standard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Yes Index test interpretedwithout knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice.
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements.
Withdrawals explained?
All tests
No No details of withdrawals given.
Palomaki 2004a
Clinical features and settings High-risk referral for invasive testing.
Participants 2,055 participants.
USA - multicentre study.
January 2001 - January 2003.
Pregnant women with mean age 38.9 years.
15-20 weeks’ gestation.
Study design Prospective cohort study.
Target condition and reference standard(s) Down’s syndrome: 28 cases.
Reference standard: amniocentesis.
Index and comparator tests Urinary invasive trophoblastic antigen (ITA) (B207 (detection) and B152 (capture) anti-
hCG monoclonal antibodies)
Follow-up 100% karyotyping.
Aim of study To evaluate ITA as a potential marker for Down’s syndrome in the second trimester of
pregnancy
Notes Clean catch of random urine provided. Sent same day at 4 degrees Celcius on an ice
pack. Aliquoted into 1 mL plastic tubes. 1 urine aliquot shipped to lab for testing. Rest
stored at -70 degrees Celcius. Most samples assayed within 24 hours of reaching lab and
all within 48 hours. Anti-ITA antibody produced. Sample corrected for creatinine levels
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Palomaki 2004a (Continued)
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk population as done
in practice
Acceptable reference standard?
All tests
Yes Amniocentesis.
Partial verification avoided?
All tests
Yes All women had a reference standard.
Differential verification avoided?
All tests
Yes All women had the same reference standard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Yes Index test interpretedwithout knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
Spencer 1996
Clinical features and settings High-risk referral for invasive testing.
Participants 429 participants: 29 cases and 400 controls.
UK.
Date not specified.
Pregnant women.
Singleton pregnancies.
14-24 (cases) and 9-22 (controls) weeks’ gestation.
Study design Case-control study.
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Spencer 1996 (Continued)
Target condition and reference standard(s) Down’s syndrome: 29 cases.
Reference standards: amniocentesis or CVS.
Index and comparator tests Urine free beta hCG (CIS immunoradiometric assay).
Urinary beta core fragment (Ciba Corning diagnostics UGP enzyme immunoassay)
Follow-up 100% karyotyping.
Aim of study To evaluate whether free beta hCG is elevated in the urine of pregnancies affected by
Down’s syndrome and investigate whether urine free beta hCG may be used as possible
screening markers
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes Amniocentesis or CVS.
Partial verification avoided?
All tests
Yes All women had a reference standard.
Differential verification avoided?
All tests
No Women had different reference standards.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Yes Index test interpretedwithout knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice.
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
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Wald 2003
Clinical features and settings Routine screening.
Participants 606 participants: 101 cases, 505 controls matched for gestation, duration of storage and
centre
UK and Austria - multicentre trial.
September 1996 - April 2000.
Pregnant women.
9-13 and 14-20 weeks’ gestation.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 101 cases.
Reference standards: invasive testing (following second trimester screening) or follow-
up to birth
Index and comparator tests First trimesterNT (midsagittal section, optimal magnification of thickness of translucent
space between inner skin surface and fascia covering cervical spine (white black interface
(outer) - black white interface (inner), 41 models of ultrasound machine, 20 minutes
allotted scanning time)
First and second trimester serum AFP, hCG, uE3, PAPP-A, free beta hCG (time resolved
fluoroimmunoassay, AutoDELFIA)
First and second trimester inhibin A (Sandwich enzyme-linked immunosorbent assay,
Oxford Bio-innovation)
First and second trimester urinary beta core fragment, total hCG, ITA and free beta
hCG (ITA and beta core fragment, Quest diagnostics USA)
Follow-up Follow-up by: 1) Staff at local hospitals completed a study outcome form at, or just
after. delivery, 2) Study records of CVS, amniocentesis or karyotype at birth linked to
information from cytogenic laboratories, 3) Study records linked to records of cases
of Down’s syndrome from the National Down’s Syndrome Cytogenetic Register, 4)
Information obtained from local obstetrical outcome records, 5) Forms sent to all women
with a request to return details of the outcome of their pregnancy, 6) Individual searches
in respect of women whose outcomes of pregnancy had not been obtained by any of
the previous methods. 4% of women in the total cohort did not have a documented
outcome of pregnancy. Unclear if any of these women were included in this nested case-
control study
Aim of study To identify the most effective, safe and cost-effective strategy for antenatal screening for
Down’s syndrome using NT, maternal serum and urine markers in the first and second
trimesters of pregnancy and maternal age in various combinations
Notes Performance of screening assessed at 17 weeks’ gestation. Study tried to be non-interven-
tional in the first trimester - second trimester testing was aimed to be used as the basis
for any referral for invasive testing
Table of Methodological Quality
Item Authors’ judgement Description
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Wald 2003 (Continued)
Representative spectrum?
All tests
Yes Routine screening of typical pregnant population.
Acceptable reference standard?
All tests
Yes Karyotyping or follow-up to birth.
Partial verification avoided?
All tests
Unclear Unclear if all women received a reference standard.
Differential verification avoided?
All tests
No Women received different reference standards.
Incorporation avoided?
All tests
Yes Reference standard was independent of the index test.
Reference standard results blinded?
All tests
No Reference standard interpreted with knowledge of index test
results
Index test results blinded?
All tests
Unclear Serum testing conducted after reference standard and unclear if
interpreted without knowledge of reference standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard clinical practice.
Uninterpretable results reported?
All tests
Yes Rates of NT failure on average 9%. Pre-10 weeks’ gestation, >
33% failure rate, declined to 7% at 12 weeks
Withdrawals explained?
All tests
No No details of withdrawals given.
Weinans 2000
Clinical features and settings High-risk referral for invasive testing.
Participants 63 participants: 8 cases and 55 controls matched for gestational and maternal age, ma-
ternal weight, duration of storage and smoking history
The Netherlands - single hospital.
October 1997 to May 1999.
Pregnant women.
10-11 weeks’ gestation.
Study design Case-control study.
Target condition and reference standard(s) Down’s syndrome: 8 cases.
Reference standard: CVS.
Index and comparator tests Urinary hyperglycosylated hCG, (procedures previously described in Cole 1999a).
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Weinans 2000 (Continued)
Follow-up 100% karyotyping.
Aim of study To investigate the value of H-hCG measurements in very early pregnancy (prior to 12
weeks’ gestation)
Notes
Table of Methodological Quality
Item Authors’ judgement Description
Representative spectrum?
All tests
Yes Selective testing of high-risk women as done in
practice.
Acceptable reference standard?
All tests
Yes CVS.
Partial verification avoided?
All tests
Yes All women had a reference standard.
Differential verification avoided?
All tests
Yes All women had the same reference standard.
Incorporation avoided?
All tests
Yes Reference standard was independent of the in-
dex test.
Reference standard results blinded?
All tests
Yes Reference standard interpreted without knowl-
edge of index test results
Index test results blinded?
All tests
Yes Index test interpretedwithout knowledge of ref-
erence standard results
Relevant clinical information?
All tests
Yes Information available as would be in standard
clinical practice
Uninterpretable results reported?
All tests
No Nodetails given for test failures/uninterpretable
measurements
Withdrawals explained?
All tests
No No details of withdrawals given.
AFP: alpha-fetoprotein
ßhCG: beta human chorionic gonadotrophin
CVS: chorionic villus sampling
hCG: human chorionic gonadotrophin
ITA: invasive trophoblast antigen
NT: nuchal translucency
PAPP-A: Pregnancy-associated plasma protein A
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SD: standard deviation
uE3: unconjugated oestriol
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abbas 1995 Unable to extract useful data.
Abdul-Hamid 2004 No Down’s syndrome pregnancies.
Abraha 1999 Unable to extract useful data.
Adekunle 1999 Unable to extract useful information.
Aitken 1993 Unable to extract useful data.
Aitken 1996a Fewer than 80% of pregnancies had gestational age confirmed by USS
Aitken 1996b Fewer than 80% of pregnancies had gestational age confirmed by USS
Akbas 2001 Less than 5 Down’s syndrome pregnancies.
Antona 1998 Likely fewer than 80% of pregnancies dated by USS.
Antsaklis 1999 Women screened at greater than 24 weeks’ gestation.
Ashwood 1987 Unable to extract useful data.
Asrani 2005 Review article.
Audibert 2001b Data were not relevant to this review - this study was not looking at urine tests for Down’s syndrome
screening
Axt-Fleidner 2006 Unable to extract useful data.
Azuma 2002 Unable to extract useful data.
Baghagho 2004 Unable to obtain paper.
Bahado-Singh 1995 USS markers greater than 14 weeks’ gestation.
Bahado-Singh 1996 USS markers greater than 14 weeks’ gestation.
Bahado-Singh 1999b USS markers greater than 14 weeks’ gestation.
Bahado-Singh 2002 USS markers greater than 14 weeks’ gestation.
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(Continued)
Bahado-Singh 2003 Review article.
Bar-Hava 2001 No Down’s pregnancies in study population.
Barkai 1996 No Down’s pregnancies in study population.
Barnabei 1995 No Down’s pregnancies in study population.
Bartels 1988 Unable to extract useful data.
Bartels 1993 No Down’s pregnancies in study population.
Barth 1991 Second trimester ultrasound study.
Baviera 2004 Unclear method of confirmation of gestational age.
Bazzett 1998 Male versus female fetuses.
Bellver 2005 No Down’s syndrome pregnancies in study.
Benn 1995 Less than 80% follow-up.
Benn 1996 Less than 80% follow-up.
Benn 1997 No Down’s pregnancies in study population.
Benn 1998 Less than 80% follow-up.
Benn 2001 Statistical modelling (computer simulation).
Benn 2002 Modelled data.
Benn 2003a Less than 80% of pregnancies dated by USS.
Benn 2003b Editorial.
Benn 2005a No Down’s pregnancies included.
Benn 2005b Mathematical model.
Berry 1995 Less than 80% of pregnancies USS dated.
Berry 1997 Less than 80% of pregnancies USS dated.
Bersinger 1994 Gestational age not USS estimated.
Bersinger 2000 Unable to extract useful data.
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Bersinger 2001 No Down’s syndrome pregnancies in study population.
Bersinger 2003 Unable to extract useful data.
Bersinger 2004 No Down’s syndrome pregnancies in study population.
Bersinger 2005 No Down’s syndrome pregnancies in study population.
Biggio 2004 Cost-effectiveness analysis.
Bindra 2002 Review article.
Blundell 1999 Unable to extract useful data.
Boots 1989 Population risk factor calculations.
Borruto 2002 Unable to extract useful data.
Boue 1990 Review article.
Bradley 1994 Screen-negative population gestations not confirmed by ultrasound
Braithwaite 1996 Review article.
Brambati 1995 USS screening inclusive of women greater than 14 weeks’ gestation
Brambati 1996 Review article.
Brizot 1995a Unable to extract useful data.
Brizot 1995b Unable to extract useful data.
Brizzi 1989b Second trimester ultrasound.
Brock 1990 Unable to extract useful data.
Campogrande 2001 Unable to extract useful data.
Canick 1988 Unable to extract useful data.
Canick 1995b Unable to extract useful data.
Canini 2002 No Down’s syndrome pregnancies in study population.
Cans 1998 Second trimester ultrasound.
Carreras 1991 Second trimester ultrasound.
Chen 1999 Review article.
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Chen 2002 No Down’s syndrome pregnancies in study population.
Chen 2004 Less than 5 Down’s cases in study population.
Chen 2005 Unable to extract useful data.
Cheng 1993 Likely that fewer than 80% of gestational age confirmed by USS
Cheng 1999 Case series. No Down’s syndrome pregnancies in study population
Cheng 2004a No Down’s syndrome pregnancies in study population.
Cheng 2004b No Down’s syndrome pregnancies in study population.
Chitayat 2002 Less than 5 Down’s cases in study population.
Christiansen 2002 Unable to extract useful data.
Christiansen 2007 Unable to extract useful data.
Chung 2000 Less than 5 Down’s syndrome pregnancies in study population.
CNGOF 1996 Unable to obtain translation.
Cole 1996 Review article.
Comas 2001 USS at greater than 14 weeks.
Comas 2002a USS at greater than 14 weeks.
Comas 2002b USS at greater than 14 weeks.
Comstock 2006 Unable to extract useful data.
Conde-Agudelo 1998 Review article.
Crossley 1991 Less than 80% of pregnancies had gestational age confirmation by ultrasound
Crossley 1993 Less than 80% of pregnancies had gestational age confirmation by ultrasound
Crossley 1996 No Down’s syndrome pregnancies in study population.
Crossley 2002a Adjustment factors for smokers.
Cuckle 1984 Gestational age not confirmed by USS.
Cuckle 1987a Gestational age not confirmed by USS.
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Cuckle 1987b No gestational age limits given.
Cuckle 1990 Paper presenting adjustment factors.
Cuckle 1996 Data modelled on 4 meta-analysed studies.
Cuckle 1999b Unable to extract useful data.
Cuckle 1999c Review article.
Cullen 1990 Abnormal scans only in study population.
Cusick 2004 Less than 5 Down’s syndrome pregnancies in study population.
D’Ottavio 1997 Second trimester USS.
Dancoine 2001 No Down’s syndrome pregnancies in study population.
De Biasio 2000 Unable to extract useful information.
De Biasio, 1999 Unable to ascertain whether overlapping populations between several papers - attempted to contact
author with no response
De Biasio, 2001 Unable to ascertain whether overlapping populations between several papers - attempted to contact
author with no response
De Graaf 1991 Unable to extract useful data.
De Graaf 1999 Modelled data.
DeVore 2001 Second trimester ultrasound.
Dickerson 1994 Comment.
Dimaio 1987 Gestational age by USS only in screen-positive population.
Doran 1986 Ultrasound confirmation of gestational age performed in screen-positive women only
Drugan 1996a Second trimester ultrasound.
Drugan 1996b Unable to extract useful data.
Drysdale 2002 Fewer than 5 Down’s syndrome pregnancies in population.
Ebell 1999 Review article.
Economides 1998 Unable to extract useful data.
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Erickson 2004 No Down’s syndrome pregnancies in population.
Evans 1996 No Down’s syndrome pregnancies in population.
Falcon 2005 Unable to extract useful data.
Falcon 2006 Unable to extract useful data.
Ford 1998 Audit.
Frishman 1997 No Down’s syndrome pregnancies in population.
Fukada 2000 Unable to extract useful data.
Ghidini 1998 Comparison of male versus female fetuses.
Goldie 1995 Fewer than 80% of study population had gestational age confirmed by USS
Gonçalves 2004 Greater than 14 weeks USS screening.
Goodburn 1994 Likely that fewer than 80% of pregnancies had gestational age estimated by USS
Grozdea 2002 Unable to extract useful data.
Gyselaers 2004a Less than 80% follow-up.
Gyselaers 2004b Less than 80% follow-up.
Gyselaers 2006a Unaffected pregnancies only.
Gyselaers 2006b Unable to extract useful data.
Hackshaw 1995 No Down’s syndrome pregnancies in population.
Hackshaw 2001 No Down’s syndrome pregnancies in population
Haddow 1992 Less than 80% of pregnancies had gestational age confirmed by ultrasound scan
Hafner 1995 Less than 5 Down’s pregnancies in study population.
Hallahan 1998 Gestational age greater than 24 weeks.
Harrison 2006 Less than 80% of pregnancies had gestational age confirmed by USS
Harry 2006 Editorial.
Hayashi 1995 Unable to extract useful data.
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Hayashi 1996 Less than 5 Down’s pregnancies in study population.
Heikkila 1997 Fewer than 80% of pregnancies had gestational age confirmed by USS
Heinonen 1996 No Down’s syndrome pregnancies in population.
Herman 2000 No Down’s syndrome pregnancies in study population.
Herman 2003 Correlation between markers, not evaluation of screening tests
Herrou 1992 Unable to extract useful data.
Hershey 1985 Gestation unclear.
Hershey 1986 Gestation based on LMP.
Hewitt 1993 Unable to extract useful data.
Hogdall 1992 Unclear method of determination of gestational age. Unable to extract useful data
Hong Kong Practitioner 2001 CME.
Howe 2000 Second trimester USS.
Hsiao 1991 Unable to obtain translation.
Hsieh 1999 No Down’s syndrome pregnancies in study population.
Hsu 1997b Adjustment factors.
Hsu 1998a No Down’s syndrome pregnancies in study population.
Hsu 1999b No Down’s pregnancies.
Huang 2003 No Down’s syndrome pregnancies in study population.
Huggon 2004 Study of cardiac function in pregnancies with normal and abnormal NT results
Hui 2003 No Down’s syndrome pregnancies in population.
Hui 2005 No Down’s syndrome pregnancies in population.
Hultén 2004 Editorial/commentary.
Hung 2003 Modelling.
Hurley 1993 Unable to extract useful data.
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Huttly 2004 No Down’s syndrome pregnancies in population.
Hwa 2004 Less than 5 Down’s pregnancies in population.
Iles 1996 Review.
Ind 1994 Unable to extract useful data.
Jean-Pierre 2005 Review article.
Johnson 1991 Gestatiojnal age estimated by USS in fewer than 80% of cases
Johnson 1993 Normal pregnancies only.
Jorgensen 1999 Gestation greater than 14 weeks for USS.
Josefsson 1998 No Down’s syndrome pregnancies in study population.
Jou 2001 Less than 5 Down’s syndrome pregnancies in study population.
Kagan 2006 Screen-positive pregnancies only.
Kautzmann 1995 Fewer than 80% pregnancies had gestational age estimated by USS
Keith 1992 Summary article.
Kelekci 2004 Less than 5 Down’s syndrome pregnancies in population.
Kellner 1995a Less than 5 Down’s syndrome pregnancies in population.
Kellner 1995b Less than 80% follow-up. Unable to ascertain proportion of population with gestational age con-
firmed by USS
Kellner 1997 Assumption of normal karyotype without reference standard in significant proportion of control
pregnancies
Knight 1990 Review article.
Knight 2001 Validation of a specific assay.
Knight 2005 Less than 80% of pregnancies had gestational age confirmed by USS
Koos 2006 Review article.
Kornman 1996 Less than 5 Down’s syndrome pregnancies in population.
Kornman 1997 Unable to extract useful information.
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Kramer 1998 No Down’s syndrome pregnancies in study population.
Krantz 1996 Modelled data.
Krantz 2005 Adjustment factor.
Kulch 1993 No Down’s cases in population.
Lai 1998 Modelled population.
Lai 2003 No Down’s syndrome pregnancies in study population.
Laigaard 2006a Unable to extract useful data.
Laigaard 2006b Simulation.
Lam 1997 Unable to extract useful data.
Lam 1998 Fewer than 80% pregnancies had gestational age estimated by USS
Lam 1999a No Down’s syndrome pregnancies in population.
Lam 1999b Unable to extract useful data.
Lam 2000 Study of women’s decisions about screening.
Lam 2001 Male versus female fetuses.
Lambert-Messerlian 1996 Fewer than 80% of pregnancies USS dated.
Lambert-Messerlian 1998 Unable to extract useful data.
Lehavi 2005 Down’s syndrome pregnancies only.
Leung 2006 Unable to separate twins from singletons therefore unable to extract useful data
Leymarie 1993 Appears to be a review article (French).
Li 1998 Unable to obtain translation.
Li 1999 Unable to obtain translation.
Liao 1997 Unable to obtain translation.
Liao 2001 Unable to extract useful data.
Lim 2002 Second trimester ultrasound.
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Lippman 1987 Editorial.
Liu 2003 Unable to obtain translation.
Lustig 1988 Gestational age by LMP only.
MacDonald 1991 Fewer than 80% of gestational ages estimated by USS.
Macintosh 1994 Unable to extract useful data.
Macintosh 1997 Unable to extract useful data.
Macri 1994 Likely fewer than 80% evaluated for gestational age by ultrasound examination
Macri 1996 Likely fewer than 80% evaluated for gestational age by ultrasound examination
Malone 1998 Review article.
Malone 2003 Review article.
Mangione 2001 Abnormal screening results only.
Maymon 2001a No Down’s syndrome pregnancies in study population.
Maymon 2001b No normal test results included therefore unable to extract meaningful data
Maymon 2002 No Down’s syndrome pregnancies in study population.
Maymon 2004 No Down’s syndrome pregnancies in study population.
Maymon 2005 Modelled data.
McDuffie 1996 USS dating on screen-positive women only.
Meier 2002 Observed versus expected cases of Down’s syndrome in a population
Merkatz 1984 Gestational age not confirmed by USS.
Merz 2005 Editorial.
Metzenbauer 2001 Normal pregnancies only.
Metzenbauer 2002 Unable to extract useful data.
Mikic 1999 No Down’s syndrome pregnancies in study population.
Miller 1991 Unable to extract useful data.
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Milunsky 1989 Fewer than 80% gestational age estimated by USS.
Milunsky 1996 Fewer than 80% gestational age estimated by USS.
Minobe 2002 Gestational age greater than specified limits.
Miyamura 1999 Unable to extract useful data.
Moghadam 1998 Unable to extract useful data.
Monni 2000 Less than 5 Down’s syndrome pregnancies.
Monni 2002 Review article.
Mooney 1994 Greater than 24 weeks’ gestation.
Muller 1994 No Down’s syndrome pregnancies in study population.
Muller 1996b Unable to extract useful data.
Muller 1999 Unable to extract useful data.
Muller 2002a Getstional age greater than 24 weeks.
Muller 2002b Unable to extract meaningful data - unable to separate double and triple test data
Muller 2003 No Down’s syndrome pregnancies in study population.
Murta 2002 Unable to extract useful data.
Musone 2000 Unable to extract useful data.
Musto 1986 Fewer than 80% USS dated.
Myrick 1990 Unable to extract useful data.
Neveux 1996a No Down’s syndrome pregnancies in population.
Neveux 1996b Unable to extract useful data.
Ng 2004 Unable to extract useful data.
Nicolaides 1992 Study of outcomes of abnormal NT results.
Nicolaides 2000 Review article.
Nicolaides 2004 Review article.
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Nicolaides 2005a Unable to obtain translation - appears to be a review article
Nicolaides 2005b Unable to obtain translation - appears to be a review article
Nicolaides 2005c Unable to obtain translation - appears to be a review article
Nicolaides 2005d Unable to obtain translation - appears to be a review article
Nicolaides 2005e Unable to obtain translation - appears to be a review article
Nicolaides 2005f Review article.
Niemimaa 2001 No Down’s pregnancies in study population.
Niemimaa 2002 No Down’s syndrome pregnancies in population.
Niemimaa 2003 No Down’s syndrome pregnancies in population.
Noble 1997 Unable to extract useful data.
Norgaard-Pedersen 1990 Less than 80% of gestational ages confirmed by USS.
Norton 1992 Unable to extract useful data.
O’Brien 1997a No Down’s syndrome pregnancies in population.
O’Brien 1997b No Down’s syndrome pregnancies in population.
Odibo 2004 Gestational age greater than 14 weeks in USS population.
Ognibene 1999 Unable to extract useful data.
Olajide 1989 Unable to extract useful data.
Onda 1996 Unable to extract useful data.
Onda 1998 Unable to extract useful data.
Onda 2000 Less than 80% follow-up.
Orlandi 2002 No Down’s syndrome pregnancies in study population.
Palka 1998 Twin data used in calculation of the median.
Palomaki 1989 Fewer than 80% USS dated.
Palomaki 1993 No Down’s syndrome pregnancies in population.
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(Continued)
Palomaki 1994 No Down’s syndrome pregnancies in population.
Palomaki 1996 Meta-analysis.
Palomaki 2005 Unable to extract meaningful data.
Panburana 2001 Less than 5 Down’s syndrome pregnancies in population.
Pandya 1994 Study of outcomes of abnormal NT results.
Pandya 1995 Review article.
Paul 2001 Unable to extract useful data.
Peralta 2005 Unable to extract useful data.
Perenc 1998 No Down’s syndrome pregnancies in study population.
Perheentupa 2002 No Down’s syndrome pregnancies in population.
Perona 1998 Smokers versus non smokers.
Petervari 2000 Unable to extract useful data.
Petrocik 1989 Likely fewer than 80% USS dated.
Phillips 1992 Gestational age confirmed by USS in less than 80% of population
Phillips 1993 Gestational age confirmed by USS in less than 80% of population
Pinette 2003 Women screened prior to recruitment.
Platt 2004 Unable to extract useful data.
Podobnik 1995 Abnormal results only.
Prefumo 2002 Comparison of prevalence and prediction.
Prefumo 2004 Comparison of a marker in women of different ethnic origins.
Price 1998 Unable to extract useful data.
Páez 2004 Unable to obtain translation.
Raty 2000 No Down’s syndrome pregnancies in population.
Rembouskos 2004 Unable to extract useful data.
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(Continued)
Ren 1992 Review article.
Renier 1998 Method of ascertainment of gestational age unclear. Twin gestations included in general population
Resta 1990 Second trimester USS.
Reynders 1997 Fewer than 5 Down’s cases.
Reynolds 1989 Explanation of mathematical techniques.
Reynolds 1999 Unable to extract useful data.
Ribbert 1996 No Down’s syndrome pregnancies in study population.
Rice 2005 Down’s syndrome pregnancies excluded from study.
Rich 1991 Unable to extract useful data.
Roberts 1995 No Down’s syndrome pregnancies in study population.
Robertson 1991 Editorial.
Rode 2003 No Down’s pregnancies.
Ronge 2006 Editorial - summary of FASTER trial results.
Rose 1995 Review article.
Ross 1997 Review article.
Rotmensch 1996 Unable to extract useful data.
Rotmensch 1999 No Down’s syndrome pregnancies in study population.
Rozenberg 2006 USS greater than 14 weeks’ gestation.
Rudnicka 2002 No Down’s syndrome pregnancies in population.
Ryall 1992 Unable to determine method of confirmation of gestational age
Ryall 2001 High-risk results only included (i.e. no screen-negative group for comparison)
Räty 2002 No Down’s pregnancies in population.
Sabriá 2002 Unable to ascertain how numbers calculated and from which populations
Sacchini 2003 Unable to extract useful data.
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(Continued)
Saller 1997 Down’s syndrome secondary to Robertsonian translocation only. No controls
Salomon 2001 No Down’s syndrome pregnancies in population.
Salonen 1997 Fewer than 80% had gestational age estimated by USS.
Saltvedt 2005 Gestation greater than 14 weeks for nuchal scanning.
Saridogan 1996 Down’s syndrome and Edward’s syndrome affected pregnancies only
Savoldelli 1993 Unable to extract useful data.
Schiott 2006 Unable to extract useful data.
Schuchter 1998 No Down’s pregnancies in study population.
Scott 1995 Less than 5 Down’s syndrome pregnancies in study population.
Seeds 1990 Review article.
Seki 1995 No Down’s syndrome pregnancies in study population.
Shenhav 2003 No Down’s syndrome pregnancies.
Shintaku 1989 Unable to extract useful data.
Shulman 2003 No Down’s syndrome pregnancies in population.
Simon-Bouy 1999 Review article.
Simpson 1986 Gestational age confirmed by USS in less than 80% of population
Smith 1990 Analysis of screen-positive results.
Smith 1996 Review/meta-analysis.
Smith 1999 Unable to extract useful data.
Smith-Bindman 2001 Meta-analysis of second trimester ultrasound markers.
Smith-Bindman 2003 Population study, not examining DTA.
Snijders 1995 Study of prevalence, not screening.
Snijders 1999 Study of prevalence, not screening.
Soergel 2006 Less than 80% follow-up.
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(Continued)
Sokol 1998 Observation of Down’s prevalence stratified by age.
Sonek 2003 Editorial.
Spencer 1985 Fewer than 80% USS dated.
Spencer 1991a Likely fewer than 80% USS dated.
Spencer 1991b Unable to extract useful data.
Spencer 1992 Unable to extract useful data.
Spencer 1993a Fewer than 80% USS dated.
Spencer 1993b No Down’s pregnancies in study population.
Spencer 1993c Unable to extract useful data.
Spencer 1993d Fewer than 80% of pregnancies had gestational age confirmed by USS
Spencer 1993e Unable to extract useful data.
Spencer 1995 No Down’s pregnancies in population.
Spencer 1996a Fewer than 80% of pregnancies had gestational age confirmed by USS
Spencer 1997 Statistical modelling, aneuploid pregnancies only in study population
Spencer 1998a No Down’s pregnancies in population.
Spencer 1998b Unable to extract useful data.
Spencer 1999a Review.
Spencer 1999b Statistical methods paper.
Spencer 2000a Examination of median shifts rather than an evaluation of screening
Spencer 2000b No Down’s syndrome pregnancies in population.
Spencer 2000c No Down’s syndrome pregnancies in population.
Spencer 2000d No Down’s cases.
Spencer 2000e Male versus female fetuses.
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Spencer 2000f No Down’s cases in population.
Spencer 2000g No Down’s pregnancies in population.
Spencer 2000h No Down’s pregnancies in population.
Spencer 2000i Comparsison of fetal sex.
Spencer 2001 No Down’s syndrome pregnancies in population.
Spencer 2001a Unable to extract useful data.
Spencer 2001b Unable to extract useful data.
Spencer 2001c Unable to extract useful data.
Spencer 2001d No Down’s syndrome pregnancies in population.
Spencer 2002a No Down’s pregnancies.
Spencer 2002b Risk validation study.
Spencer 2002c No Down’s syndrome pregnancies in population.
Spencer 2002d Demonstration of median changes with time, rather than evaluation of screening
Spencer 2003a No Down’s pregnancies in population.
Spencer 2003b No Down’s pregnancies in population.
Spencer 2003c Calculation of weight correction factor.
Spencer 2003d Fewer than 5 Down’s syndrome pregnancies.
Spencer 2004 Calculation of smoking correction factor.
Spencer 2005a No Down’s pregnancies.
Spencer 2005b No Down’s pregnancies.
Spencer 2005c Comparison of 2 different assays - not actual screening evaluation
Spong 1999 Comparison of male and female fetuses.
Stevens 1998 Literature review.
Stoll 1992 Review article.
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Su 2002a Unable to extract useful data.
Suchet 1995 Review article.
Suchy 1990 Unable to ascertain method of confirmation of gestational age
Summers 2003a Fewer than 80% had gestational age estimated by USS.
Summers 2003b No Down’s syndrome pregnancies in study population.
Suntharasaj 2005 Examination of inter-observer variation in NT scanning.
Sutton 2004 Unable to extract useful data.
Suzuki 1998 Unable to extract useful data.
Tabor 1987 Geststional age not confirmed by USS.
Tanski 1999 Information on screen-positive pregnancies only.
Thilaganathan 1998 No Down’s syndrome pregnancies in study population.
Thilaganathan 1999 Editorial.
Tislaric 2002 No Down’s syndrome pregnancies in population.
Torok 1997 Unable to extract useful data.
Tsai 2001 Less than 5 Down’s syndrome pregnancies in study population.
Valerio 1996 Fewer than 80% pregnancies had gestational age estimated by USS
Van Blerk 1992 Unable to extract useful data.
Van Heesch, 2006 No Down’s syndrome pregnancies in study population. Software comparison study
Van Lith 1991 Unable to extract useful data.
Van Lith 1993 Unable to extract useful data.
Van Lith 1994 Unable to extract useful data.
Veress 1986 Unable to extract useful data.
Veress 1988 Unable to extract useful data.
Vintzileos 2003 Second trimester USS.
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Wald 1988a Less than 80% had gestational age confirmed by ultrasound.
Wald 1988b Gestational age not confirmed by USS.
Wald 1991 No Down’s pregnancies in study.
Wald 1992a Less than 80% had gestational age confirmed by ultrasound.
Wald 1992b No Down’s pregnancies in study.
Wald 1992c No Down’s pregnancies in study.
Wald 1993 Fewer than 80% had gestational age estimated by USS
Wald 1994a No Down’s syndrome pregnancies in population.
Wald 1994b Review article.
Wald 1996a No Down’s pregnancies.
Wald 1996b Fewer than 80% had gestational age estimated by USS
Wald 1996d No Down’s syndrome pregnancies in population.
Wald 1996e Gestational age greater than 24 weeks.
Wald 1997 Data modelled on 3 separate populations of women.
Wald 1998 Unable to extract useful data.
Wald 1999a Unable to extract useful data.
Wald 1999b Gestational age not confirmed by USS.
Wald 1999c No Down’s syndrome pregnancies.
Wald 1999d Modelled on several studies, some of which have no USS dating
Wald 2003b No cases.
Wald 2003c Less than 80% had gestational age confirmed by USS.
Wald 2006 Modelled on SURRUS data.
Wallace 1994 Unable to extract useful data.
Wallace 1997 No Down’s syndrome pregnancies in study population.
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(Continued)
Ward 2005 Review article.
Watt 1996a No Downs syndrome pregnancies in study population.
Watt 1996b No Down’s syndrome pregnancies in study population.
Weinans 2001 Unable to extract useful data.
Weinans 2004 Study of women’s views on screening.
Welborn 1994 Abnormal results only (cystic hygroma).
Wenstrom 1993 Less than 80% of pregnancies had gestational age confirmed by USS
Wenstrom 1995a Adjustment factors.
Wenstrom 1995b Less than 80% of pregnancies had gestational age confirmed by USS
Whitlow 1998a Unable to extract useful data.
Whitlow 1998b Unable to extract useful data.
Whitlow 1999 Unable to extract useful data.
Williamson 1994 Fewer than 80% had gestational age estimated by USS.
Wilson 2000 Review.
Wojdemann 2001 No Down’s syndrome pregnancies in study population.
Wong 2003 Less than 5 Down’s syndrome pregnancies in population.
Wright 2006 Mathematical model.
Yagel 1998 Second trimester USS.
Yamamoto 2001a Unable to extract useful data.
Yamamoto 2001b Method of determination of gestational age unclear.
Yamamoto 2001c Unable to extract useful data.
Yaron 2001 Male versus female fetuses.
Ye 1995 Unable to obtain translation.
Yoshida 2000 Fewer than 80% pregnancies had gestational age estimated by USS
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Zeitune 1991 Only aneuploid pregnancies included in study.
Zelop 2005 No Down’s cases in population.
Zhao 1998 Unable to obtain translation.
Zoppi 2003 Inappropriate study design.
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D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 Betacore, 1st trimester urine test,
5% FPR
1 516
2 Betacore, 2nd trimester urine
test, 5% FPR
6 9613
3 Betacore, 2nd trimester urine
test, cutpoint mixed
7 10124
4 Gonadotropin, 2nd trimester
urine test, risk 1:100
1 105
5 Gonadotropin, 2nd trimester
urine test, risk 1:384
1 105
6 Gonadotropin, 2nd trimester
urine test, 95% percentile
1 105
7 ITA, 1st trimester urine test, 5%
FPR
2 579
8 ITA, 2nd trimester urine test,
3.74MoM
1 2051
9 ITA, 2nd trimester urine test,
5% FPR
3 2748
10 Total hCG, 1st trimester urine
test, 5% FPR
1 516
11 Total hCG, 2nd trimester urine
test, 5% FPR
1 390
12 Free ßhCG, 1st trimester urine
test, 5% FPR
1 516
13 Free ßhCG, 2nd trimester
urine test, 5% FPR
3 1517
14 Oestriol, 2nd trimester urine
test, 5% FPR
2 1472
15 Betacore to oestriol ratio, 2nd
trimester urine test, 5% FPR
2 1649
16 Betacore and oestriol, 2nd
trimester 5% FPR
1 315
17 AFP and ITA, 2nd trimester
urine test, 3% FPR
1 524
18 AFP and ITA, 2nd trimester
urine test, 5% FPR
1 524
19 AFP and ITA, 2nd trimester
urine test,10% FPR
1 524
20 AFP and ITA, 2nd trimester
urine test, 15% FPR
1 524
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21 AFP, uE3 and ITA, 2nd
trimester urine test, 3% FPR
1 524
22 AFP, uE3 and ITA, 2nd
trimester urine test, 5% FPR
1 524
23 AFP, uE3 and ITA, 2nd
trimester urine test, 10% FPR
1 524
24 AFP, uE3 and ITA, 2nd
trimester urine test, 15% FPR
1 524
25 Age, betacore, 2nd trimester
urine test, 1% FPR
2 2083
26 Age, betacore, 2nd trimester
urine test, 3% FPR
2 2083
27 Age, betacore, 2nd trimester
urine test, 5% FPR
5 3419
28 Age, betacore, 2nd trimester
urine test, 10% FPR
1 926
29 Age, betacore, 2nd trimester
urine test, 15% FPR
1 953
30 Age, betacore, 2nd trimester
urine test, 20% FPR
1 926
31 Age, ITA, 2nd trimester urine
test, 5% FPR
1 1016
32 Age, oestriol, 2nd trimester
urine test, 5% FPR
1 474
33 Age, free ßhCG, 2nd trimester
urine test, 5% FPR
2 879
34 Age, betacore to oestriol ratio,
2nd trimester urine test, 1%
FPR
1 1157
35 Age, betacore to oestriol ratio,
2nd trimester urine test, 3%
FPR
1 1157
36 Age, betacore to oestriol ratio,
2nd trimester urine test, 5%
FPR
3 2088
37 Age, free ßhCG to oestriol
ratio, 2nd trimester urine test,
5% FPR
1 474
38 Age, oestriol and free ßhCG,
2nd trimester, 5% FPR
1 474
39 Age, betacore to free ßhCG
ratio, 2nd trimester, 5% FPR
1 474
40 Age, betacore and oestriol, 2nd
trimester 1% FPR
1 1157
41 Age, betacore and oestriol, 2nd
trimester, 3% FPR
1 1157
42 Age, betacore and oestriol, 2nd
trimester, 5% FPR
2 1631
43 Age, AFP and betacore to
oestriol ratio, 2nd trimester,
risk 1:10
1 356
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44 Age, AFP and betacore to
oestriol ratio, 2nd trimester,
risk 1:20
1 356
45 Age, AFP and betacore to
oestriol ratio, 2nd trimester,
risk 1:30
1 356
46 Age, AFP and betacore to
oestriol ratio, 2nd trimester,
risk 1:58
1 356
47 Age, AFP and betacore to
oestriol ratio, 2nd trimester,
risk 1:270
1 356
48 Age, AFP and betacore to
oestriol ratio, 2nd trimester,
risk 1:526
1 356
Test 1. Betacore, 1st trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 1 Betacore, 1st trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003 9 22 77 408 0.10 [ 0.05, 0.19 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 2. Betacore, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 2 Betacore, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cole 1999b 15 54 8 1080 0.65 [ 0.43, 0.84 ] 0.95 [ 0.94, 0.96 ]
Cuckle 1995b 19 15 5 276 0.79 [ 0.58, 0.93 ] 0.95 [ 0.92, 0.97 ]
Cuckle 1999a 9 329 30 6256 0.23 [ 0.11, 0.39 ] 0.95 [ 0.94, 0.96 ]
Isozaki 1997 8 35 5 674 0.62 [ 0.32, 0.86 ] 0.95 [ 0.93, 0.97 ]
Spencer 1996 6 19 23 357 0.21 [ 0.08, 0.40 ] 0.95 [ 0.92, 0.97 ]
Wald 2003 9 16 56 309 0.14 [ 0.07, 0.25 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 3. Betacore, 2nd trimester urine test, cutpoint mixed.
Review: Urine tests for Down’s syndrome screening
Test: 3 Betacore, 2nd trimester urine test, cutpoint mixed
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1998 11 16 7 477 0.61 [ 0.36, 0.83 ] 0.97 [ 0.95, 0.98 ]
Cole 1999b 15 54 8 1080 0.65 [ 0.43, 0.84 ] 0.95 [ 0.94, 0.96 ]
Cuckle 1995b 19 15 5 276 0.79 [ 0.58, 0.93 ] 0.95 [ 0.92, 0.97 ]
Cuckle 1999a 9 329 30 6256 0.23 [ 0.11, 0.39 ] 0.95 [ 0.94, 0.96 ]
Isozaki 1997 8 35 5 674 0.62 [ 0.32, 0.86 ] 0.95 [ 0.93, 0.97 ]
Spencer 1996 6 19 23 357 0.21 [ 0.08, 0.40 ] 0.95 [ 0.92, 0.97 ]
Wald 2003 9 16 56 309 0.14 [ 0.07, 0.25 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 4. Gonadotropin, 2nd trimester urine test, risk 1:100.
Review: Urine tests for Down’s syndrome screening
Test: 4 Gonadotropin, 2nd trimester urine test, risk 1:100
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Canick 1995 11 2 3 89 0.79 [ 0.49, 0.95 ] 0.98 [ 0.92, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 5. Gonadotropin, 2nd trimester urine test, risk 1:384.
Review: Urine tests for Down’s syndrome screening
Test: 5 Gonadotropin, 2nd trimester urine test, risk 1:384
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Canick 1995 13 5 1 86 0.93 [ 0.66, 1.00 ] 0.95 [ 0.88, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 6. Gonadotropin, 2nd trimester urine test, 95% percentile.
Review: Urine tests for Down’s syndrome screening
Test: 6 Gonadotropin, 2nd trimester urine test, 95% percentile
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Canick 1995 12 5 2 86 0.86 [ 0.57, 0.98 ] 0.95 [ 0.88, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 7. ITA, 1st trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 7 ITA, 1st trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003 5 22 81 408 0.06 [ 0.02, 0.13 ] 0.95 [ 0.92, 0.97 ]
Weinans 2000 3 3 5 52 0.38 [ 0.09, 0.76 ] 0.95 [ 0.85, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 8. ITA, 2nd trimester urine test, 3.74MoM.
Review: Urine tests for Down’s syndrome screening
Test: 8 ITA, 2nd trimester urine test, 3.74MoM
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Palomaki 2004a 15 101 13 1922 0.54 [ 0.34, 0.72 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 9. ITA, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 9 ITA, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cuckle 1999 17 13 21 256 0.45 [ 0.29, 0.62 ] 0.95 [ 0.92, 0.97 ]
Palomaki 2004a 13 49 15 1974 0.46 [ 0.28, 0.66 ] 0.98 [ 0.97, 0.98 ]
Wald 2003 26 16 39 309 0.40 [ 0.28, 0.53 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 10. Total hCG, 1st trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 10 Total hCG, 1st trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003 15 22 71 408 0.17 [ 0.10, 0.27 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 11. Total hCG, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 11 Total hCG, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003 20 16 45 309 0.31 [ 0.20, 0.43 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 12. Free ßhCG, 1st trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 12 Free hCG, 1st trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wald 2003 4 22 82 408 0.05 [ 0.01, 0.11 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 13. Free ßhCG, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 13 Free hCG, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cole 1997a 7 35 6 674 0.54 [ 0.25, 0.81 ] 0.95 [ 0.93, 0.97 ]
Spencer 1996 12 19 17 357 0.41 [ 0.24, 0.61 ] 0.95 [ 0.92, 0.97 ]
Wald 2003 8 16 57 309 0.12 [ 0.05, 0.23 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 14. Oestriol, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 14 Oestriol, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cole 1999b 3 54 20 1080 0.13 [ 0.03, 0.34 ] 0.95 [ 0.94, 0.96 ]
Cuckle 1995b 8 15 16 276 0.33 [ 0.16, 0.55 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 15. Betacore to oestriol ratio, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 15 Betacore to oestriol ratio, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cole 1997b 9 24 3 456 0.75 [ 0.43, 0.95 ] 0.95 [ 0.93, 0.97 ]
Cole 1999b 17 54 6 1080 0.74 [ 0.52, 0.90 ] 0.95 [ 0.94, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 16. Betacore and oestriol, 2nd trimester 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 16 Betacore and oestriol, 2nd trimester 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cuckle 1995b 20 15 4 276 0.83 [ 0.63, 0.95 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 17. AFP and ITA, 2nd trimester urine test, 3% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 17 AFP and ITA, 2nd trimester urine test, 3% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 2000a 16 15 8 485 0.67 [ 0.45, 0.84 ] 0.97 [ 0.95, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 18. AFP and ITA, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 18 AFP and ITA, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 2000a 19 25 5 475 0.79 [ 0.58, 0.93 ] 0.95 [ 0.93, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 19. AFP and ITA, 2nd trimester urine test,10% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 19 AFP and ITA, 2nd trimester urine test,10% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 2000a 21 50 3 450 0.88 [ 0.68, 0.97 ] 0.90 [ 0.87, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 20. AFP and ITA, 2nd trimester urine test, 15% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 20 AFP and ITA, 2nd trimester urine test, 15% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 2000a 22 75 2 425 0.92 [ 0.73, 0.99 ] 0.85 [ 0.82, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 21. AFP, uE3 and ITA, 2nd trimester urine test, 3% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 21 AFP, uE3 and ITA, 2nd trimester urine test, 3% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 2000a 18 15 6 485 0.75 [ 0.53, 0.90 ] 0.97 [ 0.95, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 22. AFP, uE3 and ITA, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 22 AFP, uE3 and ITA, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 2000a 19 25 5 475 0.79 [ 0.58, 0.93 ] 0.95 [ 0.93, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 23. AFP, uE3 and ITA, 2nd trimester urine test, 10% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 23 AFP, uE3 and ITA, 2nd trimester urine test, 10% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 2000a 22 50 2 450 0.92 [ 0.73, 0.99 ] 0.90 [ 0.87, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 24. AFP, uE3 and ITA, 2nd trimester urine test, 15% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 24 AFP, uE3 and ITA, 2nd trimester urine test, 15% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 2000a 22 75 2 425 0.92 [ 0.73, 0.99 ] 0.85 [ 0.82, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 25. Age, betacore, 2nd trimester urine test, 1% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 25 Age, betacore, 2nd trimester urine test, 1% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1999a 6 9 15 896 0.29 [ 0.11, 0.52 ] 0.99 [ 0.98, 1.00 ]
Cole 1999b 7 11 16 1123 0.30 [ 0.13, 0.53 ] 0.99 [ 0.98, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
102Urine tests for Down’s syndrome screening (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Test 26. Age, betacore, 2nd trimester urine test, 3% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 26 Age, betacore, 2nd trimester urine test, 3% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1999a 11 27 10 878 0.52 [ 0.30, 0.74 ] 0.97 [ 0.96, 0.98 ]
Cole 1999b 11 34 12 1100 0.48 [ 0.27, 0.69 ] 0.97 [ 0.96, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 27. Age, betacore, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 27 Age, betacore, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1999 10 22 3 422 0.77 [ 0.46, 0.95 ] 0.95 [ 0.93, 0.97 ]
Bahado-Singh 1999a 13 30 8 875 0.62 [ 0.38, 0.82 ] 0.97 [ 0.95, 0.98 ]
Cole 1999b 15 54 8 1080 0.65 [ 0.43, 0.84 ] 0.95 [ 0.94, 0.96 ]
Hsu 1999 34 20 35 385 0.49 [ 0.37, 0.62 ] 0.95 [ 0.92, 0.97 ]
Spencer 1996 12 19 17 357 0.41 [ 0.24, 0.61 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 28. Age, betacore, 2nd trimester urine test, 10% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 28 Age, betacore, 2nd trimester urine test, 10% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1999a 16 91 5 814 0.76 [ 0.53, 0.92 ] 0.90 [ 0.88, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 29. Age, betacore, 2nd trimester urine test, 15% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 29 Age, betacore, 2nd trimester urine test, 15% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1999a 16 136 5 796 0.76 [ 0.53, 0.92 ] 0.85 [ 0.83, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 30. Age, betacore, 2nd trimester urine test, 20% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 30 Age, betacore, 2nd trimester urine test, 20% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1999a 18 181 3 724 0.86 [ 0.64, 0.97 ] 0.80 [ 0.77, 0.83 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 31. Age, ITA, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 31 Age, ITA, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 2000 16 50 7 943 0.70 [ 0.47, 0.87 ] 0.95 [ 0.93, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 32. Age, oestriol, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 32 Age, oestriol, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hsu 1999 34 20 35 385 0.49 [ 0.37, 0.62 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 33. Age, free ßhCG, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 33 Age, free hCG, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hsu 1999 39 20 30 385 0.57 [ 0.44, 0.68 ] 0.95 [ 0.92, 0.97 ]
Spencer 1996 17 19 12 357 0.59 [ 0.39, 0.76 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 34. Age, betacore to oestriol ratio, 2nd trimester urine test, 1% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 34 Age, betacore to oestriol ratio, 2nd trimester urine test, 1% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cole 1999b 5 11 18 1123 0.22 [ 0.07, 0.44 ] 0.99 [ 0.98, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 35. Age, betacore to oestriol ratio, 2nd trimester urine test, 3% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 35 Age, betacore to oestriol ratio, 2nd trimester urine test, 3% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cole 1999b 13 34 10 1100 0.57 [ 0.34, 0.77 ] 0.97 [ 0.96, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 36. Age, betacore to oestriol ratio, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 36 Age, betacore to oestriol ratio, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1999 11 22 2 422 0.85 [ 0.55, 0.98 ] 0.95 [ 0.93, 0.97 ]
Cole 1999b 18 54 5 1080 0.78 [ 0.56, 0.93 ] 0.95 [ 0.94, 0.96 ]
Hsu 1999 40 20 29 385 0.58 [ 0.45, 0.70 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 37. Age, free ßhCG to oestriol ratio, 2nd trimester urine test, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 37 Age, free hCG to oestriol ratio, 2nd trimester urine test, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hsu 1999 44 20 25 385 0.64 [ 0.51, 0.75 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 38. Age, oestriol and free ßhCG, 2nd trimester, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 38 Age, oestriol and free hCG, 2nd trimester, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hsu 1999 47 20 22 385 0.68 [ 0.56, 0.79 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 39. Age, betacore to free ßhCG ratio, 2nd trimester, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 39 Age, betacore to free hCG ratio, 2nd trimester, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hsu 1999 46 20 23 385 0.67 [ 0.54, 0.78 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 40. Age, betacore and oestriol, 2nd trimester 1% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 40 Age, betacore and oestriol, 2nd trimester 1% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cole 1999b 9 11 14 1123 0.39 [ 0.20, 0.61 ] 0.99 [ 0.98, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 41. Age, betacore and oestriol, 2nd trimester, 3% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 41 Age, betacore and oestriol, 2nd trimester, 3% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cole 1999b 17 34 6 1100 0.74 [ 0.52, 0.90 ] 0.97 [ 0.96, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 42. Age, betacore and oestriol, 2nd trimester, 5% FPR.
Review: Urine tests for Down’s syndrome screening
Test: 42 Age, betacore and oestriol, 2nd trimester, 5% FPR
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Cole 1999b 19 54 4 1080 0.83 [ 0.61, 0.95 ] 0.95 [ 0.94, 0.96 ]
Hsu 1999 47 20 22 385 0.68 [ 0.56, 0.79 ] 0.95 [ 0.92, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 43. Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:10.
Review: Urine tests for Down’s syndrome screening
Test: 43 Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:10
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1998b 4 4 6 342 0.40 [ 0.12, 0.74 ] 0.99 [ 0.97, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 44. Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:20.
Review: Urine tests for Down’s syndrome screening
Test: 44 Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:20
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1998b 5 6 5 340 0.50 [ 0.19, 0.81 ] 0.98 [ 0.96, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 45. Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:30.
Review: Urine tests for Down’s syndrome screening
Test: 45 Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:30
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1998b 8 11 2 335 0.80 [ 0.44, 0.97 ] 0.97 [ 0.94, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 46. Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:58.
Review: Urine tests for Down’s syndrome screening
Test: 46 Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:58
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1998b 9 16 1 330 0.90 [ 0.55, 1.00 ] 0.95 [ 0.93, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 47. Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:270.
Review: Urine tests for Down’s syndrome screening
Test: 47 Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:270
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1998b 9 63 1 283 0.90 [ 0.55, 1.00 ] 0.82 [ 0.77, 0.86 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 48. Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:526.
Review: Urine tests for Down’s syndrome screening
Test: 48 Age, AFP and betacore to oestriol ratio, 2nd trimester, risk 1:526
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bahado-Singh 1998b 10 97 0 249 1.00 [ 0.69, 1.00 ] 0.72 [ 0.67, 0.77 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. Direct comparisons of the diagnostic accuracy of five urine tests in combination with maternal age
Ratio of DORs (95%
CI); P values (studies)
Second trimester AFP
and ß-core fragment to
oestriol ratio, risk 1:58
Second
trimester ß-core frag-
ment and oestriol, 5%
FPR
Second trimester ITA,
5% FPR
Second
trimester ß-core frag-
ment to oestriol ratio,
5% FPR
Second
trimester ß-core frag-
ment and oestriol, 5%
FPR
-
Second trimester ITA,
5% FPR
- -
Second
trimester ß-core frag-
ment to oestriol ratio,
5% FPR
- 1.5 (0.7 to 3.0); P = 0.27
(K = 2)
Second trimester ß-
core fragment, 5% FPR
- 2.2 (1.1 to 4.5); P = 0.02
(K = 2)
- 1.5 (0.8 to 2.8); P = 0.21
(K = 3)
Direct comparisons were made using only data from studies that compared each pair of tests in the same population. Ratio of diagnostic
odds ratios (DOR)s were computed by division of the DOR for the test in the column by the DOR for the test in the row. If the
ratio of DORs is greater than one, then the diagnostic accuracy of the test in the column is higher than that of the test in the row;
if the ratio is less than one, the diagnostic accuracy of the test in the row is higher than that of the test in the column.
AFP: alpha-fetoprotein; CI: confidence interval; DORs: diagnostic odds ratio; FPR: false positive rate; ITA: invasive trophoblast
antigen
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Table 2. Indirect comparisons of the diagnostic accuracy of five urine tests in combination with maternal age
Ratio of
DOR (95% CI)
; P value
Second trimester
AFP and ß-
core fragment to
oestriol ratio, risk
1:58
Second trimester
ß-core fragment
and oestriol, 5%
FPR
Second trimester
ITA, 5% FPR
Second trimester
ß-core fragment
to oestriol ratio,
5% FPR
Studies 1 2 1 3
Studies DOR (95% CI) 186 (22, 1560) 50 (30 to 84) 43 (17 to 110) 38 (24 to 59)
Second
trimester ß-core
fragment and
oestriol, 5%
FPR
2 50 (30 to 84) 3.7 (0.4 to 33.0); P
= 0.24
Second
trimester ITA,
5% FPR
1 43 (17 to 110) 4.3 (0.4 to 44.0); P
= 0.22
1.2 (0.4 to 3.4); P
= 0.78
Second
trimester ß-core
fragment
to oestriol ratio,
5% FPR
3 38 (24 to 59) 4.9 (0.6 to 43.4); P
= 0.15
1.3 (0.7 to 2.6); P
= 0.41
1.1 (0.4 to 3.2); P
= 0.80
Second
trimester ß-core
fragment, 5%
FPR
5 25 (18 to 36) 7.3 (0.8 to 63.1); P
= 0.07
2.0 (1.1 to 3.7); P
= 0.03
1.7 (0.6 to 4.6); P
= 0.30
1.5 (0.8 to 2.6); P
= 0.18
Indirect comparisons were made using all available data. Ratio of diagnostic odds ratios (DOR)s were computed by division of the
DOR for the test in the column by the DOR for the test in the row. If the ratio of DORs is greater than one, then the diagnostic
accuracy of the test in the column is higher than that of the test in the row; if the ratio is less than one, the diagnostic accuracy of
the test in the row is higher than that of the test in the column.
AFP: alpha-fetoprotein; CI: confidence interval; DORs: diagnostic odds ratio; FPR: false positive rate; ITA: invasive trophoblast
antigen
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A P P E N D I C E S
Appendix 1. Search strategy
Database: Ovid MEDLINE
--------------------------------------------------------------------------------
1 exp Prenatal Diagnosis/
2 nuchal translucency.mp.
3 exp Pregnancy-Associated Plasma Protein-A/
4 pregnancy associated plasma protein a.mp.
5 papp-a.mp.
6 exp Chorionic Gonadotropin, beta Subunit, Human/
7 (b-hcg or bhcg).mp.
8 human chorionic gonadotropin.mp.
9 exp alpha-Fetoproteins/
10 alphafetoprotein$.mp.
11 alpha-fetoprotein$.mp.
12 afp.mp.
13 (unconjugated estriol or unconjugated oestriol).mp.
14 ue3.mp.
15 exp INHIBINS/
16 inhibin a.mp.
17 ultrasound.mp.
18 amniocentesis/
19 chorion$ vill$ sampling.mp.
20 Chorionic Villi-Sampling/
21 nasal bone.mp.
22 tricuspid regurgitation.mp.
23 ductus venosus.mp
24 marker$.mp.
25 screen$.mp.
26 detect$.mp.
27 accura$.mp.
28 predict$.mp.
29 ROC.mp.
30 ROC curve/
31 AUC.mp.
32 Area under curve/
33 exp false negative reactions/ or exp false positive reactions/
34 (false positive$ or false negative$).mp.
35 likelihood ratio$.mp.
36 sensitiv$.mp.
37 specific$.mp.
38 diagnos$.ti,ab.
39 “reproducibility of results”.mp.
40 reference value$.mp.
41 reference standard$.mp.
42 exp Down Syndrome/
43 downs syndrome.mp.
44 down syndrome.mp.
45 trisomy 21.mp.
46 Aneuploidy/
47 aneuploidy.mp.
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48 Mosaicism/
49 mosaicism.mp.
50 or/1-41
51 or/42-49
52 50 and 51
53 (antenatal$ or prenatal$ or trimester$ or pregnan$ or fetus or foetus or fetal or foetal).mp.
54 52 and 53
55 animal/ not (humans/ and animal/)
56 54 not 55
*******************************************************
EMBASE via Dialog Datastar
1. PRENATAL-DIAGNOSIS#.DE.
2. FETUS-ECHOGRAPHY#.DE.
3. PREGNANCY-ASSOCIATED-PLASMA-PROTEIN-A#.DE.
4. CHORIONIC-GONADOTROPIN-BETA-SUBUNIT#.DE.
5. HCG.AB.
6. PAPP.AB.
7. ALPHA-FETOPROTEIN#.DE.
8. AFP.AB.
9. ALPHA ADJ FETOPROTEIN$
10. ALPHAFETOPROTEIN$
11. BETA ADJ HUMAN ADJ CHORIONIC ADJ GONADOTROPIN
12. PREGNANCY ADJ ASSOCIATED ADJ PLASMA ADJ PROTEIN
13. (UNCONJUGATED ADJ ESTRIOL OR UNCONJUGATED ADJ OESTRIOL).TI.
14. (UNCONJUGATED ADJ ESTRIOL OR UNCONJUGATED ADJ OESTRIOL).AB.
15. UE3
16. INHIBIN-A#.DE.
17. INHIBIN ADJ A
18. ULTRASOUND
19. AMNIOCENTESIS
20. CHORION-VILLUS-SAMPLING.DE.
21. NASAL ADJ BONE
22. TRICUSPID ADJ REGURGITATION
23. DUCTUS ADJ VENOSUS
24. MARKER ORMARKERS
25. SCREEN OR SCREENING
26. DETECT OR DETECTING OR DETECTION
27. FALSE ADJ POSITIVE$
28. FALSE ADJ NEGATIVE$
29. SENSITIVITY OR SENSITIVE OR SENSITIVITIES
30. SPECIFICITY OR SPECIFICITIES
31. (DIAGNOSE OR DIAGNOSIS OR DIAGNOSTIC OR DIAGNOSTICS OR DIAGNOSES
OR DIAGNOSED).TI.
32. (DIAGNOSE OR DIAGNOSIS OR DIAGNOSTIC OR DIAGNOSTICS OR DIAGNOSES
OR DIAGNOSED).AB.
33. ROC.AB.
34. AUC.AB.
35. AREA-UNDER-THE-CURVE.DE.
36. ROC-CURVE.DE.
37. ACCURA$
38. PREDICT$
39. REPRODUCIBILITY.DE.
40. REFERENCE ADJ VALUE$
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41. REFERENCE-VALUE.DE.
42. REFERENCE ADJ STANDARD$
43. DOWN-SYNDROME#.DE.
44. DOWN ADJ SYNDROME OR DOWNS ADJ SYNDROME
45. TRISOMY ADJ ’21’
46. MOSAICISM
47. ANEUPLOIDY
48. ANTENATAL$ OR PRENATAL$ OR PREGNANCY OR PREGNANT OR TRIMESTER$ OR MATERNAL OR FETUS
OR FOETUS OR FOETAL OR FETAL
49. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19
OR 20 OR 21 Or 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 35 OR 36 OR
37 OR 38 OR 39 OR 40 OR 41 OR 42
50. 43 OR 44 OR 45 OR 46 OR 47
51. 48 AND 49 AND 50
52. HUMAN=YES
53. 51 AND 52
ADJ = adjacent AB = abstract
TI = title $ = truncation symbol DE = descriptor (similar to MeSH)
*******************************************************
CINAHL via OVID
--------------------------------------------------------------------------------
1 exp Prenatal Diagnosis/
2 nuchal translucency.mp.
3 pregnancy associated plasma protein.mp.
4 papp$.ti,ab.
5 exp Gonadotropins, chorionic/
6 (b-hcg or bhcg).mp.
7 human chorionic gonadotropin.mp.
8 exp alpha-Fetoproteins/
9 alphafetoprotein$.mp.
10 alpha-fetoprotein$.mp.
11 afp.mp.
12 (unconjugated estriol or unconjugated oestriol).mp.
13 ue3.mp.
14 inhibin$.mp.
15 ultrasound.mp.
16 amniocentesis/
17 chorion$ vill$ sampling.mp.
18 Chorionic Villi-Sampling/
19 nasal bone.mp.
20 tricuspid regurgitation.mp.
21 ductus venosus.mp.
22 marker$.mp.
23 screen$.mp.
24 detect$.mp.
25 accura$.mp.
26 predict$.mp.
27 ROC.mp.
28 ROC curve/
29 AUC.mp.
30 “area under curve”.mp.
31 exp false negative reactions/ or exp false positive reactions/
32 (false positive$ or false negative$).mp.
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33 likelihood ratio$.mp.
34 sensitiv$.mp.
35 specific$.mp.
36 diagnos$.ti,ab.
37 “reproducibility of results”.mp.
38 reference value$.mp.
39 reference standard$.mp.
40 exp Down Syndrome/
41 downs syndrome.mp.
42 down syndrome.mp.
43 trisomy 21.mp.
44 aneuploidy.mp.
45 mosaicism.mp.
46 (antenatal$ or prenatal$ or trimester$ or pregnan$ or fetus or foetus or fetal or foetal).mp.
47 or/1-39
48 or/40-45
49 47 and 48 and 46
*******************************************************
Search terms and instructions for Biosis
The following search terms were entered separately in standard search box (select ‘Titles/subject/abstract’ from the drop-down box on
the right of the search box).
1. “reference standard*”
2. “reference value*”
3. “reproducibility of results”
4. diagnos*
5. sensitiv*
6. specific*
7. “likelihood ratio*”
8. “false negative*
9. “false positive”
10. “area under curve”
11. ROC
12. AUC
13. predict*
14. detect*
15. marker*
16. screen*
17. accura*
18. “ductus venosus”
19. “nasal bone”
20. “tricuspid regurgitation”
21. “chorion* vill* sampling”
22. amniocentesis
23. ultrasound
24. inhibin*
25. “unconjugaed oestriol”
26. “unconjugated estriol”
27. afp
28. “alpha fetoprotein*”
29. alphafetoprotein*
30. “ bhcg”
31. “human chorionic gonadotrophin”
32. “papp a”
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33. “pregnancy associated plasma protein”
34. “nuchal translucency”
35. foetal
36. fetal
37. foetus
38. foetal
39. prenatal*
40. antenatal*
41. pregnan*
42. maternal*
43. “trisomy 21”
44. mosaicism
45. “down* syndrome”
The search then used the history function to combine terms:
1-34 - combine using OR
35 - 42 - combine using OR
43 - 45 - combine using OR
The three sets were combined using AND
The combined search strategy had the form
(((((((al: “trisomy 21”) or (al: (mosaicism))) or (al: “down* syndrome”))) and (((((((((((((((((((((((((((((((((((al: “reference stan-
dard*”) or (al: “reference value*”)) or (al: “reproducibility of results”)) or (al: (diagnos*))) or (al: (specific*))) or (al: (sensitiv*)))
or (al: “likelihood ratio*”)) or (al: “false negative*”)) or (al: “false positive*”)) or (al: “area under curve”)) or (al: (auc))) or (al:
(roc))) or (al: (predict*))) or (al: (accura*))) or (al: (detect*))) or (al: (screen*))) or (al: (marker*))) or (al: “ductus venosus”))
or (al: “tricuspid regurgitation”)) or (al: “nasal bone”)) or (al: “chorion* vill* sampling”)) or (al: (amniocentesis))) or (al:
(ultrasound))) or (al: (inhibin*))) or (al: “unconjugated oestriol”)) or (al: “unconjugated estriol”)) or (al: (afp))) or (al: “alpha
feto protein*”)) or (al: “alpha fetoprotein*”)) or (al: “b hcg”)) or (al: “human chorionic gonadotropin”)) or (al: “papp a”))
or (al: “pregnancy associated plasma protein”)) or (al: “nuchal translucency”)))) and (((((((((al: (foetal)) or (al: (fetal))) or (al:
(foetus))) or (al: (fetus))) or (al: (pregnan*))) or (al: (trimester*))) or (al: (prenatal*))) or (al: (antenatal*))))))
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The protocol intended to investigate several additional outcomes downstream from test accuracy, should they be reported in the test
accuracy studies. When we attempted to extract this information however, it was found to be available in very few studies. Where
such information was found, it was difficult to extract meaningful data to allow for comparison between studies because data were not
reported in a universal manner. In several studies such outcomes were estimated rather than measured. Often they were not reported
at all. The outcomes stated in the protocol which have not been included are: harms of testing; need for further testing; side effects
of tests; interventions and side effects; other abnormalities detected by testing; spontaneous miscarriage; miscarriage subsequent to
invasive procedure, with or without normal karyotype; fetal karyotype; termination of pregnancy (prior to definitive testing or in
a karyotypically normal pregnancy and following confirmation of Down’s syndrome or following detection of other chromosomal
abnormalities); stillbirth; livebirth of affected and unaffected fetus; uptake of definitive testing by women.
The following refinements to the eligibility criteria were imposed to ensure that the quality of the included literature remained high.
We excluded studies that identified fewer than five Down’s syndrome pregnancies in their study population. We excluded studies that
had less than 80% follow- up of participants.
In addition, the analytical strategy was informed by the volume of tests and studies included, so that we focused on key tests and test
combinations by a) only meta-analysing tests that were included in four or more studies, or b) showed more than 70% sensitivity
with at least a 95% specificity. In addition, a requirement that a minimum of 10 studies for a single test was required before subgroup
analysis was undertaken. Consequently several possible sources of heterogeneity were not investigated due to lack of data.
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N O T E S
This review belongs to a suite of planned systematic diagnostic test reviews examining antenatal screening for Down’s syndrome which
include four other titles: First trimester serum tests for Down’s syndrome screening; Second trimester serum tests for Down’s syndrome screening
(Alldred 2012); First trimester serum and ultrasound tests for Down’s syndrome screening; and First and second trimester serum tests with
and without first trimester ultrasound tests for Down’s syndrome screening. The plans for these reviews were described in a generic protocol
(Alldred 2010) published in the Cochrane Library in 2010. The project as a whole has been much larger than initially anticipated,
both in terms of size and statistical complexity. The initial search was completed in 2007 and an updated search in August 2011. After
identifying studies appropriate for inclusion, a significant amount of time has been devoted to data management and analysis.
The authors are conscious of the time lag from the latest literature search to publication, and the potential for the introduction of new
urine tests in this time frame. The authors are also conscious of the potential for publication of new data pertaining to tests included in
this review. Whilst not fulfilling the usual Cochrane up-to-date criteria, this review is published because it provides historical context
in what is a rapidly-changing field, and because it is unlikely to ever be repeated.
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